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1 Introduction 
1.1 The Hepatitis C Virus 
The Hepatitis C Virus (HCV) is a major cause of acute and chronic hepatitis in 
humans and is considered as a serious public-health problem. According to 
estimates of the World Health Organization (WHO) about 130–170 million people are 
chronically infected and 3-4 million people are newly infected with the blood-borne 
virus each year (WHO, 2011b). While 20% to 40% of acute hepatitis patients 
eliminate the virus and recover from the infection, 60% to 80% develop chronic 
hepatitis. About 10% to 20% of chronically infected individuals progress to cirrhosis 
and 1% to 5% of hepatic cirrhosis patients develop hepatocellular carcinoma (HCC) 
(WHO, 2011b). In the western industrial countries, HCV is the major cause of liver 
transplantations (Brown, 2005). Lasting beneficial treatment of chronic HCV 
infections can only be achieved by treating patients with pegylated interferon alpha 
(IFN-α) in combination with Ribavirin. However, usually only in 50% to 80% of 
patients a sustained virological response (SVR) is achieved, depending on the viral 
genotype (Zeuzem, 2004). The current improved understanding of the reproductive 
machinery of HCV has led to the discovery of numerous potential targets for antiviral 
therapy including processing and replication of the HCV polyprotein, viral entry and 
fusion, RNA translation, virus assembly and release, and several host cell factors. 
Inhibitors of the non-structural proteins 3/4A (NS3/4A) protease seem to be the best 
initial target and are currently the most advanced drugs in clinical development. The 
first two successful compounds, VX950 (Telaprevir) and SCH503034 (Boceprevir) 
were approved by the Food and Drug Administration (FDA) in May 2011, each given 
in combination with standard care. The results achieved with this treatment led to 
SVR rates to as high as 75% in genotype 1 (Jensen, 2011). Although constantly 
studies of alternative targets are under way, improved formulations of current HCV 
therapies are also being developed. However, in future a combination of antiviral 
agents with different mechanisms of action may lead to the eventual possibility of 
interferon-free regimens (Vermehren and Sarrazin, 2011). This situation clearly 
shows the need for new prophylactic and therapeutic approaches that prevent the 
spread of HCV and would provide more efficient antiviral therapy for individuals 
suffering from HCV. 
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Despite the permanent progress which is been made in the development of 
treatment, a prophylactic vaccine is the most important aim to significantly reduce the 
number of HCV infections in the future.  
 
1.1.1 Morphology of the virion 
HCV virions have a diameter of 55 to 65 nm (Fig. 1.1 A). The virus has been 
classified as the only member of the Hepacivirus genus and was assigned to the 
family of Flaviviridae due to its similarity to other viruses in this family. HCV particles 
adopt to a classical icosahedral scaffold by anchoring to the host cell-derived double-
layer lipid membrane containing the two envelope proteins 1 (E1) and 2 (E2). The 
genomic RNA of the virus is encapsidated by the nucleocapsid which lies underneath 
the membrane and is formed by multiple copies of the core protein (Fig. 1.1 B). In the 
serum of an infected host HCV circulates in various forms: virions bound to very-low-
density lipoproteins and low-density lipoproteins (representing the infectious fraction), 
virions bound to immunoglobulins and free virions. Also viral particles exhibiting 
physicochemical, morphologic, and antigenic properties of non-enveloped HCV 
nucleocapsids have been detected in plasma (Penin et al., 2004). 
 
          A.  
 
 
B. 
Fig. 1.1: The Hepatitis C Virus 
A. Electron microscopic picture of a recombinant virus particle. The diameter corresponds to 50 nm 
(Wakita et al., 2005). B. Schematic drawing of a HCV particle. The c stands for the viral core protein 
(nucleocapsid) [modified from:(Steinmann and Pietschmann, 2010)]. 
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1.1.2 The genome organization 
HCV contains a single-stranded, uncapped, positive-sense RNA molecule of 9.6 kilo 
bases (kb) in length. Translation of one single open reading frame (Pestka et al., 
2007) produces one large polyprotein of about 3000 amino acids (Bartenschlager et 
al., 1993) which is proteolytically cleaved, by host and viral proteases, to yield ten 
viral proteins: core, E1, E2, p7, NS2, NS3, NS4A and NS4B and NS5A and NS5B 
(Fig. 1.2). The open reading frame is flanked by the most conserved regions of the 
genome; the 5’ and 3’ untranslated regions (UTRs) (Pestka et al.). The 5’-UTR is a 
well-conserved, 341 nucleotide sequence element that precedes the internal 
ribosome entry site (IRES) mediating translation of the polyprotein (Tsukiyama-
Kohara et al., 1992). Downstream of the coding region the approximately 200 
nucleotides long 3’-UTR is located. It can be divided in 3 parts (Hsu et al., 2003): The 
stop codon of the ORF is followed by a variable region (approx. 40 nucleotides (nt)), 
a poly-uracil track of 20 to 90 nucleotides and a highly conserved sequence of 98 
nucleotides which is essential for replication (Kolykhalov et al., 1996), (Yanagi et al., 
1999).  
 
On the basis of the dissimilarity of nucleotide sequences, HCV can be classified into 
7 major genotypes as well as into numerous subtypes. These 7 genotypes differ from 
each other by more than 30% - 35% at the nucleotide level leading to differences in 
disease progression, mode of transmission and worldwide distribution. The most 
common one is HCV genotype 1 which is also the most difficult to treat (Hnatyszyn, 
2005). HCV is characterized by a very high sequence variability which arises from 
the error-prone RNA polymerase in combination with high selective immune 
pressure. Therefore, in an infected host HCV virions circulate in a large population of 
closely related but still distinct genetic variants or so called quasispecies (Simmonds, 
2004). 
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Fig. 1.2: Genomic organization of the HCV genome: polyprotein processing and cleavage 
products [modified from: (Knipe, 2007)] 
Precursor and mature proteins generated by the proteolytic processing cascade are indicated by 
boxes below the genome. Nonstructural proteins are white, whereas structural proteins are colored 
shaded. The cleavage sites for host signalase ♦ and the viral serine protease (downward arrow) are 
indicated. The NS2/3 cleavage is mediated by the NS2 cystein autoprotease (open bullet). The frame 
shift protein is indicated by an “F” in a black box.
 
While the structural proteins of HCV are located at the amino-terminus (N-terminus) 
of the genome, the non-structural proteins are located at its carboxy-terminus (C-
terminus). The first structural protein encoded by HCV is the core (c) protein which 
encapsidates and probably interacts with the genomic RNA (Baumert et al., 1998).  
 
HCV glycoproteins E1 and E2 are targeted to the endoplasmatic reticulum (ER) 
where they are released from the polyprotein by a host signal peptidase cleavage 
(Dubuisson et al., 2002). E1 and E2 are type-I transmembrane glycoproteins of about 
35 kilo Dalton (kD) and 70 kD (746 amino acids (aa)) respectively, with a large N-
terminal extracellular domain and a C-terminal transmembrane domain. They 
assemble as noncovalent heterodimers (Deleersnyder et al., 1997). The 
transmembrane domain of E1 and E2 contains two short (< 20 aa) hydrophobic 
stretches separated by fully conserved charged residues. The second hydrophobic 
stretch acts as an internal signal peptide for the downstream protein (Cocquerel et 
al., 2002). The transmembrane domains are not conical but dynamic changes have 
been shown to occur in these domains after cleavage by the signal peptidase. Before 
cleavage the transmembrane domains adopt a hairpin structure while after cleavage, 
the signal-like sequence is reoriented towards the cytosol which in turn leads to a 
transmembrane passage (Cocquerel et al., 2001). 
The E1/E2 heterodimer is mainly retained in the ER, although when over-expressed 
the HCV glycoproteins can be detected at the plasma membrane (Rouille et al., 
2006), (Duvet et al., 1998). In addition to a membrane-proximal heptad repeat 
sequence in E2, the determinants for ER retention have been mapped in the 
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transmembrane domains of E1 and E2 (Cocquerel et al., 2001). Furthermore, it was 
shown that these domains are essential for E1/E2 heterodimerization (Op De Beeck 
et al., 2000).  
The ectodomains of E1 and E2 are heavily modified by N-linked glycans (up to 6 and 
11 glycosylation sites, respectively) and contain multiple disulfide-linked cysteins 
(Bartenschlager et al., 2004). Some glycans have been shown to be strongly 
conserved among HCV genotypes and are important for proper folding, secretion, 
assembly, and release of HCV particles (Goffard et al., 2005).  
 
The E2 glycoprotein contains a hypervariable region I (HVRI) which is encoded by 
the first N-terminal 27 residues (aa 384 to 410). In this region most likely the major 
neutralizing epitope of HCV is located (Kato et al., 1992). Antibodies against this 
region are in principle neutralizing and until now are the only ones assumed to be 
protective (Farci et al., 1996). The HVRI does not only show a high level of sequence 
variability (even within a single patient), which is largely driven by antibody selection 
of immune escape-variants, but also appears to play an important role in E2 function 
(Dubuisson, 2007). Thus, in the whole viral genome the highest sequence variability 
can be found in the HVRI. However, some functional constrains narrow this 
variability, which is evident since this region was recently shown to play an important 
role during virus entry (Penin et al., 2001). The involvement of the HVRI in entry and 
the immune response during an HCV infection will be discussed in more detail in 
section 1.1.4 and 1.3.3. 
 
A second hypervariable region, HVRII, has been described in the E2 protein which 
includes a stretch of 9 aa (position 474 to 482) (Weiner et al., 1991) and has been 
proposed to modulate E2 host receptor CD81 binding (Roccasecca et al., 2003). 
Recently a third hypervariable region, HVRIII (aa 431 to 466), positioned in between 
HVRI and HVRII was integrated in the canonical model of E2 (Torres-Puente et al., 
2008), (Law et al., 2008). 
 
Following the structural region of the HCV polyprotein is a small integral membrane 
protein, p7 (Dubuisson, 2007). p7 is an ion-channel, that is required for HCV particle 
release (Stgelais et al., 2009).  
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The remainder of the polyprotein consists of the nonstructural proteins NS2, NS3, 
NS4A, NS4B, NS5A and NS5B. NS2 is acting as a membrane protein which is 
essential for HCV RNA replication. (Blight et al., 2000). The HCV NS3 is a 
multifunctional protein, serving as both a proteolytic enzyme and a helicase. 
Together with NS2 and NS4A, NS3 process the presumed NS region of the 
polyprotein. The C-terminal part of the NS3 protein contains the RNA 
helicase/nucleoside triphosphate hydrolase (NTPase) domain that is essential for 
translation and RNA replication (Bartenschlager et al., 1993). The NS4A protein is a 
membrane protein, forming the membrane structure and supporting RNA replication 
(Egger et al., 2002). NS4B is an integral membrane protein, that reorganizes the 
cellular membrane during replication (Liefhebber et al., 2009). The NS5A 
phosphoprotein is important for RNA replication, and a potential involvement in 
suppression of PKR (protein kinase regulated) mediated antiviral cellular response is 
still discussed (Gale, Blakely et al. 1998). NS5B is the RNA-dependent RNA 
polymerase needed for viral replication (Dubuisson, 2007). 
 
In addition to the large ORF encoding the polyprotein, the HCV genome contains an 
overlapping +1 reading frame which overlaps the sequence of the core protein 
(Branch et al., 2005). This alternative reading frame protein (ARF) or frame shift 
protein (F protein) lacks an in-frame AUG stop codon with a frameshift efficiency of 
1% to 2%. The role of the F protein in the HCV life cycle and/or pathogenesis 
remains unclear. However, the F protein is not required for HCV RNA replication. 
(Dubuisson, 2007) 
 
1.1.3 The replication cycle 
An infection with HCV starts with the binding of the viral particle to the cell surface 
(Fig. 1.3) which is belived to be facilitated by the interaction of E1 and E2 proteins 
with glycosaminoclycanes (GAGs), dendritic cell-specific intracellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN), liver/lymph node-specific intracellular 
adhesion molecules-3 grabbing non-integrin (L-SIGN) as well as the binding of the 
virus to the (very)-low-density lipoprotein receptor ((V)LDL) (Sabahi, 2009). Binding 
of the latter receptor is presumably mediated by the apolipo-protein E which is an 
integral component of an infectious viral particle (Jiang and Luo, 2009). While this 
interaction at the surface of the hepatocyte only “fixes” the virus, 4 different 
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molecules are responsible for the ultimate infection: tetraspanin CD81, SR-B1 as well 
as both tight junction components Claudin-1 and Occludin (Popescu and Dubuisson, 
2009). Due to the receptor-mediated endocytosis the virus reaches the endosomes. 
It is assumed that acidification of the endosomes alters the conformation of the viral 
envelope which interferes with the fusion of the viral lipid-envelope with the 
endosomal membrane. Up to now, it is only known that uncoating of the viral genome 
takes place at the cytoplasm of the rough ER where the viral genome is transcribed 
and the polyprotein is cleaved. Following the polyprotein processing, the proteins 
retain either directly or indirectly associated at the membrane of the ER (Welsch et 
al., 2009). In an event not yet exactly understood, a so called “membraneous web” is 
formed. RNA replication takes place in invaginations of the membrane in which the 
viral genome is transcribed into minus-strand-copies. These copies are used as a 
template for new copies of the genome ((+) RNA) which in turn are utilized for the 
translation of new viral polyproteins, repeated synthesis of minus-strand-copies or for 
assembly of newly formed virus particles. Assembly of infectious particles occurs 
directly at or close to the lipid droplets which are integral components of the 
membraneous web (Moradpour et al., 1996), (Barba et al., 1997).    
 
 
 
Fig. 1.3: Schematic representation of the major steps of the HCV replication cycle (Dubuisson, 
2007) 
Post infection of the cell, the viral RNA is delivered to the cytoplasm and translated. After processing 
of the proteins, the RNA is replicated in the replication-complex bound to the ER and packed into 
newly formed virions. The viral particles are then secreted. 
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1.1.4 The role of envelope proteins during entry 
Virus entry is defined as the steps from particle binding to the host cell up to the 
delivery of the viral genome to its replication site within the target cell, which, in case 
of HCV, is the human hepatocyte. Viral entry is a complex multistep process based 
on specific interactions between virus components, mainly envelope proteins and 
multiple cellular factors (Burlone and Budkowska, 2009).  
 
Virus receptors actively promote entry, whereas attachment factors serve to bind the 
particles and thus help to concentrate viruses on the cell surface (Dubuisson et al., 
2008). One of these attachment factors was identified as GAGs. The GAG heparan 
sulphate (HS), a glycosaminoglycan chain on cell surface proteoglycans, serves 
usually as attachment site for the binding of a number of viruses and other 
microorganisms (Barth et al., 2003). Attachment of the virus to GAGs, which serve as 
‘primary’, low affinity, but abundant receptors, may play an essential role in the early 
steps of HCV infection (Fig. 1.4). The pre-treatment of HCVpp (HCV pseudoparticle 
system) and HCVcc (HCV cell culture derived system) with heparinase (an enzyme 
degrading HS) inhibited the infectivity of Huh7 cells (Koutsoudakis et al., 2006), 
(Basu et al., 2007). However, the exact role of GAGs in HCV entry is still not 
completely revealed (Callens et al., 2005).  
 
CD81 was discovered early as an entry receptor (Pileri et al., 1998) followed by the 
discovery of SR-B1 (Fig. 1.4) (Scarselli et al., 2002). CD81 is ubiquitously expressed 
as a 25 kDa unglycosylated membrane protein belonging to the tetraspanin family 
(Levy and Shoham, 2005). Studies in non-permissive human hepatoma cell lines 
such as HepG2 and HH29, both not expressing CD81, confirmed the role of CD81 in 
HCV infections as these cells become susceptible to HCVcc and HCVpp infection 
upon ectopic expression of CD81 after transduction (Bartosch et al., 2003a), (Zhang 
et al., 2004), (Cormier et al., 2004), (Lavillette et al., 2005). Antibodies against CD81 
and human recombinant CD81 LEL (large extracellular loop of CD81) inhibited HCV 
infection only after virus attachment. This and other studies suggest that CD81 acts 
as a post-binding entry molecule (Cormier et al., 2004), (Flint et al., 2006), 
(Koutsoudakis et al., 2006). The cellular pathways triggered by HCV binding to CD81 
were also elucidated. Engagement of CD81 plays a fundamental role in HCV 
infectivity through the activation of Rho guanosine triphosphate hydolase (GTP-ases) 
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and the actin-dependent relocalization of the E2/CD81 complex to cell-cell contact 
areas. Here CD81 comes in contact with the tight junction proteins Occludin and 
CLDN-1, two other HCV co-receptors (explained in more detail below). Finally, post-
entry steps of the virus life cycle are affected by CD81 engagement activating the 
Raf/upstream mitogen-activated protein kinase (upstream MAPK, also called MEK) / 
extracellular signal-regulated kinase (also called MAPK) (Raf/MEK/ERK) signalling 
cascade (Brazzoli et al., 2008).     
 
SR-B1 is a 82 kDa glycoprotein with 2 cytoplasmic domains, 2 transmembrane 
domains and a large extracellular loop with 9 potential N-glycosylation sites. It is 
expressed in various mammalian cells, but is mostly expressed in the liver and 
steroidogenic tissues (Acton et al., 1994), (Calvo and Vega, 1993), (Rhainds and 
Brissette, 2004). SR-B1 binds to various classes of lipoproteins, high-, low- and very-
low-density lipoproteins (HDL, LDL and VLDL, respectively), as well as to chemically 
modified lipoproteins like oxidized and acetylated LDL and thus was referred to as 
being a ‘multi-ligand’ receptor (Fig. 1.4). Mouse SR-B1 does not bind sE2 which 
shows that SR-B1 appears to be species-specific. It was also shown that the deletion 
of the HVRI region of E2 impairs the interaction between SR-B1 and sE2 and 
reduces HCVpp infectivity (Scarselli et al., 2002), (Bartosch et al., 2003a). 
Furthermore, antibodies against SR-B1 also significantly reduce HCVpp infectivity 
(Bartosch et al., 2003b). Similar to CD81, SR-B1 acts as ‘post-binding’ receptor 
which was demonstrated by antibodies inhibiting infection against both receptors 
when added until 60 min after virus binding (Cormier et al., 2004), (Zeisel et al., 
2007). It was shown that HDL enhances the HCVcc infectivity only when CD81 is 
expressed suggesting that SR-B1 co-operatively interacts with CD81 in HCV cell 
entry (Fig. 1.4) (Zeisel et al., 2007). In contrast to the enhancing effect, other natural 
ligands of SR-B1 like VLDL and oxidized LDL had significant inhibitory effects on 
serum HCV and HCVpp cell entry (Fig. 1.4) (Maillard et al., 2006), (von Hahn et al., 
2006). The crucial role of SR-B1 in cell infection by HCV can be underlined by the 
finding that the antiviral action of interferon is linked to a decrease in the expression 
levels of SR-B1 on the cell surface, thereby restricting virus attachment and entry into 
hepatocytes (Murao et al., 2008). 
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Tight junctions are major components of cell-cell adhesion complexes that separate 
apical from basolateral membrane domains and maintain cell polarity by forming an 
intramembrane (Shin et al., 2006). The tight junction protein CLDN1, a member of 
the Claudin family, has also been identified as being involved in HCV entry (Fig. 1.4) 
(Evans et al., 2007). It is composed of 211 aa with two extracellular loops, four 
transmembrane segments and three intracellular domains (Van Itallie and Anderson, 
2006). Although CLDN1 is expressed in all epithelial tissues, it is predominantly 
expressed in the liver where it forms networks at tight junctions (Furuse et al., 1998). 
HCV entry was shown to be likely mediated by the highly conserved domain in the 
first extracellular loop (EL1), as non-hepatic cell lines such as 293T and SW13 
become susceptible to HCVpp infection when expressing CLDN1 (Evans et al., 
2007).  
 
After showing that human cell lines such as HeLa and HepH (CD81- and SR-B1-
positive) remained HCV-resistant when over-expressing CLDN1 it was suggested 
that additional factors are needed for a successful HCV entry (Evans et al., 2007). 
Thereby another transmembrane component of the tight junctions, Occludin, was 
identified as a co-receptor for HCV (Fig. 1.4) (Liu et al., 2009). Occludin is a 60 kDa 
protein with four transmembrane regions, two extracellular loops and N- and C-
terminal cytoplasmic regions (Furuse et al., 1993). After targeting CLDN1 and 
Occludin by siRNA and shRNA interference it was demonstrated that the reduction of 
the expression of both of these molecules inhibited HCVpp and HCVcc cell entry (Liu 
et al., 2009). Moreover, it was shown that human Occludin renders murine cells 
infectable with HCVpp (Ploss et al., 2009). 
 
As already mentioned above, in the serum of an infected host HCV particles are 
mostly found to be associated with lipoproteins and most circulating particles are of 
low density due to their association with ß-lipoproteins (Thomssen et al., 1992), 
(Prince et al., 1996), (Agnello et al., 1999). It was already shown that apolipoprotein 
B (ApoB) is associated with virus particles and plays a key role in the initial 
interaction of the receptor by serum-derived authentic HCV, as these virions did not 
recognize SR-B1 directly via viral envelope glycoproteins. In this context the 
lipoprotein receptor LDL-R was also shown to be involved in the HCV infection 
process (Fig. 1.4). The usual role of LDL-R is a sequestering of cholesterol in the 
form of LDL and VLDL from the circulation. The correlation of cell surface expression 
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of LDL-R in patients with chronic HCV infection and with a high viral load has 
demonstrated the involvement of LDL-R in the viral replication cycle (Petit et al., 
2007). Moreover, treatment of hepatocytes with monoclonal antibodies against LDL-
R of LDL also inhibited HCV infection (Molina et al., 2007).  
The main lipoprotein component in HCV patient sera is the triglyceride-rich VLDL, 
produced and secreted by hepatocytes (Shelness and Sellers, 2001). Studies 
already demonstrated that HCV-associated lipoproteins are not simply absorbed at 
the surface of virions circulating in patient sera, but that VLDLs are an integral part of 
HCV particles (Nielsen et al., 2006). This underlines the importance of VLDL in the 
assembly and secretion of infectious HCV particles (Fig. 1.4). 
 
With regard to the current knowledge it is possible that HCV infection is initiated by 
the interaction between the lipoprotein-associated virus particle and lipoprotein 
receptors SR-B1 and/or LDL-R. In addition, cell surface proteoglycans facilitate 
infection, probably in a lipoprotein-dependent manner (Burlone and Budkowska, 
2009). 
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Fig. 1.4: Model of natural ApoB-associated HCV entry into to the hepatocytes [modified from: 
(Burlone and Budkowska, 2009)] 
Virus binding and internalization is initiated by the interaction between HCV-associated lipoproteins 
(mainly VLDL) with lipoprotein receptors SR-B1 and/or LDL-R and/or GAGs. HCV cooperates with the 
SR-B1–CD81 complex and the virus is subsequently transferred by CD81 to tight junction proteins 
CLDN-1 and occludin. Virus enters the cell from the tight junction via endocytosis and fusion is 
mediated by envelope glycoproteins; this event permits the virus to escape the lipoprotein degradation 
pathway. Lipoprotein-mediated HCV cell entry is inhibited by natural ligands of lipoprotein receptors 
such as VLDL, LDL and oxidized LDL. Cell entry can also be inhibited by serum amyloid A (SAA, an 
acute phase protein produced primarily by hepatocytes during infection), enhanced by HDL and 
regulated by LPL. This model corresponds to the cell entry of HCVcc and natural HCV from patient 
sera, which are associated to various extents with ApoB-containing lipoproteins (Burlone and 
Budkowska, 2009). 
 
Fewer is known about the interaction of the envelope proteins E1/E2 with the cellular 
receptors during entry. However, studies using HCVpp provided evidence for the 
involvement of the E1/E2 heterodimer in virus entry, as HCVpp expressing E1 or E2 
separately are non-infectious (Drummer et al., 2003), (Bartosch et al., 2003a). In 
addition, E2 has been shown to interact with CD81 (Pileri et al., 1998), SR-B1 
(Scarselli et al., 2002), DC-SIGN and L-SIGN (Gardner et al., 2003), (Pohlmann et 
al., 2003), and glycosaminoglycans (Barth et al., 2003). Experiments indicated that at 
least CD81 and SR-B1 play a role in HCVpp entry (Bartosch et al., 2003a), (Bartosch 
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et al., 2003b), (Hsu et al., 2003), (Lavillette et al., 2005), (Zhang et al., 2004). 
Furthermore, the CD81 binding region of E2 is required to be correctly folded for the 
interaction between the virus and CD81 and SR-B1 (Flint et al., 1999), as several 
regions in E2 have been identified to be engaged in CD81 binding (Flint et al., 1999), 
(Owsianka et al., 2001), (Clayton et al., 2002). Moreover, specific amino acid 
residues have been identified (W420, Y527, W529, G530 and D535) which are 
critical for CD81 binding and thus are conserved across all genotypes (Owsianka et 
al., 2006).  
Beside these binding regions more and more is reported about the modulation of the 
accessibility of HVRI to either SR-B1 or CD81, since deletion of HVRI increased 
binding to CD81 but abrogated binding to SR-B1 (Scarselli et al., 2002), (Roccasecca 
et al., 2003). The conformation and structural properties of HVRI are highly 
conserved and HVRI is a globally basic stretch, with basic residues located at 
specific sequence positions, suggesting that these residues within HVRI might affect 
the interaction of E2 with molecules involved in HCV entry (Penin et al., 2001), 
(Callens et al., 2005). Indeed it was shown that in the absence of basic residues, 
infectivity was reduced to the same level as that of a mutant deleted of HVRI. In 
addition, HCVpp infectivity increased with the number of basic amino acids in HVRI, 
and the presence or absence of basic residues at specific positions modulated 
HCVpp infectivity (Callens et al., 2005).     
Up to now it is still unclear how HCV actually associates with lipoproteins and which 
viral determinants modulate this interaction. However, the recent observation of 
Bankwitz et al. showed that the deletion of HVRI reduces the number of VLDL-HCV 
particles which suggests that HVRI may influence the interplay between HCV lipids 
or lipoproteins. Furthermore, it was observed that soluble CD81 (hCD81-LEL) is able 
to neutralize and precipitate ΔHVRI particles much more readily than wild-type 
particles. These data indicate that HVRI masks the viral CD81 binding site. It is 
possible that until the interaction with a host factor which elicits a conformational 
change, fully exposing the CD81 binding site, the conserved CD81 binding site in 
wild-type particles is mostly hidden, thus preparing the virus for contact with this 
crucial receptor. This kind of strategy would be in line with the interplay of HIV-1 with 
CD4 and the chemokine receptors (Bankwitz et al., 2010). HVRI has been reported 
as a target for neutralizing antibodies (nAbs) (Farci et al., 1996) which would be 
reminiscent with the above mentioned strategy which may facilitate successful 
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evasion from neutralizing immune response through protection of conserved viral 
epitopes necessary for essential receptor interactions (Bankwitz et al., 2010).   
Because the HVRI seems to be important for virus replication and persistence in 
several ways; it is involved in assembly and release of virus particles with optimal 
composition, it influences the HCV membrane fusion process, and this domain 
physically protects a conserved neutralizing epitope (the viral CD81 binding site). 
This knowledge should be used for devising vaccine formulations that induce potent 
neutralizing antibody responses (Bankwitz et al., 2010). 
The role of E1 in HCV infection remains poorly understood, but it appears to be 
involved in the fusion process (Garry and Dash, 2003), (Lavillette et al., 2007). 
 
1.2 Model systems of HCV infection 
The only species in which both, early antiviral immune responses and pathogenesis 
of HCV can be studied is the chimpanzee. Because of the extremely narrow species 
tropism of HCV, all rodent models require xenografting of human cells and 
constitutive lack of immune rejection toward these engrafted cells (Boonstra et al., 
2009).  
 
1.2.1 in vitro models 
To study the complexity of the HCV life cycle, a series of in vitro models were 
developed over the last decades. The two most important systems frequently used, 
are described in the following:  
 
The HCV pseudoparticle-system (HCVpp): 
This very successful cell-based model system is based on pseudotyping of particles 
produced by other viruses, including lentiviral or retroviral core particles, with HCV E1 
and E2 glycoproteins (Lagging et al., 1998), (Drummer et al., 2003), (Bartosch et al., 
2003a), (Lavie et al., 2007). For most assembly platforms of HCVpp, Murine 
Leukemia Virus (MLV) or Human Immunodeficiency Virus (HIV) vectors were used 
because their cores can incorporate a variety of different cellular and viral 
glycoproteins (Ott, 1997), (Sandrin et al., 2002). Furthermore, they can easily 
package and integrate genetic markers into DNA of infected cells (Negre et al., 
2002). Monitoring of viral infection is possible due to the pseudoparticles expressing 
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E1/E2 at their surface and packaging of a reporter gene. HCVpp are produced by 
transfection of human embryonic kidney 293T cells with expression vectors encoding 
the E1/E2 polyprotein, the retroviral Gag-Pol core proteins, and a packaging-
competent retroviral derived genome encoding a reporter gene like the green 
fluorescent protein (GFP) or the firefly luciferase gene (Fig. 1.5). The produced 
HCVpp are infectious for cell lines of hepatocyte origin, principally for Huh7.5 cells 
and their derivatives as well as for human primary hepatocytes (Bartosch et al., 
2003a), (Hsu et al., 2003).  
HCVpp can mimic the early steps of HCV infection, because they exhibit a 
preferential tropism for hepatic cells and they are specifically neutralized by anti-E2 
monoclonal antibodies as well as sera from HCV-infected patients (Bartosch et al., 
2003a), (Hsu et al., 2003), (Op De Beeck et al., 2004). Furthermore, HCVpp led to 
the identification of multiple viral entry receptors, such as glycosaminoglycan, low-
density lipoprotein receptor, DC-SIGN, L-SIGN, Claudin-1, -6 and -9, and Occludin 
(von Hahn and Rice, 2008), (Ploss et al., 2009). Therefore, HCVpp represent the 
best tool available to study functional HCV envelope glycoproteins (Flint et al., 2004).   
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Fig. 1.5: Production of HCV pseudoparticles (HCVpp) (Lavie et al., 2007) 
293T cells are transfected with three expression vectors. The first vector encodes retroviral Gag 
andPol protein. Gag proteins are responsible for particle budding at the plasma membrane and RNA 
encapsidation via recognition of the specific retroviral encapsidation sequence (Ψ). The second 
vector harbors a Ψ sequence for encapsidation and encodes a reporter protein (Luciferase). This 
vector also contains retroviral sequences that are necessary for the reverse transcription of genomic 
RNA into proviral DNA by retroviral protein Pol encoded by the first vector. The third vector encodes 
HCV envelope glycoproteins, which are responsible for the cell tropism and fusion of HCVpp with the 
target cell membrane (Lavie et al., 2007). 
 
 
The HCV cell-culture derived virus-system (HCVcc) 
The finding of an HCV subgenomic and, a few years later, a full genomic replicon 
system led to completely new opportunities to study different aspects of HCV 
replication. HCV replicons became extremely valuable in many laboratories 
worldwide (Lohmann et al., 1999), (Blight et al., 2002), (Lohmann et al., 2003), (Blight 
et al., 2003). However, the disadvantage of these replicons was despite their 
relatively high rates of HCV RNA replication their inability to produce infectious 
virions. A different situation emerged when the first genotype 2a consensus genome 
was established (Kato et al., 2001), (Kato et al., 2003). A subgenomic replicon that 
did not require adaptive mutations for replication in vitro and replicated up to 20-fold 
higher in Huh7 cells was constructed from a clone called JFH-1, isolated from a 
Japanese patient with fulminant Hepatitis C (Wakita et al., 2005). This system was 
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based on the transfection of Huh7.5.1 cells with the in vitro-transcribed full length 
JFH-1 genome or a recombinant chimeric genome with another genotype 2a isolate, 
J6. Transfection resulted in the secretion of viral particles that were infectious in 
cultured cells, chimeric mice, and in chimpanzees, thus referred to as a cell-culture 
derived virus or HCVcc (Wakita et al., 2005), (Zhong et al., 2005), (Lindenbach et al., 
2005), (Lindenbach et al., 2006). Neutralization of infectivity of cells could be 
achieved by antibodies against the HCV receptor CD81, antibodies against E2, or 
immunoglobulins from chronically infected patients. Furthermore, in this system IFN-
α as well as several HCV-specific antiviral compounds were able to inhibit replication 
of cell-cultured HCV (Lindenbach et al., 2005). Up to now, chimeric JHF-1-based 
genomes have been constructed of all seven known HCV genotypes (Pietschmann 
et al., 2006), (Gottwein et al., 2009). Thus, the HCVcc system provides an excellent 
opportunity to study the complete HCV life cycle.  
 
1.3 The immune response during an HCV infection 
1.3.1 The innate immune response 
In the early phase of an HCV infection the innate immune response is induced. The 
first response is thought to be type I interferon (IFN-α/ß) production by infected 
hepatocytes and plasmacytoid dendritic cells (pDC) which is initiated by the pattern 
recognition receptors Toll-like receptors (TLR3) and retinoic-acid-inducible gene I 
(RIG-I) (Saito et al., 2008). Natural killer (NK) cells which are frequently found in the 
liver get also activated by type I IFN and are able to rapidly exert cytotoxicity and 
release cytokines. This process initiates hepatitis (Ahlenstiel et al., 2008). In turn the 
destruction of hepatocytes stimulates myeloid DCs (mDC). These DCs subsequently 
promote the secretion of IFN-γ through the activation of NK cells and natural killer T-
cells (NKT). IFN-γ then activates hepatic macrophages to enhance local inflammation 
(Racanelli and Rehermann, 2006). However, the virus has evolved several 
mechanisms to attenuate IFN response and is thus able to persist within the liver. 
One of the key players is the HCV NS3/4A protein (Foy et al., 2003), (Li et al., 2005). 
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1.3.2 The cellular immune response 
Although the innate immune response can be observed relatively early in HCV 
infection, the adaptive cellular response seems to be essential for viral clearance. 
The acute phase of an HCV infection endures approximately 6 month post infection. 
While the viral load in the serum increases exponentially during the first weeks, the 
first T-cells can only be detected in the periphery after four to eight weeks (Thimme 
et al., 2001). CD8+ T-cells are detectable in the blood of acutely infected patients 
regardless of virological outcome (Kaplan et al., 2007). Spontaneous clearance of the 
virus in the acute phase of infection is associated with a long lasting vigorous T-cell 
response which is accompanied by the intrahepatic production of cytokines (Cooper 
et al., 1999), (Lechner et al., 2000). Subsequently to antigen contact, CD8+ T-cells 
produce IFN-γ and TNF-α in the blood and in the liver and develop cytotoxic activity 
which by means of perforin and granzyme induces Fas-mediated apoptosis (Grakoui 
et al., 2003). In parallel to a vigorous CD8+ T-cell response a strong CD4+ T-cell 
response also seems to be essential for viral clearance. These cells are required for 
the induction and maintenance of virus-specific CD8+ T-cells (Grakoui et al., 2003).  
Chronic infection is associated with weak or no detectable CD4+ and CD8+ T-cell 
responses (Wedemeyer et al., 2002), (Cox et al., 2005). Detectable cells show only 
decreased cytotoxicity, cytokine secretion and proliferation (Ulsenheimer et al., 
2003). Reasons for the impaired T-cell response seem to be dysfunction or an 
increasing exhaustion during presence of high viremia. Mechanisms causing the T-
cell failure include HCV escape mutations (Timm et al., 2004), induction of regulatory 
T-cells (Sugimoto et al., 2003), or the increased expression of the co-receptor 
programmed death-1 (PD-1) on T-cells (Rutebemberwa et al., 2008).  
 
1.3.3 Envelope proteins and the humoral immune response 
The immune system of the host recognizes viral proteins as non-self and induces the 
production of antibodies (Abs). During the natural course of infection, Abs targeting 
both structural and non-structural proteins are produced. Only a small fraction of Abs 
demonstrates antiviral activity and is able to bind viral particles. These Abs are 
directed against epitopes that play an essential role in virus entry and are referred to 
as “neutralizing Abs” (nAbs) (Keck et al., 2008a). Antibody binding can lead to virus 
neutralization which is mediated by aggregation of virus particles, preventing virus 
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entry through steric hindrance (Burton et al., 2001). Virus neutralization will be higher 
with high affinity antibodies, whereas non-neutralizing Abs do not bind to the virion 
surface or bind with low affinity only (Houghton, 1996).  
The role of the humoral immune response in controlling HCV infection remains 
controversial, as patients with persistent infection develop high titers of neutralizing 
antibodies that do not appear to clear the infection. Moreover, once chronic HCV 
infection is established nAbs increase in titer and breadth, typically exhibiting cross-
reactivity against multiple HCV genotypes (Logvinoff et al., 2004). At this stage nAbs 
continue to exert selection pressure on viral variants and contribute to the evolution 
of HCV envelope sequences throughout the course of infection but they fail to clear 
the virus (Farci et al., 2000), (von Hahn et al., 2007). In chronic HCV the overall 
concentration of Immunoglobulin G (IgG) and the frequency of IgG-secreting B-cells 
is also increased. Most of these Igs, and the B-cells that secrete them, are not HCV 
specific. Therefore it was assumed that HCV stimulates B-cells in a B-cell receptor-
independent manner (Racanelli et al., 2006). 
On the other hand, HCV can be cleared without humoral immune response in 
immunocompromised (e.g., hypogammaglobulinemic) patients (Semmo et al., 2006). 
In immunocompetent patients, nAbs appear late and are isolate-specific (Pestka et 
al., 2007), (Dowd et al., 2009). However, in a single-source outbreak of HCV 
involving multiple subjects, HCV clearance was associated with rapid induction of 
neutralizing antibodies in the early phase of infection. In contrast, in the same cohort 
of patients it was shown that chronic HCV infection was characterized by absence or 
low-titer of nAbs in the early phase of infection (Pestka et al., 2007).  
About 20 to 25% of patients in the acute phase of the disease are able to clear 
viremia. A study of intravenous drug users, in which a comparison of patients without 
evidence of previous HCV infection (HCV Ab negative and RNA negative) with those 
of previously infected (HCV Ab positive and RNA negative) was performed, showed 
that individuals with evidence of a previous infection were 12 times less likely than 
those with first time exposure to develop HCV persistence, suggesting that humoral 
immunity can prevent disease progression (Mehta et al., 2002).  
These findings suggest that a strong broad nAb-response may contribute to control 
HCV in the acute phase of infection and moreover points to the use of nAbs for 
therapeutical purpose. 
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The involvement of the complete E2 protein: 
The majority of nAbs generated during acute infection have been mapped to the 
envelope glycoproteins E1 and E2 (Kato et al., 1993), (Owsianka et al., 2005; Keck 
et al., 2008b; Meunier et al., 2008). As described in section 1.1.4 it was already 
demonstrated that E2 is critical for host cell entry and represents an important target 
for virus neutralization. Several discontinuous regions of E2 contain highly conserved 
residues involved in CD81 binding and are targeted by nAbs (Owsianka et al., 2006). 
The mouse monoclonal antibody (mAb) AP33 and the rat mAb 3/11 have broad 
neutralizing activity that can be attributed to the importance of the targeted region in 
CD81 binding and the extreme conservation of their epitopes (Owsianka et al., 2005), 
(Tarr et al., 2006) (Sabo et al., 2011).  
E1/E2 N-glycosylation sites are highly conserved across all genotypes (>97%), 
suggesting that the glycans associated with these proteins play an essential role in 
the HCV life cycle (Helle et al., 2007). Recently experiments in the HCVcc system 
demonstrated that at least five glycans on E2 (E2N1, E2N2, E2N4, E2N6 and 
E2N11) reduce HCVcc sensitivity to neutralization. This indicated that glycans limit 
the recognition of neutralizing epitopes at the surface of E2 (Helle et al., 2010). 
Indeed, the absence of one of these glycans leads to a higher sensitivity to 
neutralization by Abs purified from HCV seropositive patients, as well as mAbs (Helle 
et al., 2007), (Falkowska et al., 2007).  
 
The HVRI and its involvement in the humoral immune response: 
Early studies in chimpanzees showed that the onset of acute infection could be 
delayed with IgG therapy (Krawczynski et al., 1996) and HVRI-specific antibodies are 
able to protect them partially from infection with HCV that encodes the immunizing 
HVRI (Lee, Suh et al. 1997), (Farci et al., 1996), (Esumi et al., 1999). Also in 
humans, early induction of HVRI-specific antibodies correlates with viral clearance 
and Abs from chronically infected patients are directed against the HVRI (Rosa et al., 
1996), (Owsianka et al., 2001). In chimpanzees, a deletion of HVRI within an HCV 
genome was infectious, although the resulting virus was highly attenuated (Forns et 
al., 2000). Thus, the HVRI region of E2 was identified as being the major target for 
nAbs. HVRI possesses multiple linear epitopes between aa 384 and 410. In vivo 
antibodies targeting HVRI have been identified (Weiner et al., 1992), (Kato et al., 
1993), (Kato et al., 1994), however these Abs tend to be highly strain-specific 
(Shimizu et al., 1996; Vieyres et al., 2011). A study on the structural conformation of 
                                                                                                                  1 Introduction 
 
 
21
HVRI showed either a broad amino acid repertoire at each position despite a 
remarkable residue conformation in specific sites or replacements with amino acids 
with similar physicochemical properties, usually positively charged basic residues, in 
the most variable parts. A substantial conformational conservation was revealed by 
the very similar hydropathy and antigenicity profiles of HVRI variants. These data 
provide a plausible explanation for the extensive cross-reactivity demonstrated by 
Abs and confirming the existence of an active selection process (Penin et al., 2001). 
The epitopes recognized by HVRI-specific mAbs that also show neutralizing capacity 
have been mapped within the C-terminal portion of HVRI (aa 396-407) (Hsu et al., 
2003), (Vieyres et al., 2011). In contrast, the non-neutralizing mAbs bind to the N-
terminal portion of HVRI (aa 384-395) (Hsu et al., 2003). Thus, it appears that there 
are two immunogenic regions within the HVRI, with the C-terminal portion containing 
the neutralizing determinants.  
As already mentioned earlier it was shown that the HVRI is also able to mask nAb 
epitopes within E2. A panel of human mAbs and patient sera, targeting the CD81-
binding site within the E2 protein, made HVRI deletion mutants much more 
susceptible to neutralization (Bankwitz et al., 2010), (Prentoe et al., 2011). This is 
likely due to masking of the CD81-binding site, as HVRI may function to protect viral 
entry determinants within E2 against neutralization during early stages of entry 
(Bankwitz et al., 2010). Thus initial contact with SR-B1 may be needed to unmask the 
CD81- binding region on E2 and enable the particle to interact with CD81. It has 
been suggested that the lipoproteins associated with the viral particle interact with 
this entry factor, although also a direct interaction between HVRI and SR-B1 could 
take place (Maillard et al., 2006). Accordingly, HVRI may act as an immunological 
decoy that shields conserved neutralizing epitopes and stimulates a strong Ab 
response towards HVRI that does not result in viral clearance, but instead drives the 
selection of antibody-escape mutants (Ray et al., 1999).     
 
Other mechanisms used by HCV to escape from humoral immune response: 
An additional strategy used by HCV may represent lipid shielding to evade antibody 
response. As already mentioned earlier, in patient sera low density particles of HCV 
are the most infectious, and recent data suggest that key neutralizing epitopes are 
less accessible on LVPs which are associated with VLDL such as apoB and apoE. 
Furthermore, several in vitro studies have demonstrated that HDL components of 
human serum (such as apoCl) can enhance the infectivity of HCVpp and HCVcc via 
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an HVRI-dependent mechanism (Meunier et al., 2005), (Bartosch et al., 2005), 
(Dreux et al., 2007). HDL can also reduce the sensitivity of HCVpp to Ab 
neutralization which probably takes place by accelerating the entry of HCV via SR-
B1-mediated lipid uptake (Dreux et al., 2006). And ApoCl is able to further enhance 
infectivity by promoting fusion between viral and cellular membranes (Dreux et al., 
2007). Thus, lipids clearly play a crucial role in the infectivity and entry of viral 
particles as well as the neutralization sensitivity.     
More recently, HCV has been found to be capable of direct cell-to-cell transmission, 
which is largely resistant to Ab neutralization (Timpe et al., 2008), (Witteveldt et al., 
2009). Nevertheless, some antibodies could be detected that are able to partially 
inhibit cell-to-cell transmission. Cell-to-cell transmission requires all four entry 
receptors: CD81, SR-B1, Claudin1 and Occludin. However, SR-B1 appears to be 
particularly important (Brimacombe et al., 2011). The exact mechanism of HCV cell-
to-cell transmission is still unknown, nevertheless this route of virus transmission 
represents an ideal method of immune evasion and may explain why nAbs do not 
always clear the virus. Moreover, many other enveloped viruses, including Herpes 
Simplex Virus 1, Human T-cell Lymphotropic Virus and Measles Virus, also utilize 
this way to evade the host immune response (Mothes et al., 2010). However, as 
mentioned before it was already demonstrated that HCV cell-to-cell transmission can 
be limited by antibodies, notably those targeting HVRI (Brimacombe et al., 2011).   
Lastly, the presence of non-nAbs in patient sera has been postulated to bind distinct 
epitopes within E2 and block or inhibit the binding of nAb to neutralizing epitopes 
(Zhang et al., 2007), (Zhang et al., 2009).  
 
Involvement of the E1 protein: 
Antibodies targeting epitopes within the E1 protein are generally rare, as they can be 
detected in only a few patient sera (Pestka et al., 2007). This might be due to 
technical difficulties in detecting E1 responses which appear because of protein 
misfolding (unless co-translated with E2) (Dubuisson et al., 1994). Alternatively, the 
presence of E2 might mask E1 epitopes or be immunologically dominant (Garrone et 
al., 2011).  
 
As a result, the failure of nAbs in controlling HCV infection could be caused by 
several different factors. In an infected individual HCV can rapidly evolve into many 
quasispecies outpacing the nAb response; surrounding cells can be infected by HCV 
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through cell-to-cell contact which avoids the exposition to nAbs; virion-associated 
lipoproteins and glycans may protect the envelope glycoproteins from nAbs; and due 
to the possible enhancement of virus entry by HDL the time window during which Abs 
can bind to and neutralize the virus is reduce (Zeisel et al., 2008), (Angus and Patel, 
2011). However, all the present findings about the involvement of E2 in the humoral 
immune response are required to be fully elucidated in the future. Nevertheless, the 
importance of HVRI in this context was already clearly demonstrated. To overcome 
the natural diversity of a virus such as HCV, the generation of broadly reactive 
antibodies may represent a useful approach, suggesting that mimotope-based 
vaccines can be used as potentially effective HCV immunogens. 
 
1.4 Vaccination trials in HCV infection 
Developing a prophylactic vaccine against HCV is a complex task concerning all the 
above mentioned mechanisms of HCV to evade from immune response. However, 
since HCV infection can be cleared by an appropriate immune response, numerous 
HCV vaccine approaches have been carried out with varying degrees of success 
over the last decade. Four main vaccine strategies have been investigated in human 
clinical studies: recombinant protein vaccines, peptide vaccines, DNA vaccines and 
vector vaccines. The details of this studies are reviewed in (Halliday et al., 2011). 
However, the most promising vaccine approaches for HCV include virus-like particle 
(VLP) or rather capsid-like particle (CLP)-based vaccines that have been 
successfully applied for viral infections such as hepatitis B (Hilleman, 2001), (Kao 
and Chen, 2002). CLPs are multimeric structures that lack the viral genome but 
mimic the organization and conformation of authentic native viruses. In case of HCV 
it was already assumed that induction of a vigorous, long-lasting, and cross-reactive 
antiviral antibodies as well as a multispecific cellular immune response that includes 
both helper and cytotoxic T-lymphocytes are necessary for an effective HCV vaccine 
(rev. by (Lechmann and Liang, 2000), (Shiina and Rehermann, 2006), (Inchauspe 
and Michel, 2007), (Mikkelsen and Bukh, 2007), (Lauer and Chung, 2007), 
(Strickland et al., 2008), (Thimme et al., 2008)). Thus, CLPs bearing the HCV 
epitopes would be attractive candidates for the role of such a potent protein-
containing immunogen, which should be able to induce vigorous humoral and cellular 
immune responses. The most promising variant of such CLP is the Hepatitis B Virus 
core antigen (HBcAg) (Pumpens and Grens, 2001), which will be described in more 
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detail in the next section. However, a major intrinsic advantage of recombinant HBc 
particles is their improved immunogenicity due to formation of a covalent link 
between B- and helper T-cell epitopes (Th-epitopes), and the ability of HBcAg to act 
as both T-cell dependent and independent antigen. As a result, the HBc particles 
induce high titres of antibodies and vigorous T-cell proliferative responses. 
Furthermore, HBc-CLPs show a high epitope density on a well organised particle 
which means that foreign epitopes can be exposed to the surface and the correct 
folding of the monomeric proteins results in preservation of conformational antigenic 
determinants. Moreover, it is feasible to simultaneously insert different epitopes at 
two and, probably, three different positions. Finally, it is relatively easy to generate 
and purify recombinant HBc-CLPs to vaccine quality (Pumpens and Grens, 2001). A 
CLP approach could create new and very promising possibilities for the development 
of a prophylactic vaccine to HCV. 
In most cases vaccines are administered mixed with adjuvants, which is also the 
case in pre-clinical studies using animals. Adjuvants are substances that enhance 
the immune response to an antigen with which it is mixed (Murphy et al., 2008). By 
promoting rapid, long-lasting and broad immunity this leads to an enhanced 
protection provided by the vaccine (Pulendran and Ahmed, 2006). A lot of different 
adjuvants have been developed, each stimulating an immune response by its specific 
action. Due to their actions adjuvants can be classified into: depot/carrier-, 
immunostimulation and carrier-, and immunostimulation-adjuvants (Guy, 2007). Two 
prominent examples belonging to the class of immunistimulating and carrier-
adjuvants are, Incomplete Freunds Adjuvant (IFA) and the adjuvant AS03 which are 
water-in-oil and oil-in water-emulsions, respectively. IFA is often used in 
immunization trials in mice while AS03 is an approved adjuvant for human use, 
applied for instance in the human influenza vaccine (H5N1 A/Vietnam/1194/04 split 
virus + AS03A) (Leroux-Roels et al., 2007). While water-in-oil emulsions (like IFA) are 
believed to stimulate a TH1-response, oil-in-water emulsions (like AS03) are known to 
induce TH2-responses (Guy, 2007). These two adjuvants were also used in the 
immunization trials in the current study. 
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1.5 The Hepatitis B Virus 
The Hepatits B virus (HBV) is the causative agent of acute and chronic hepatitis in 
humans. According to the WHO, about 2 billion people worldwide have been infected 
of which approximately 350 million chronically (WHO, 2011a). However, in contrast to 
HCV, there is already a prophylactic vaccine for HBV available, consisting of viral 
surface proteins produced in recombinant yeast. HBV is the main representative of 
Hepadnaviridea. The name of this family implies hepatotrophic DNA viruses which 
show tropism of the liver and posses a circular, partially double stranded DNA as 
genetic material. The molecular biology of HBV is reviewed in detail in (World J 
Gastroenterol 2007 January 7;13(1): 22-38), (Beck and Nassal, 2007), (Nassal and 
Schaller, 1996). In short, HBV consists of 7 proteins: 3 envelope proteins (L-, M-and 
S-protein), the polymerase (P-protein), the pre-core protein, the core protein (HBc), 
and the x-protein. The HBc protein is described in more detail in the next section. 
 
1.5.1 The HBc Protein 
The HBc protein of HBV can be divided into two parts (Fig. 1.6). Firstly, an assembly 
domain consisting of the first 140 amino acids which form the protein shell of the 
nucleocapsid (Birnbaum and Nassal, 1990). This region also includes the 
immunodominant c/e1 epitope which is targeted by the most antibodies. Secondly, 
the C-terminus of the core protein (starting from amino acid 150) which covers the 
nucleic acid binding domain that binds the viral RNA.  
 
 
The core protein is largely helical with two large central helices (Fig. 1.7 A & B.). The 
central helices are connected by a flexible loop that contains the c/e1-epitope. When 
 
 
Fig. 1.6: Primary sequence of the HBV core protein 
The assembly domain contains amino acids 1-140. The immunodominant c/e1 epitope spans amino 
acids 75-82. A short linker sequence (aa 140-150) links the assembly domain with the nucleic acid 
binding domain. The nucleic acid binding domain is characterized by a large amount of basic amino 
acids (++++). 
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two core proteins form a dimer the central helices of each core protein form a four-
helix bundle that protrudes as spikes from the capsid surface (Wynne et al., 1999). 
HBV capsids consist of 240 core protein monomers arranged in icosahedral 
symmetry (Fig. 1.7 C.).  
 
A.                                 B.   C. 
 
 
Fig. 1.7: Structure of the HBV-core protein and the HBV-capsid  
A. Tertiary structure of the core monomer obtained from x-ray cristallography (Wynne et al., 1999). B. 
Structure of the core monomer obtained from cryo-electonmicroscopy (Wynne et al., 1999). The c/e1 
epitope is located at the tips of the spikes of the core protein C. 3-dimensional reconstruction of the 
HBV-capsid obtained from cryo-electronmicroscopy. The demonstrated particle with a triangulation 
number T=4 consists of 120 core-protein dimers arranged in icosahedral symmetry (Wynne et al., 
1999).   
 
As already stated above, the repetitive and symmetric arrangement of the HBV 
capsid has unique immunological features (Pumpens and Grens, 2001). HBcAg is 
able to trigger T-cell dependent as well as T-cell independent immune responses 
(Milich and McLachlan, 1986) abd the spikes of the capsid are able to unspecifically 
cross-link B-cell receptors (BCRs) (Bottcher et al., 1997). 25 ng of particulate core 
protein are able to induce immune response without any adjuvant, whereas 
denatured core protein is not (Milich and McLachlan, 1986). After investigation of the 
T-cell dependent immune response it was shown that HBV capsids which contain the 
nucleic acid binding domain and consequently also RNA (Fig. 1.6), induced 
predominantly a TH1 immune response. In contrast, HBV capsids without this domain 
rather induced a TH2-response (Riedl et al., 2002). At the same time it was shown 
that only packed RNA serves as TH1-adjuvant. The reason for this is that only packed 
RNA is able to activate intravesicular TLR-7 and 8 (Takeda and Akira, 2007). 
The core protein can be recombinantly expressed in E. coli which spontaneously 
assembles to icosahedral shaped capsid-like particles (CLPs) of extreme 
immunogenicty (Pumpens and Grens, 2001). This immunogenicity can be assigned 
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to foreign proteins especially if they are inserted into the surface exposed but 
centrally located c/e1-epitope of the core protein. The presentation of short peptides 
and selected full-length proteins like the GFP and the outer surface protein C (OspC) 
of Borrelia burgdorferi, has already been established (Skamel et al., 2006), (Kratz et 
al., 1999). However, many other foreign sequences impair the formation of CLPs. 
This originates from sterical constrains induced by the unavoidable two-sided linkage 
of the insert with the carrier protein (Walker et al., 2008). To solve this problem 
Walker et al. designed a system where the core protein is split within the c/e1-epitope 
into two fragments, CoreN and CoreC. CoreN consists of the first 80 aa, CoreC of the 
rest of the core protein either with or without the nucleic acid binding domain. When 
co-expressed in E. coli the two fragments can self-complement each other and are 
able to assemble to CLPs that are undistinguishable from wild type CLPs in 
electronmicroscopy. These so called SplitCore CLPs have now two artificial surface 
exposed termini that can be used for further protein fusions (Walker et al., 2011) (Fig. 
1.8). 
 
A. Native sequence of the HBc protein 
 
 
 
B. Sequence of the SplitCore-System  
 
 
Fig. 1.8: Schematic demonstration of the SplitCore construct 
A. In the used plasmids, translation of the core protein is initiated by a ribosome-binding-site (RBS) in 
front of the core protein. B. To split the core protein in two fragments, an artificial stop-codon is 
inserted behind proline79. Translation-initiation of the second fragment is mediated by a directly 
joined second RBS that is identical to the first RBS. 
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All the described features of SplitCore CLPs offer entirely new possibilities to use the 
concept of recombinant HBc particles as a carrier of foreign B and T-cell epitopes 
and thus for the creation of a new type of HCV immunogen.  
 
1.6 Aim of the study 
The standard antiviral therapy against HCV is successful only in 50% to 80% of 
patients and still difficult to tolerate. This makes therapy against HCV in most cases 
not satisfactory. However, due to the different genotypes and the rapid turnover rate 
of HCV which results in many distinct but closely related HCV variants found in each 
infected individual, the development of a prophylactic vaccine is a significant 
challenge. In order to circumvent the high genetic variability of HCV a new 
vaccination strategy is necessary. The most promising approach includes the 
application of capsid-like particle (CLP)-based vaccines. The CLPs formed by the 
HBV core protein (HBc), are able to induce cellular as well as humoral immune 
responses which can be used to present HCV envelope proteins. It was shown that 
the HVRI of HCV envelope protein 2 is involved in the first contact between the 
cellular receptor SR-B1 and the virus. For this reason, antibodies against this region 
are neutralizing and until now the only ones assumed to be protective. Moreover, it 
was demonstrated that the HVRI is involved in the direct spread of HCV from cell to 
cell. Despite the high variability of the HVRI, sequence data revealed that the HVRI is 
not a truly hypervariable region. It contains highly conserved residues surrounded by 
variable amino acids. The HVRI can adopt only a few related conformations which 
still allow binding its cellular receptor SR-B1. It is widely accepted that antibodies are 
able to neutralize the virus. To circumvent the problem of the high variability of the 
amino acids, artificially selected cross-reactive HVRI-variants (mimotopes), as well as 
the naturally occurring HVRI-variants, cross-reacting with a large panel of sera from 
chronically infected HCV patients, can be used. To enhance the immunogenicity of 
these short peptides and to induce vigorous humoral immune response, CLPs 
bearing these HCV epitopes should be applied. Thus, the aim of this study is to 
evaluate the innovative prophylactic vaccination strategy based on HBc-CLPs, 
expressing different variants of the HVRI in mice and guinea pigs. 
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In order to achieve this goal, the following steps are performed: 
• Generation of plasmids bearing different variants of the HVRI.  
 
• Testing the generated recombinant particles for their expression, the ability to 
self-assemble and maintain the antigenicity of the inserted foreign epitopes.  
 
• Evaluation of the ability of the HVRI-CLPs to induce specific and broad cross-
reacting antibodies against the HVRI in mice and guinea pigs. 
 
• Characterization of the cross-neutralizing HVRI-antibody response using the HCV 
pseudoparticle-system.  
 
As a result of the project we expect to generate a set of recombinant HVRI-CLPs 
which induce antibodies with a broad neutralizing activity and can be used as a 
prototype HCV vaccine. 
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2 Materials  
2.1 Laboratory animals 
2.1.1 Wild-type mice 
Ten weeks old female C57BL/6 mice (genotype H-2b/b) were kept under specific 
pathogen-free (SPF) conditions in Essen. The mice had free access to drinking water 
and standard food. They were purchased from Harlan Winkelmann Laboratories 
(Borchen, Germany).  
 
2.1.2 Guinea pigs 
Six weeks old female guinea pigs (Cavia procellus) were kept in Cairo, Egypt with 
cooperation partners. 
 
2.2 Anesthetics 
Isofluran        Delta Select, Germany 
 
2.3 Bacteria strains 
Eschrichia coli BL21*CP     F– ompT gal [dcm] [lon] hsdSB 
(Novagen, USA)  (rB–mB–;an E.coli B strain) with 
E3, a λ prophage carrying the 
T7 RNA polymerase gene 
     
Eschrichia coli Top10     F-mcrA Δ(mrr-hsdRMS-mcrBC)  
(Invitrogen, Germany) φ80lacZΔM15 ΔlacX74 nupG 
recA1 araD139 Δ(ara-leu)7697 
galE15 galK16 rpsL(StrR)endA1 
λ- 
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Eschrichia coli XL-10 Gold    endA1 glnV44 recA1 thi-1 
(Stratagene, USA)  gyrA96 relA1 lac Hte 
(mcrA)183 Δ(mcrCB-hsdSMR-
mrr)173 tetRF'[proAB 
lacIqZΔM15 Tn10(TetR Amy 
CmR)]    
   
2.4 Eukaryotic cell lines 
2.4.1 Human Hepatoma cell line Huh7.5  
Huh7.5 cells are a subline derived from Huh7 hepatoma cells (Blight et al., 2002). 
Huh7 cells were established from hepatocellular carcinoma which was found to 
replicate continuously in a chemically defined medium (Nakabayashi et al., 1982). 
The subline Huh7.5 was established by “curing” a cell clone containing a Con1 
subgenomic replicon by prolonged treatment with α-interferon. The receptors, 
important for the initiation of virus entry, are expressed on the viral surface and can 
therefore be used for studying virus entry. 
 
2.4.2 Human Embryonic Kidney 293T cells 
293T cells are modified 293 cells that constitutively express the Simian Virus 40 (SV-
40) large T-antigen (Patel and Tikoo, 2006). The presence of this antigen allows 
episomal replication of transfected plasmids containing the SV40 origin of replication. 
In the current study 293T cells were used for generation of HCVpp. 
 
2.5 Chemicals and reagents 
Acetic acid, Cesium chloride, EDTA solution pH 8.0,  
Saccharose, SDS (sodium dodecyl sulphate), Tween 20  AppliChem, Germany  
 
Acrylamide solution, Ethidium bromide,  
Hydrogen peroxide, LB-Agar (Luria/Miller),  
LB Medium (Luria/Miller), Milk powder    Roth, Germany 
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Boric acid        JT Baker, Netherlands 
 
Bradford staining solution      BioRad, Germany 
 
BSA (bovine serum albumin) fraction IV    Serva, Germany 
 
D-PBS, TBE ultrapure 10x, Trypan Blue, Trypsin  Invitrogen, Germany 
 
Glycine, Tris-Base        MP Biomedicals,  
         Germany 
 
HEPES, Non essential amino acids    PAA Laboratories,  
         Austria 
 
Plasmocin 25mg       Invivogen, Germany 
 
Potassium chloride, Potassium dihydrogenphosphate,  
Sodium acetate, Sodium azide, Sodium carbonate,  
Sodium chloride, Sodium dihydrogenphosphate, Sodium 
hydrogencarbonate, Sodium oxide    Merck, Germany 
 
β-mercaptoethanol, Agarose, APS (ammonium persulfate),  
Bromophenol blue, DMSO (Dimethyl sulfoxide), Ethanol,  
Freund’s Adjuvant Incomplete, Glycerol, Hydrochloric acid,  
Isopropanol, Methanol, OPD tablettes  
(o-Phenylenediamine), Orange G, TEMED, Triton X-100,  
Triton X-114         Sigma, Germany 
 
2.6 Antibiotics 
Ampicillin        AppliChem, Germany 
Carbenicillin        Serva, Germany 
Chloramphenicol      AppliChem, Germany 
Kanamycin        AppliChem, Germany 
Penicillin/Streptomycin      PAA Laboratories, Austria 
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2.7 Cell culture media 
Huh7.5 cell line      DMEM medium 
10% FCS 
1% Penicillin/Streptomycin 
1% HEPES 
1% Non essential amino acids 
 
HEK-293T cell line      DMEM medium 
10% FCS 
1% Penicillin/Streptomycin 
 
2.8 Buffers and solutions 
Coomassie Brillant-Blue Staining Solution 0.06% (w/v) Coomassie brillant-
blue R250 
 50% (v/v) Methanol 
 10 % (v/v) Acetic acid 
 
Carbonate buffer (pH 9.6) (ELISA)   3.18 g Na2CO3 
5.88 g NaHCO3 
0.2 g NaN3 
1 L H2O 
 
Destaining Solution      5 % (v/v) Methanol 
        7.5 % (v/v) Acetic acid 
 
Blocking solution (ELISA)     PBS 
5% (v/v) FCS 
 
T-PBS washing buffer (ELISA / Western blot)  PBS 
Tween 20 
 
OPD-substrate solution (ELISA)    o-Phenylenediamine (1 pill) 
10 ml PBS 
10 μl H2O2 
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STOP solution (ELISA)     0.5 N H2SO4 
 
5x DNA loading buffer     50% Glycerine 
        20 mM Tris, pH 7.5  
        50 mM EDTA, pH 8.0 
        0.025% Bromphenoleblue 
        0.025% Xylenecyanole 
 
1x TBE buffer (pH 8.4)     100 mM Tris Base 
90 mM boric acid 
1 M EDTA 
 
TTBS buffer       10 mM Tris-HCl pH 8.8 
        50 mM NaCl 
        0.2% Tween 
 
Buffer P1, pH 8.0 (plasmid preparation)   50 mM Tris Base 
12 mM Na2EDTA H2O 
100 mg RNAse 
1L H2O 
 
Lysis buffer P2 (plasmid preparation)   200 mM NaOH 
35 mM SDS 
 
Neutralisation buffer P3 (plasmid preparation)  3 M potassium acetate 
150 ml acetic acid 
1 L H2O 
 
1x TAE buffer      40 mM Tris 
        5.7 % Acetic acid 
        50 mM EDTA pH 8.0 
 
1x TE buffer (pH 8.0)     1 % (v/v) 1 M Tris-HCl 
1 mM EDTA 
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4x SDS loading buffer     Glycerine 10 % 
SDS 4 % 
Tris, pH 6.8, 125 mM 
ß-Mercaptoethanol 10 % 
Bromphenol-blue 0.02 % 
 
Blocking solution (Western blot)    PBS 
5% (m/v) milk powder 
 
10x SDM reaction buffer     100 mM KCl 
100 mM (NH4)2SO4 
200 mM Tris-HCl (pH 8.8) 
20 mM MgSO4 
         1% Triton X-100 
1 mg/ml BSA 
 
Transfer buffer (Western blot)    72 g glycine 
15 g Tris Base 
25 ml 20% SDS 
1L H2O 
 
TN150 buffer (Protein expression preparation)  20 mM Tris-HCl, pH 7.5 
150 mM NaCl 
 
TN300 buffer (Protein expression preparation)  20 mM Tris-HCl, pH 7.5 
        300 mM NaCl 
 
TNE buffer       10 mM Tris-HCl pH 7.5 
        150 mM NaCl 
        1 mM EDTA 
 
Coating buffer (ELISA)     0.1 M Carbonate buffer 
        H2O 
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2.9  Enzymes and commercial Kits 
Benzonase (250 U/µl)     Novagen, USA 
Bright-Glo Luciferase Assay System   Promega, Germany 
CalPhos mammalian transfection kit   Clontech, Germany 
ELC Western Blotting Detection Kit    GE Healthcare, UK  
Gen Elute Plasmid Miniprep Kit    Qiagen, Germany  
Glo Lysis Buffer      Promega, Germany 
Go Taq-Polymerase (1 U/µl)    Promega, Germany 
Limulus Amebocyte Lysate Pyrotell    Cape COD, USA 
KOD-Polymerase (2.5 U/µl)    Novagen, USA 
Lysozyme (46 U/µl)      Sigma, Germany 
pcDNA3.1/V5-His TOPO TA Expression Kit  Invitrogen, Germany 
Protease inhibitor cocktail complete   Roche, Germany  
QIAprep Mini-, Maxiprep Kit     Qiagen, Germany 
QIAprep Gel Extraction Kit (250)    Qiagen, Germany 
QIAquick PCR purification Kit (50)   Qiagen, Germany 
Restriction endonucleases (10 U/µl)    NEB, Germany 
T4-DNA-Ligase (20 U/µl)     NEB, Germany 
 
2.10 . Standards 
PeqGold Protein-Marker I     PeqLab, Germany 
PeqGold Prestained Protein-Marker IV   PeqLab, Germany 
Protein-MW-Marker (Low Range Rainbow)  GE Healthcare, UK 
GeneRuler 1kb Ladder Plus     Fermentas, Germany 
 
2.11 . Plasmids 
The plasmids used in this project are shown and described in the appendix section 
9.1.  
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2.12 . Antibodies 
Monoclonal mouse anti-HBV-Core antibodies 10E11, 11E2, 13C9 and CET4 used for 
Western blotting analysis, were kindly provided by Prof. Paul Pumpems (Latvian 
Biomedical Research and Study Centre, Riga, Latvia), Prof. Yuri Khudyakov (Centers 
For Disease Control and Prevention, Atlanta, USA) and C. Yuli Kong (South Korea). 
Manufacturer information of the other antibodies are also listed in table 2.1. 
 
Tab. 2.1 Antibodies and conjugates 
 
Antibody Usage  Manufacturer 
monoclonal mouse anti-HBV-Core 
(10E11) 
Western blot P. Pumpens, Riga, 
Latvia 
monoclonal mouse anti-HBV-Core 
(11E2) 
Western blot P. Pumpens, Riga, 
Latvia 
monoclonal mouse anti-HBV-Core 
(13C9) 
Western blot P. Pumpens, Riga, 
Latvia 
monoclonal mouse anti-HBV-Core 
(10E11) 
Western blot Dianova 
monoclonal mouse anti-HBV-Core 
(13A9) 
Western blot Dianova 
monoclonal mouse anti-rabbit, 
HRP-coupled 
Western blot 
ELISA 
Dianova 
monoclonal guinea pig anti-rabbit, 
HRP-coupled 
ELISA Dianova 
monoclonal human anti-HBV-Core 
(3120) 
Western blot Dianova 
monoclonal goat anti-mouse IgG1, 
HRP-coupled 
ELISA SouthernBiotech 
monoclonal goat anti-mouse IgG2a, 
HRP-coupled 
ELISA SouthernBiotech 
monoclonal goat anti-mouse IgG2b, 
HRP-coupled 
ELISA SouthernBiotech 
monoclonal goat anti-mouse IgG3, 
HRP-coupled 
ELISA SouthernBiotech 
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2.13 . Peptides 
Peptides used for coating in ELISA assays (500 ng/well) were synthetized by EMC 
microcollections (Germany). Other peptides were kindly provided by Prof. Yuri 
Khudyakov (Centers For Disease Control and Prevention, Atlanta, USA). The list of 
peptides is shown in table 2.2. 
Lyophilisates of peptides were diluted in PBS containing 10% DMSO to the 
concentration 1mg/ml, aliquoted and stored at -20 °C. 
ELISA plates were also coated with protein (50 ng/well) pET28a2-HBc_c1-79_80-
149H6 (149-St1), the vector-card is shown in the appendix. 
 
Tab. 2.2 Peptides 
 
Name Sequence 
R9 (H16) QTTVVGGSQSHTVRGLTSLFSPGASQN 
YK5807 (H19) VTYTTGGSQARHTQGVASFFTPGPAQK 
YK5829 (H20) TTTVSGGHASQITRGVTSFFSPGSAQK 
G31 (H21) TTHTVGGSVARQVHSLTGLFSPGPQQK 
preS2pep1 MKNQTFRLQGFVDGL 
 
 
2.14 . Membranes and films 
PVDF membrane      Millipore, Germany 
High performance chemiluminescence film  GE Healthcare, UK 
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2.15 . Oligonucleotides 
All oligonucleotides used in the study were synthesized by Biomers (Germany). The 
nucleotide sequence, annealing temperature (Tann) employed for PCR and usage of 
the oligonucleotides are presented in table 2.3. 
 
Tab. 2.3 Oligonucleotides 
 
Primer Orientation Sequence (5’ -> 3’) Tann 
[°C] 
Usage 
Primer-(-)-HVR-
AP33-CoreN 
anti-sense gtt tta gga tcc tca ttg ctg ttt 
agg gca gtt ctg 
- cloning 
Primer-(-)-HVR-
AP33-CoreC 
anti-sense ccc acc tct aga gtc att gct gtt 
tag ggc agt tct g 
- cloning 
Primer-(-)-HVR-
R9 
anti-sense ggt gtg ggt agg atc ctc gtt ctg 
aga agc acc ccg 
60 PCR 
Primer-(-)-HVR-
G31 
anti-sense gcc taa gga tcc tct ttc tgc tgc 
gga ccc gga gag aac aga ccg 
gtc aga gaa tga acc tgg cga 
gc aac aga acc acc cac aag 
tat ggg tct gtc cgg 
60 PCR 
Primer-(-)-HVR-
YK5807 
anti-sense gcc taa gga tcc tct ttc tag ccg 
gac ccg ggt gaa gaa aga agc 
aac acc ctg ggt gtg acg agc 
ctg aga acc acc ggt ggt gta 
agt aac ctg tcc gga gcc acc 
60 PCR 
Primer-(-)-HVR-
YK5829 
anti-sense gcc taa gga tcc tct ttc tga gca 
gaa ccc gga gag aag aaa gag 
gta aca cca cgg gtg atc tga 
gaa gcg tgt cca cca gag acg 
gta gtg gtc tgt ccg gag cc 
60 PCR 
 
 
 
 
Primer-(+)-
HCVpp-R9 
sense gct ggc gtc gac ggc cag acc 
act gtt gtg ggt ggt tct cag tct 
cac acc gtt cgt ggt ctg acc tct 
ctg ttc tct ccc ggg gct tct cag 
aac atc cag ctt ata aac acc 
60 PCR 
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Primer-(+)-
HCVpp-G31 
sense gct ggc gtc gac ggc acc acc 
cat act gtg ggt ggt tct gtt gct 
cgc cag gtt cat tct ctg acc ggt 
ctg ttc tct ccg ggt ccg cag cag 
aaa atc cag ctt ata aac acc 
60 PCR 
Primer-(+)-
HCVpp-YK5807 
sense gct ggc gtc gac ggc gtt act tac 
acc acc ggt ggt tct cag gct cgt 
cac acc cag ggt gtt gct tct ttc 
ttc acc ccg ggt ccg gct cag 
aaa atc cag ctt ata aac acc 
60 PCR 
Primer-(+)-
HCVpp-YK5829 
sense gct ggc gtc gac ggc acc act 
acc gtc tct ggt gga cac gct tct 
cag atc acc cgt ggt gtt acc tct 
ttc ttc tct ccg ggt tct gct cag 
aaa atc cag ctt ata aac acc 
60 PCR 
Primer-(+)-
HCVpp-J6-M22P 
sense cca ccg ggc gcc tga ccg cct 
gtt cga ccc ggg tcc ccg gca g 
60 PCR 
Primer-(+)-
HCVpp-J6 
 
sense gct ggc gtc gac ggc cgc cca 
cac cgt ggg cgg cag cgc cgc 
cca gac cac cgg gcg cct gac 
cag cct gtt cga cat ggg tcc 
ccg gca gaa aat cca gct tat 
aaa cac c 
60 PCR 
 
 
 
 
 
Primer-(-)-
pHCMV-Minus-
BglII 
anti-sense ggc aga ggg aaa aag atc tca 
gtg g 
52 PCR 
 
 
Primer-(-)-
phCMV-IRES-
E1+E2  
anti-sense gcc acc acc ttc tga tag gc - sequencing 
T7-promotor sense att aat acg act cac tat agg g 
 
- sequencing 
PCR 
T7-terminator anti-sense gct agt tat tgc tca gcg g - sequencing 
pcDNA3.1 anti-sense tag aag gca cag tcg agg ct - sequencing 
SV711 anti-sense tat gta cgt ggg gga tct ttg - sequencing 
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2.16 . Materials and equipment 
Balance Vibra AJ-2200CE    Shinko Denshi, Japan  
Beakers       Schott, Germany  
Capillaries (heparinised)     Hirschmann Laborgeräte, Germany 
Cell culture flasks (250 ml)    Greiner bio-one, Germany 
Cell culture plates (96-well)    Greiner bio-one, Germany  
Centrifuge Rotina 420R    Hettich, Germany 
Centrifuge Avanti J-26XPi    Beckman Coulter, Germany 
Centrifuge: Ultracentrifuge Optima L-70K  Beckman Coulter, Germany 
Centrifuge tubes (14x95 mm, 25x89 mm) Beckman Coulter, Germany 
Centrifuge 5415D      Eppendorf, Germany 
Combitips (2.5 ml; 5 ml, 10 ml)    Eppendorf, Germany 
Concentration tubes (Centricon; 30K, 100K)  Millipore, Germany  
CO2 incubator Cytoperm2    Heraeus, Deutschland 
Cryo-tubes (2 ml)      Greiner bio-one, Germany 
Dialysis tubes      Spectrapore, USA 
Dialysis cassettes      Pierce, USA 
Dishes; 10 cm2 also for cell culture  Greiner bio-one, Germany 
Disposable scalpels     HMD Healthcare, UK 
Disposable syringes (2 ml; 5 ml; 10 ml)   B. Braun, Germany 
Erlenmeyer flasks      Schott, Germany  
Electronmicroscope EM 902A   ZEISS, Germany 
Electrophoresis chambers    BioRad, Germany  
Elisa Reader Asys Expert Plus   Asys Hiteck 
Fridge / Freezer (-20 °C)     Liebherr, Germany 
Freezer (-80 °C)      Thermo Forma, Germany 
Flat-bottom 96-well microplates   Falcon BD, Germany 
Forceps (pointed and curved)    Oehmen, Germany  
Gel running chamber    peqLab, Germany 
Glomax Multi Detection System   Promega, Germany 
Heating block (Thermo mixer comfort)  Eppendorf, Germany 
Laminar flow (Hera Safe)     Heraeus, Germany 
Microscope (inverted) Primo Vert   ZEISS, Germany 
Micro screw-cap tubes (1.5 ml)   Sarstedt, Germany 
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Needles (0.4x19 mm; 0.9x40 mm)   Becton Dickinson, Germany 
NUNC Immunoplates (96-well)    NUNC, Denmark 
Parafilm       American National Can, USA 
Pipette tips (10 μl; 200 μl; 1000 μl)   STARLAB, Germany 
Plastic sterile pipettes (5 ml; 10 ml; 25 ml)  Greiner bio-one, Germany 
Reaction tubes (1.5 ml; 2 ml)    Eppendorf, Germany 
Rotary Mixer 526     Oehmen, Germany 
Scissors       Oehmen, Germany 
Screw-cap tubes (15 ml; 50 ml)    Falcon BD, Germany  
Single-, multichannel pipettes, multipettes  Eppendorf, Germany 
Shaker (GFL 3020)     GFL, Germany 
Shaker (Duomax 1030)    Heidolph, Germany 
Sonicator (Labsonic P)    Sartorius, Germany 
Spectrophotometer (Gene Quant pro)   Amersham Bioscience, USA 
Spectrophotometer Ultrospec III   Pharmacia LKB 
Thermocycler 3000     Biometra, Germany 
Thermocycler MJ Mini    BioRad, Germany 
Thermoshaker      Gerhardt, Germany 
Neubauer cell counting chamber   Marienfeld, Germany 
Transblot SemiDry transfer cell    BioRad, Germany 
UV transiluminator FLX-20M MWG  BioTech, Germany  
UV- Bioimaging System     Syngene 
Vacuum pump Integra Vacusafe   Integra, Germany 
Vortex Genie 2      Bender & Hobein AG, Switzerland 
Vortexer PV-1     Grant-bio, Germany 
Waterbath Julabo ED    Julabo, Germany 
Whatman Paper      Whatman, Germany 
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3 Methods  
3.1 Working with prokaryotic cells 
3.1.1 Transformation of chemically competent E. coli strains 
Bacterial cells (Top10 cells, XL10-Gold cells or BL21*CP cells (for strain specific 
information see 2.3.) frozen at -80 °C were thawed on ice. No more than 10% by 
volume of the DNA to be transformed was added to 50 µl bacterial cells. This mixture 
was incubated on ice for 10 minutes. To improve DNA absorption by bacteria, a heat 
shock was performed for 1 minute at 37 °C followed by a subsequent incubation on 
ice for 5 minutes. To express the resistance encoded by the transformed plasmid, the 
mixture was incubated in a shaker for 30 minutes at 37 °C after the addition of 120 µl 
LB-medium. Using a sterile spatula the complete mixture was spread over an LB-
agar plate containing the selective antibiotic. The plate was incubated over night at 
37 °C. 
 
3.1.2 Plasmid DNA preparation using commercial kits 
One bacterial colony obtained after transformation (3.1.1.) was picked and 
transferred to a flask containing LB-medium and the appropriate antibiotic (5 ml of 
medium for minipreps, 100 ml for midipreps, and 250 ml for maxipreps). The bacterial 
culture was incubated shaking at 37 °C over night. Plasmid-DNA was isolated using 
the Qiaprep kits (Qiagen) according to the manufacturer’s protocol. Purified DNA was 
resuspended in TE buffer and adjusted to a concentration of 1 µg/µl by 
spectrophotometric OD260nm measurement.  
 
3.1.3 Cultivation of E.coli for protein expression 
Competent E.coli BL21*CP cells were used for production of protein. After 
transformation (3.1.1.) and incubation over night, 5 ml of LB-medium (containing 
ampicillin and chloramphenicol) was inoculated with one colony and incubated on a 
shaker over night at 37 °C. Two and a half ml of this overnight culture was added to 
250 ml LB-medium (containing ampicillin and chloramphenicol) and cultured shaking 
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at 37 °C until reaching OD600 of 0.6-0.8. Afterwards, protein production was induced 
with 1 mM IPTG and the culture was incubated at romm temperature (RT). After 3 to 
5 hours (alternatively over night) the culture was centrifuged 15 minutes at 5,000 rpm 
and 4°C. The supernatant was discarded, the precipitate was resuspended in 25 ml 
TN300 and centrifuged again for 15 minutes at 5,000 rpm and 4 °C. The supernatant 
was discarded and the precipitate was stored at -20 °C until further analysis.  
 
3.1.4 Cell Disruption under non-denaturing conditions 
To extract protein from E.coli cells, the frozen cell pellet of the induced culture 
(3.1.5.) was thawed on ice and resuspended in 5 ml TN150 buffer. One mg/ml 
lysozyme, Triton X-114 (1.5 %) and protease inhibitor was added to the mixture. 
Lysis of the cells was performed by incubation on ice for 15 minutes. Nucleic acids 
were fragmented by addition of 10 U/ml benzonase and incubation for 10 min at RT 
while shaking. For complete cell lysis, cells were sonicated. Cell lysate was 
transferred to a 15 ml Falcon-Tube and for 2 minutes exposed to sonication at 50% 
and 1 minute cooled on ice. This procedure was repeated once. Insoluble proteins 
and cell debris were sedimented by centrifugation at 4 °C for 15 min and 14,000 rpm. 
To separate membrane vesicles the supernatant was transferred into a new Falcon-
Tube and incubated at 30 °C for 5 min which leads to phase separation of TX-114. 
Afterwards, this mixture was centrifuged at 25 °C for 15 minutes at 4000 rpm. The 
supernatant was layered over a SW40 sucrose-gradient which was then centrifuged 
for 2 hours at 20 °C and 40,000 rpm. 
 
3.2 Cell Culture 
3.2.1 Thawing of cells 
Cryo tubes containing cells were taken out of liquid nitrogen and thawed quickly. 
Afterwards, cells were suspended in 18 ml of fresh medium, placed in a 75 cm2 flask, 
and cultured at 37 °C in humidified atmosphere containing 5% CO2. 
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3.2.2 Cryoconservation of cells 
For cryoconservation, the cell suspension was centrifuged in 50 ml tubes (1200 rpm, 
5 min) and washed once with 5 ml sterile PBS. The pellet was suspended in 900 µl 
FCS and 100 µl DMSO. Cells were frozen slowly overnight in -80 °C and then 
transferred to a liquid nitrogen tank. 
 
3.2.3 Passaging of cells 
Medium was removed from adherent Huh7.5 cells and cells were washed with 5 ml 
sterile PBS. Then 3 ml of Trypsin-EDTA was added to cover the bottom of the 75 cm2 
flask. After approximately 2 minutes when the cells started to detach from the bottom 
10 ml of fresh DMEM medium was added. Cells were placed in fresh flasks in 18 ml 
of culture medium in the designated concentration.  
 
HEK-293T cells are less adherent compared to Huh7.5 cells, therefore medium was 
removed and cells were resuspended in 10 ml fresh DMEM medium. Afterwards, 
cells were placed in fresh flasks in 18 ml of culture medium in the designated 
concentration. 
 
3.2.4 Counting of viable cells using Trypan blue exclusion microscopy 
Trypan blue is a negatively charged dye that only interacts with a cell when the 
membrane is damaged. Therefore, all cells which exclude the dye are viable. 
Aliquots of the cell suspension were diluted 1:10 with Trypan blue stain and 10 μl of 
the diluted aliquot solution was transferred onto a Neubauer hemocytometer. The 
viable cells were counted and the number of cells per ml was calculated as follows: 
 
number of cells / ml = number of cells in the large square × dilution factor × 104 
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3.2.5 Transfection of HEK-293T cells 
HEK-293T cells were harvested and seeded in a 10 cm2 dish at a final concentration 
of 2.5 x 106 cells in 8 ml medium (20-30 % confluence). Prior to that, dishes were 
coated with 2 ml Poly-L-Lysine hydrobromide and washed with PBS. After dishes got 
dry, cells were added. The next day, cells were transfected with the expression 
plasmid phCMV IRES-E1/E2 in combination with a retroviral plasmid encoding for 
HIV-Gag,Pol and Luc (pHCMV-IRES-AD78-E1E2) using the Calcium Phosphate 
Transfection Kit (Clontech). One to 2 h before transfection of the cells, the medium 
was exchanged. Briefly, 500 μl HBS were put in a FACS tube. Next, using an 
Eppendorf tube 1.5 ml, the mix was prepared as follows: 
 
Tab. 3.1 Mix for the generation of HCVpp 
 
Reagent Concentration Volume [µl] 
H2O - 432.6 
Plasmid encoding Gag, Pol, Luc 1 µg/µl 2.7 
phCMV IRES-E1/E2 1 µg/µl 2.7 
CaCl2 solution (added dropwise) 2M 62 
  500 
 
This mix was added dropwise and under constant slight mixing to the tube containing 
500 μl HBS and incubated for 20 to 30 min at room temperature. Afterwards the 
solution was added dropwise to the cell culture. The dishes were incubated up to 16 
h at 37 °C. Medium was changed and the cell culture was additionally incubated for 
48 h at 37 °C. Every 24 h the supernatant containing the generated HCVpp’s was 
harvested and centrifuged for 5 min at 1200 rpm. The HCVpp preparation was kept 
at 4 °C (not longer than 4 days) and used for infectivity assay or neutralization assay. 
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3.2.6 Infectivity assay 
Huh7.5 cells were seeded in 96 flat bottom well plates. (5 x 103 cells in 100 ml). The 
next day, the medium was removed and HCVpp in 100 μl of medium was added. 
One hundred μl of fresh pre-warmed DMEM medium (containing 6% FCS) was 
added and plates were incubated for additional 72 h at 37 °C. For infectivity 
evaluation, medium was removed and 50 μl of lysis buffer (Promega) was added to 
each well and incubated for 2 h at -20 °C. Afterwards, 50 μl of prepared cell lysat 
were transferred into a luminometer 96-well plate. Fifty μl of the Bright Glo Luciferase 
Assay buffer (Promega) was added and the luciferase-activity was measured after 10 
minutes incubation time at RT in the luminescence counter (Glomax Multi Detection 
System, Promega). All cell lysates were measured in triplicates and the mean value 
was calculated. 
 
3.2.7 Neutralization assay with HCVpp’s 
Huh7.5 cells were seeded one day before preparation of neutralization assay as 
described in 3.2.6. Dilutions of mouse or guinea pig sera were prepared in DMEM 
and stored at 4 °C until the next day. The following day, HCVpp’s (harvested 4 days 
before) were mixed with the diluted sera, and incubated for 2 h at 37 °C. Afterwards, 
the mixture of HCVpp with sera in the volume of 120 μl plus 100 µl DMEM medium 
(containing 6% FCS) was added to Huh7.5 cells. The plates were incubated for 72 h 
at 37 °C. For infectivity evaluation was done as described in 3.2.6. The luciferase 
activity of all cell lysates was measured in triplicates and a mean value was 
calculated. Inhibition of infectivity by more than 50 % was considered as a positive 
neutralization. 
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3.3 Molecular biology methods 
3.3.1 Polymerase Chain Reaction  
Polymerase chain reaction is used for the amplification of DNA sequences. Therefore 
the double-stranded template DNA is denatured by heating to 95 °C. After cooling 
specific single stranded DNA-primers are able to bind to the template DNA due to 
their specific character which determines temperature (annealing temperature; TM). 
This temperature can be calculated using the following formula:   
 
TM in °C =Σ(2(A +T) + 4(G +C)) 
 
For elongation of the primer, and amplification of the DNA sequence, the PCR 
mixture is kept at a temperature at which the used polymerase is able to work best. 
This cycle; denaturation, binding of the primer and elongation, is repeated several 
times. Subsequently, the mixture is heated to 72 °C which aids the polymerase to fill 
up incomplete strands.   
The reaction mixture components and the PCR conditions used in this project are 
presented in tables 3.2 and 3.3. 
 
Tab. 3.2 Standard PCR mastermix 
 
Reagent Concentration Volume [µl] 
Template DNA  1 μg/μl 0.5  
Primer 5’- 3’  100 pmol/μl 1.0 
Primer 3’- 5’  100 pmol/μl 1.0 
MgCl2  25 mM 6.0 
dNTPs  per 10 mM 2.5 
KOD - buffer  10x 10.0 
KOD - Polymerase  2.5 U/µl 0.5 
H2O - 78.5 
  50 
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Tab. 3.3 Standard PCR Programme  
 
PCR step Temperature [°C] Time [min] Number of cycles 
Denaturation 95 5 1 
Denaturation 
Annealing 
Elongation 
95 
52-60* 
72 
0:30 
0:30 
0:30  
 
20 
Final elongation 72 5 1 
Storing 4 for ever - 
* The annealing temperature depends on the primer which was used in the PCR. 
Primer specific annealing temperatures are listed in table 2.3. 
  
3.3.2 DNA restriction digest 
To specifically cut plasmids and PCR-products, they were subjected to restriction 
digest either with a single endonuclease or with a combination of two enzymes. In the 
latter case, the set of restriction enzymes that work optimally in the same reaction 
buffer and temperature (usually 37°C) were chosen. The PCR products used for 
restriction were previously purified by gel extraction (3.3.4.). For preparative 
purposes 50 μl of restriction reaction was prepared and incubated 1-3 h (alternatively 
over night) at the optimal temperature given by the provider. The control digestion of 
successful cloning was carried out in 20 μl reaction for 1 h (Tab. 3.4). 
 
Tab. 3.4 Restriction of plasmids and PCR-products 
 
Reagent  Preparative digestion Control digestion 
DNA 5 µg 10  µl 
Enzyme I 0.5 – 1 µl 0.25 µl 
Enzyme II 0.5 – 1 µl 0.25 µl 
10x buffer 5 µl 2 µl 
10x BSA (if required) 5 µl 2 µl 
H2O add 50 µl add 20 µl 
 
The products of the restriction reaction were separated by agarose gel 
electrophoresis and purified using the QIAquick Gel Extraction Kit (Qiagen) (3.3.4.). 
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3.3.3 Agarose gel electrophoresis 
Gel electrophoresis is used for the separation of molecules according to their mass. 
In agarose gels, agarose forms a netlike matrix in which DNA fragments can be 
separated. After applying voltage (mostly 80 - 120 V) the smaller fragments move 
faster through the gel than shorter ones. For the separation of DNA fragments of 
approximately 300 to 2,500 bp, a 1.0 % agarose gel was used (10 ml 1x TAE-buffer 
per 0.1 g agarose). To visualize the DNA after separation, ethidium bromide was 
added. The visualization of the separated DNA fragments was performed using a 
UV- Bioimaging System (Syngene). 
 
3.3.4 DNA extraction from agarose gels  
After separation of DNA (from restriction digest or PCR) on an agarose gel, DNA can 
be extracted from the agarose and used for further analysis. Therefore, the desired 
DNA fragment was cut out of the gel (visualized by UV light) and stored in an 
Eppendorf tube. DNA extraction was done using the QIAprep Gel Extraction Kit (250) 
according to the manufacturer’s protocol.  
 
3.3.5 Cloning of PCR-products in intermediate plasmids 
An easy step for rescue of PCR products is the usage of the invitrogen pTOPO-
vector. The pTOPO-vector is a linearized plasmid with single overhanging 3’ 
deoxythymidine (T) residues that are kept together by the topoisomerase. Taq 
polymerase shows a terminal transferase activity which is nontemplate-dependent 
and adds a single deoxyadenosine (A) to the 3’ ends of PCR products, which then 
are inserted by the topoisomerase into the pTOPO-vector. As already mentioned, the 
plasmid vector (pcDNA3.1/V5-His-TOPO; Invitrogen) has single overhanging 3’ 
deoxythymidine (T) residues which allow PCR inserts to ligate efficiently with the 
vector (Invitrogen, 2004). For insertion, the PCR product was stored on ice and 1 µl 
Go Taq-Polymerase was added. This mixture was incubated at 72 °C for 10 minutes 
and cooled on ice afterwards. The pTOPO cloning mixture was prepared as follows 
after manufacturer’s protocol: 
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Tab. 3.5 pTOPO cloning mixture 
 
Reagent Volume [µl] 
PCR product (treated with Taq) 2.0  
Salt solution 1.0 
pTOPO3.1-vector 1.0 
H2O 2.0 
 6.0 
 
After mixing and centrifugation of this mixture, the sample was incubated for 
10 minutes at RT. Two µl mixture was added to 25 µl TOP 10 cells following standard 
transformation procedure (3.1.1.). Alternatively, 1 µl solution was added to 25 µl XL 
10 Gold cells.  
 
3.3.6 Ligation of DNA fragments 
For the ligation of DNA fragments T4-DNA-ligase was used. 
 
Tab. 3.6 Ligation mixture 
 
Reagent Volume / Concentration 
Vector 50-200 ng  
Fragment 100-400 ng 
10x t4-buffer 2.0 µl 
H2O add 20 µl 
 
0.5 µl T4-DNA-ligase was added to this mixture and incubated for at least 1 h at RT. 
After transformation (3.1.1.), single clone picking and Mini-DNA preparation (3.1.2.) 
of TOP 10 cells (alternatively XL 10 Gold cells) with 2.5 µl ligation solution, the 
isolated plasmid-DNA was tested for correctness using restriction digest (3.3.2.) or 
sequencing methods (3.3.7.).   
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3.3.7 DNA-Sequencing 
Sequencing was outsourced to the company AGOWA in Berlin. Primers used for 
sequencing are indicated in table 3.7. A standard sequencing mixture is shown in the 
table below. 
 
Tab. 3.7 Sequencing mixture 
 
Reagent Volume / Concentration 
Plasmid DNA 0.5-1 ng  
Primer 20 ng* 
H2O add 14 µl 
          * was added either by self or by AGOWA 
 
3.4 Protein-biochemical methods 
3.4.1 Determination of the protein concentration 
To determine protein concentration the Bradford method was used. For that, 10 µl 
standard BSA concentrations (50 ng, 75 ng, 100 ng, 200 ng, 300 ng, 500 ng) as well 
as 10 µl of a 1:2, 1:5 and 1:10 dilution of the protein-solution to be measured were 
added to a 96-well plate. Subsequently, 200 µl of a 1:5 diluted Bradford solution were 
added to each well and incubated for 5 minutes. Finally, the absorption at 595 nm 
was measured and the protein concentration was calculated in consideration of the 
dilution factor.   
 
3.4.2 SDS-PAGE 
In discontinuous SDS-PAGE (sodiumdodecylsulfate-polyacrylamide-gel 
electrophoresis) proteins are separated due to their denaturation with SDS and 
hence consistent negative charge. Separation occurs predominantly according to the 
mass of the proteins. During electrophoresis samples are focused in the stacking gel 
and subsequently separated within the separation gel. Prior to application of the 
samples to the gel they were denatured for 5 min at 100 °C. Electrophoresis was 
done at 220 V until bromophenole blue was leaking out of the gel. The ingredients 
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needed for preparation of 15% separation gel and 5% stacking gel are presented in 
Tab. 3.8. 
 
Tab. 3.8 Reagents used for preparation of SDS gels 
 
Reagent  Stacking Gel (5%) Separation Gel (15%) 
30% Acrylamid solution (29:1) 0.75 ml 5.0 ml 
Tris-HCl (1 M, pH 6.8) 0.62 ml - 
Tris-HCl (1.5 M, pH 8.8) - 2.5 ml 
SDS 10% 0.05 ml 0.1 ml 
H2O   3.55 ml 2.4 ml 
 
For polymerisation 1:500 saturated APS solution and 1:1000 TEMED was added per 
gel. 
 
3.4.3 Native Gel electrophoresis 
In native agarose gel electrophoresis, proteins are separated in their native form 
according to their isoelectric point. For that purpose 5x DNA loading dye was added 
to the protein samples which were then separated on a 1% agarose gel (3.3.3.). 
When HBV core protein with nucleic binding domain is expressed in E.coli, the CLPs 
contain unspecific packed mRNA (see section 3.3.). In case of HBV-CLPs with 
nucleic acid binding domain and ethidium bromide within the gel, nonspecifically 
packed RNA can be detected under UV-light. 
 
3.4.4 Coomassie-Brilliant-Blue Staining 
Staining of the proteins after separation was done using Coomassie brilliant-blue 
staining solution while shaking for approximately 30 minutes at RT. Subsequent to 
staining, the gel was put in destaining solution. After complete destaining, the gel 
was put into water until drying. 
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3.4.5 Immunoblot Analysis (Western Blot) 
After separation with SDS-PAGE, proteins were transferred from the gel to a PVDF-
membrane by means of electrophoretic transfer. In this process membrane and gel 
were both put between three layers of Whatman paper, free from air bubbles. The gel 
was turned towards the cathode and the membrane was turned towards the anode. 
Beforehand, gel and membrane were soaked in western-blot-transfer-buffer for 5 
minutes. Additionally the PVDF-membrane was soaked in methanol for 1 minute prior 
to the buffer. Transfer took place per gel for 15 minutes at 7.5 V using a SemiDry-
transfer chamber. In this procedure, proteins were immobilized to the membrane. To 
block free protein binding sites the membrane was incubated in blocking solution (5% 
milk powder + 0.05% Tween in PBS) for 1 h at RT. Incubation with the first antibody 
(concentration antibody-dependent) was done over night at 4 °C while shaking in 
TTBS with 5% milk powder. Unbound antibody was removed by washing the 
membrane three times with TTBS for 10 minutes. Incubation with the second isotype 
specific antibody (1:5000) was done for 1 h at RT in TTBS. This antibody was 
coupled to horseradish-peroxidase (HRP). Subsequently the membrane was again 
washed three times with TTBS and incubated 5 minutes with ECL-solution for HRP 
detection. Thereby a luminiferous reaction starts so that proteins marked with 
antibodies can be visualized using a radiographic film.  
 
3.4.6 Native Capillary Transfer 
After separation by native gel electrophoresis, proteins were transferred from the gel 
to a PVDF-membrane using capillary transfer. The agarose gel was washed two 
times for 5 minutes in TNE-buffer. An inverted gel tray was put into a large bowl 
which was filled with 500 ml TNE-buffer. Two Whatman papers were put along and 
across onto the gel tray facilitating buffer uptake. After putting the gel with the top 
downwards onto the Whatman papers, the membrane was placed onto the setup 
without air bubbles. Three more Whatman papers were used to cover the membrane. 
Whatman paper and the membrane were previously soaked in TNE-buffer (5 
minutes) and methanol (60 seconds) respectively. Due to the capillary flow, proteins 
were transferred, in native form, from the gel to the membrane. To maintain a 
constant flow 30 layers of thick paper were put above the Whatman paper. 
Evaporation of the buffer was prevented by covering the buffer reservoir with a foil. 
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Transfer was done over night. Afterwards the membrane was treated as in 
immunoblot analysis (3.4.4.). 
 
3.4.7 Analytical Sucrose Density Gradient Centrifugation  
To investigate the formation of CLPs from the core fusion-proteins, an analytical 
sucrose gradient was used. The density is highest at the bottom of the tubes and 
gets lower towards the top of the tubes. This prevents faster sedimentation of the 
proteins when moving farther away from the driveshaft. For analysis a sedimentation 
gradient was used. A gradient with a total volume of 9 ml was used. To do so, a 
discontinuous sucrose-gradient was prepared in a polycarbonate-tube (Beckmann). 
First, 60% sucrose (w/v) in TN300-buffer was added to the tube. In steps of 10% the 
concentration was reduced to 10% sucrose. Afterwards the top sucrose 
concentration was layered with the sample. Exactly balanced centrifuge tubes were 
centrifuged for 120 minutes at 40000 rpm at 20 °C. In 14 equal fractions the gradient 
was then picked up from the top to the bottom. Fractions were analysed for protein 
by SDS-PAGE (3.4.1.) 
 
3.4.8 Preparative Dialysis 
For further usage, samples of the sucrose gradient had to be dialysed. Briefly, peak 
fractions of the preparative sucrose gradient were pooled and were put into a dialysis 
tube (Cellulose-ester, 100,000 Da elimination-volumes) and dialysed against buffer 
TN150. Per 1 ml pooled sucrose fraction, 500-1000 ml TN150-buffer were used. For 
concentration, the sample was added to a concentration tube (Centricon 100,000 Da 
elimination-volume) and concentrated by centrifugation. 
 
3.4.9 Triton X-114 phase separation 
To reduce the endotoxin content, a method which uses the hydrophobic character of 
endotoxins (especially the lipopolysaccharides) was applied. In a solution which 
contains sufficient detergent to reach the critical micelle concentration (CMC), the 
critical micelle temperature (CMT) is that temperature at which the detergent is 
mainly present in its micellular form. At a certain temperature above the CMT non-
ionic detergents become cloudy and a separation in a detergent-rich and a detergent-
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poor phases takes place. This temperature is called “cloudy point” and can be 
explained by the decrease of the hydrate shell at the polar end. 
Triton X-114 is a non-ionic detergent with a CMC of 0.35 mM and a cloudy point of 
22 °C. To reach the CMC, the sample was mixed with 1% Triton X-114 (~20 mM) and 
gently mixed for 20 min at 4 °C. Subsequently, this mixture was incubated for 5 min 
and heated above the CMC at 25 °C leading to phase separation (turbidity). The two 
phases were separated by centrifugation for 10 min at 13,000 rpm and 25 °C. After 
collection of the aqueous phase in a new collection tube, the phase separation was 
repeated two times. The detergent-rich phase was stored at -20 °C for future 
analysis. The aqueous phase contains 0.35 mM Triton X-114, however the 
endotoxin-concentration of samples purified with this method lies between 5 to 500 
endotoxin units (EU)/mg protein (Liu et al., 1997).  
 
3.4.9.1 Elimination of excessive Triton X-114  
For the elimination of excessive Triton X-114 in the detergent-poor phase, samples 
were dialysed against PBS. To prevent endotoxin contamination of purified samples 
sterile buffers and equipment was used. In brief, the sample was added in a sterile 
dialysis cassette (Pierce, Slide-A-Lyzer, MWCO 10 kDa) using a syringe. Excessive 
Triton X-114 was removed via dialysis, which means per 1 ml of the sample 1000 ml 
PBS was used for dialysis. Dialysis was carried out at 4 °C for 12 hours and repeated 
twice with fresh PBS. Microbial growth in the sample was prevented by sterile 
filtration and subsequent storage at 4 °C. 
 
3.4.10 Endotoxin determination 
To determine endotoxin or lipopolysaccharide (LPS) content of a sample, the Limulus 
amoebocyte-lysate-test was used. Limulus amoebocyte-lysate is an aqueous extract 
of blood cells (amoebocytes) of the horseshoe crab Limulus polyphemus. During 
contact with gram negative bacteria or cell wall extracts, coagulation takes place. 
This enzymatic reaction is not completely understood, yet; it is known that the 
enzyme cascade is activated by lipopolysaccharides and in the last a clotting factor is 
cleaved by an activated clotting enzyme, this leads to coagulation (Levin and Bang, 
1964b), (Levin and Bang, 1964a), (Levin and Bang, 1968).  
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3.4.10.1 Quantification of endotoxin using Pyrotell® 
The Pyrotell® endotoxin quantification test is a coagulation-test with a sensitivity of 
0.03 EU/ml (threshold value). This means, after reaching the threshold value a tightly 
formed gel matrix can be observed. The LPS concentration of the samples to be 
measured can be determined by the preparation of different dilutions. For analysis, 
endotoxin-free micro tubes and sterile injection water or limulus reagent water (LRW) 
was used. In brief, the freeze-dried lyophilisate was incubated with reconstitution 
buffer (Pyrosol) for 5-10 min on ice and mixed gently. To reach the threshold value 
samples were diluted with LRW in a ratio of 1:100, 1:500, 1:1000, 1:5000 and 
1:10000. A standard-row of 10 - 10000 pg/ml LPS was used as positive control. As 
negative control LRW was used. Afterwards, 100 µl of the sample was added to a 
sterile micro screw-cap tube and the coagulation was started after addition of 100 µl 
reconstituted Pyrotell. This mixture was incubated free from vibration for 60 min at 37 
°C. To analyse the results of this test the reaction tubes were gently taken out of the 
thermo-block one by one, and inverted 180 °C. If, after turning of the reaction tube a 
tight, not collapsing, gel could be observed the test was assessed as positive. The 
endotoxin-concentration can be calculated with the following formula:       
 
Endotoxin Units /ml (EU/ml) = S x V 
                              S= sensitivity of the test (0.3 EU/ml) 
V= lowest positive dilution 
 
The maximum dose of endotoxin approved for intravenous products in humans is 5 
EU/kg/h (European-Pharmacopoeia, 2008). As suggested by Malyala and Singh 
(Malyala and Singh, 2008), this safety value should also be followed in animal 
experiments as well. The maximum allowed endotoxin concentration of the sample 
can be calculated with the following formula: 
 
Max.EU = 5 EU x h / (d/g)  
 
h: hour 
d: administered dose in mg 
g: weight of the animal in kg 
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In case of immunizations the maximum dose per day is applied (h =24) 
 
Max.EUday =  5 EU x 24 / (d/g) 
 
The results of several LAL-measurements are shown in the appendix in table 9.1. 
 
3.5 Animal experiments 
All animal experiments were carried out in accordance with the “Guide for the Care 
and Use of Laboratory Animals“ and were approved by the local Animal Care and 
Use Committee (Animal Care Center, University of Duisburg-Essen, Essen, Germany 
and the district government of Düsseldorf, Germany). 
 
3.5.1 Anesthetization 
For blood withdrawal and immunization mice were anesthetized for several seconds 
with isofluran vapor. Mice were put in a glass jar filled with Isofluran-soaked cloth 
until the animals got numb. 
 
3.5.2 Blood withdrawal 
Blood withdrawal was carried out from anesthetized mice by retroorbital punction 
using 3 mm heparin-coated glass capillaries. The blood was collected in 1.5 ml 
Eppendorf tubes. 
Blood withdrawal from guinea pigs was done by punctuation of the Vena saphena 
lateralis using 0.4×19 mm needles. The blood was collected in 1.5 ml Eppendorf 
tubes. 
 
3.5.3 Immunization trials 
Intramuscular (i.m.) injections of mice were performed into the Tibialis anterior 
muscle of the hind limbs using 0.4×19 mm needles. Subcutaneous (s.c.) injections 
were administered into the loose skin fold of the neck skin. Peptides were diluted to 
the given concentration in 1 ml of sterile PBS and equal volume of 100 μl was 
injected into each muscle (50 µl per leg), 100 μl was injected into the neck skin fold. 
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Each vaccine preparation was equally diluted 1:2 in incomplete Freund’s adjuvant 
(IFA) or AS03. 
 
Subcutaneous injections of guinea pigs were also administered into the loose skin 
fold of the neck skin. Peptides were diluted to the given concentration in 1 ml of 
sterile PBS and equal volume of 200 μl was injected into the loose skin fold of the 
neck skin. Each vaccine preparation was equally diluted 1:2 in incomplete Freund’s 
adjuvant.  
 
3.5.3.1. Immunization of C57BL/6 mice with four different HBc-HVRI plasmids 
Five different groups (each group contained 6 mice, 4 mice formed the control group) 
of ten week old female C57BL/6 mice were vaccinated subcutaneously with 20 µg 
peptide in IFA at day zero. Mice were boosted at day 14, 28 and 56 with µg peptide 
in IFA. Serum obtained after 1st (day 28), 2nd (day 56) and 3rd (day 84) 
immunization was pooled for further analysis. Serum taken at day zero served as 
zero value. Mice which were immunized with wild type HBc-protein served as 
controls. Mice were sacrificed one week after the last immunization. 
 
3.5.3.2. Immunization of C57BL/6 mice with a pool of four different HBc-HVRI 
plasmids 
A group of six ten weeks old female C57BL/6 mice were injected (s.c.) with a pool of 
four different HBc-HVRI plasmids (5 µg/variant) in IFA at day zero. Mice (four 
animals) which were immunized with wild type HBc-protein (20 µg) served as 
controls. The immunization scheme was done as explained in 3.5.3.1. 
 
3.5.3.3. Immunization of C57BL/6 mice with a pool of four different HBc-HVRI 
plasmids; second trial 
Three different groups of ten week old female C57BL/6 mice were vaccinated with a 
pool of four different HBc-HVRI plasmids (5 µg/variant). The first group which 
comprised 10 mice was immunized i.m. with in AS03. The second group comprised 5 
mice which were immunized s.c. with 5 µg/variant in IFA. The last group of 2 mice 
served as control group. In this group mice were immunized i.m. with 100µl PBS (50 
µl per leg) in AS03. In all groups mice were immunized three times every two weeks 
with the indicated formulation. Blood was taken at day 0, 14, 28 and 42 and serum 
was used for further analysis.  
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3.5.3.4. Immunization of guinea pigs (Cavia procellus) with a pool of four different 
HBc-HVRI plasmids 
A group of five six weeks old female guinea pigs (Cavia procellus) were injected s.c. 
with 5 µg/variant vaccine preparation in IFA at days 0, 30 and 90. Blood withdrawal 
was done at days 0, 30, 90 and 120 and serum was used for further analysis. Guinea 
pigs were sacrificed one week after the third immunization. The control group (5 
animals) was treated as explained above. These animals were immunized with 20 µg 
wild type HBc-protein.  
 
3.6 Enzyme-linked Immunosorbent Assay (ELISA) 
The technique of ELISA was used to detect the presence of HCV HVRI-specific 
antibodies in mouse and guinea pig serum after immunization (3.5.3) and to 
characterize the IgG-subclasses. 
 
Nunc immunoplates were coated with 50 ng/well protein or 500 ng/well peptide in 
coating-buffer and kept over night at 4 °C. Excess protein/peptide was removed by 
washing the plates with ELISA-wash buffer (200 µl/well). After blocking unsaturated 
binding sites with blocking buffer (200 µl/well; 1h at 4 °C), nunc plates were washed 
again three times using ELISA-wash buffer. Preparing serial dilutions (dilution row 
depends on the sample), 200 µl/well of serum sample diluted in PBS/0.1% BSA was 
added to the plates and incubated slightly shaking 2 h at RT. Unbound antibody was 
removed by washing the plates three times with ELISA-wash buffer. Detection of the 
bound antibodies was carried out by adding 100 µl/well of HRP-coupled isotype 
specific secondary antibody in PBS/0.1% BSA for 1 h slightly shaking at RT. 
Unbound antibodies were again removed by washing the plates three times with 
ELISA-wash buffer. 100 μl of OPD substrate solution was added to each well in order 
to detect peroxide activity, and the plates were incubated in the dark for 10-30 min. 
The reaction was stopped by adding 25 μl/well of stop solution. Finally, the OD492nm 
was measured using the Elisa Reader Asys Expert Plus. 
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3.7 Electron microscopy 
Fractions from the sucrose gradient were examined by electron microscopy. Particles 
were visualized after being negatively stained with 2 % uranyl acetate. Micrographs 
were taken at a magnification of 140,000. Electron microscopy was done by the 
department of Pathology at the University Hospital in Essen. 
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4 Results 
4.1 Generation and characterization of SplitCore-HVRI-CLPs 
The best way for the induction of a broad immune response to HCV would probably 
comprise the presentation of the total range of epitopes or highly conserved epitopes 
(e.g. AP33) of the E2 protein on CLPs. However, previous results showed that the 
complete E2 (E2-655) is insoluble and due to this cannot be purified (master thesis 
M. Lange, 2009). Furthermore, the highly conserved epitope AP33 is not able to form 
particles and thus is unsuitable for a candidate vaccine (master thesis M. Lange, 
2009). Nevertheless, during the last decades it was demonstrated that HCV uses the 
HVRI to escape from immune response (von Hahn et al., 2007). On the other hand, 
this region is essential for virus entry into the cell and contains a neutralizing epitope 
(Scarselli et al., 2002), (Kato et al., 1992). Moreover, the use of conserved HVRI 
mimotopes has already been proposed to overcome problems of restricted specificity 
which means that Abs targeting the conserved residues may still have therapeutic 
promise (Cerino et al., 2001), (Roccasecca et al., 2001), (Zucchelli et al., 2001). 
Therefore, the HVRI might be an important target to inhibit HCV from entering the cell 
and prevent infection.   
 
The scope of this work was to find an improved and optimized vaccine strategy to 
induce a potent B-cell response against the HVRI in mice. For this purpose, particles 
expressing four different HVRI-variants on HBV-CLPs were used and HVRI 
mimotopes were compared to naturally occurring HVRI-variants (Fig. 4.1.A). The 
immunogenicity of small peptides, like the HVRI, can be considerably enhanced 
when presented on HBV-CLPs. The most promising insertion site was shown to be 
the c/e1-epitope located at the tips of the spikes of the core protein (Wynne et al., 
1999). To avoid miss-folding of core particles due to sterical constrains after fusion of 
the peptides to the core protein, the so-called SplitCore-system was used (Fig. 
4.1.B). Four different variants of the HVRI, called R9, G31, YK5829 and YK5807, 
were generated by PCR (see 3.3.1). R9 and G31 are artificial mimotopes, generated 
in the laboratory of Alfredo Nicosia (Puntoriero et al., 1998). YK5829 and YK5807 are 
naturally occurring variants which were isolated from patients (kindly provided by 
Yury Khudyakov). The amino acid sequence of the different HVRI-variants is shown 
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in Fig. 4.1.A. In order to expose the conserved C-terminal domain on the surface of 
the CLPs, the HVRI-variants were fused to CoreN (for cloning strategy and vector-
cards see appendix 9.1).  
 
 
 
Fig. 4.1: Generation of SplitCore-CLPs displaying 4 different variants of the HVRI  
A. 4 different variants were fused to the N-terminal part (CoreN) of the HBc-protein. The insertion site 
(blue circle) is located at the tips of the spikes of the core protein (the core protein with its insertion 
site is shown from the side- and from the top- view). R9 and G31 are artificial mimotopes, generated 
in the laboratory of Alfredo Nicosia; Dipartimento di Biologia Cellulare e dello Sviluppo, Università di 
Palermo, Italy. YK5829 and YK5807 are naturally occurring variants which were isolated from 
patients in the laboratory of Yury Khudyakov; Centers For Disease Control and Prevention, Atlanta, 
USA. The 4 variants show highly variable parts as well as a more conserved region located at the C-
terminus (shown in yellow). B. By usage of the SplitCore-system, the translation of the core protein is 
initiated by the ribosome-binding-site at CoreN followed by the fused HVRI-variant. Translation of 
CoreC is mediated by the directly joined second ribosome binding site (RBS). The nucleic acid 
binding domain at CoreC was removed and is now followed by 6 histidines indicated by “149H6”. The 
conserved part (yellow) of the HVRI-variants is exposed to the outside at the tips of the spikes of 
HBc. 
 
4.1.1 HVRI-CLPs displaying different HVRI-variants are assembly competent 
After successful generation of the four different constructs, namely SplitCore-R9, 
SplitCore-G31, SplitCore-YK5807, SplitCore-YK5829, their ability to form CLPs was 
analyzed (Fig. 4.2). SplitCore protein without any foreign protein fusion 
(SplitCore183-St1) was used as positive control (K). After protein expression of 
SplitCore-HVRI-CLPs in BL21*CP cells (see 3.1.3), cells were lysed under non-
denaturing conditions (see 3.1.4) and the cell lysate was added to a preparative 
sucrose gradient (see 3.4.7). After centrifugation 14 fractions were collected from the 
top and were separated by SDS-PAGE (15%) (see 3.4.2). SplitCore-HVRI-CLPs 
showed co-sedimentation of CoreN and CoreC fragments into the particle typical 
fractions 7 to 9 (Vogel et al., 2005). Some material was also detected in fractions 10 
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to 13 (Fig. 4.2 A, lane 7-13). The 12 kDa band corresponds to the CoreN-HVRI-
fragment (white arrow), the band below 9 kDa to the CoreC fragment (green arrow). 
These results indicate that all 4 SplitCore-HVRI-constructs are expressed in nearly 
equimolar amounts, complement each other and assemble to CLPs. Identity of 
CoreN and CoreC fragments was analyzed by western blotting using mAb 10E11 
(CoreN) and mAb 13A9 (CoreC). A band which corresponds to the right size (9 kDa) 
could be detected with 10E11 in fractions 6 to 11 in all SplitCore-HVRI-constructs, 
indicating that the CoreN-fragment was intact (Fig. 4.2 B). Also a band which 
corresponds to the right size (12.2 kDa) could be detected in all SplitCore-HVRI-
constructs in fractions 6 to14 (Fig. 4.2 C). Further confirmation of CLP formation was 
done by native agarose gel electrophoresis (NAGE) (see 3.4.3 and 3.4.6). The 
different fractions of the gradient were applied to a native agarose gel (1 %) and the 
proteins in their native form were separated according to their surface charge. In 
principle, protein monomers diffuse strongly and appear as smear, while particulate 
structures move through the gel as distinct bands. Aggregates are too large to enter 
the gel and typically remain in the slot. Upon staining with Coomassie, distinct bands 
could be detected in fractions 6 to 8 indicating formation of particulate structures (Fig. 
4.2 C). The blue smears, which appeared specifically in the first lanes, indicated 
protein monomers. Particle formation could be observed in fractions 6 to 14 in all 
SplitCore-HVRI-constructs, using either the particle-specific antibody 3120 or the 
CoreN-specific antibody 10E11 (Fig. 4.2 C). Further confirmation of CLP-formation 
was shown by electron microscopy (Fig. 4.2 D). Material from peak fraction number 8 
was negatively stained with 2% uranyl acetate and investigated at a magnification of 
140,000 showing regular shaped CLPs. Thus, the possibility of chimeric HBc-protein 
bearing the HVRI to form particles was demonstrated.  
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Fig. 4.2: HVRI-CLPs displaying different HVRI-variants are assembly competent 
A. Coomassie SDS-PAGE After sedimentation of non-denatured cell lysate on a sucrose gradient, 
14 fractions were separated on a 15% SDS-gel and proteins were visualized with Coomassie. The 
arrows indicate the position of bands of the corresponding HVRI-variant in the gel. Marker: PeqGold 
protein marker I; PeqLab. Wild-type core protein served as positive control (K). B. CoreN/CoreC-
specific WB Fractions were separated by SDS-PAGE and transferred to a PVDF-membrane. 
Detection was done with the CoreN specific Ab, 10E11, or the CoreC specific Ab 13A9 and a second 
antibody coupled to peroxidase. Marker: PeqGold protein marker IV; PeqLab. Wild-type core protein 
served as positive control. C. CLP-specific native agarose gel (NAGE) 10 μl aliquots of gradient 
fractions were loaded on a 1% agarose gel visualized by Coomassie. Particulate structures appear as 
distinct bands in particle-typical fractions. Alternatively, proteins on an agarose gel were transferred to 
a PVDF-membrane. Detection was done with the particle-specific Ab 3120 or 10E11. Wild-type core 
protein served as positive control. D. EM-picture HVRI-CLPs were stained with 2% uranyl acetate 
and investigated by electron microscopy (Pathology, UK Essen). 
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4.2 Immunization with HVRI-CLPs elicits an HVRI-specific immune 
response in mice  
After demonstrating that HVRI-SplitCore fusion proteins are able to assemble to 
regular particles, they were purified, concentrated and Endotoxin extracted. 
Subsequently, the immunogenicity of these HVRI-CLPs was analyzed in mice. 
 
4.2.1 Single HVRI-CLPs are highly immunogenic in mice 
In order to test the immunogenicity of the HVRI-CLPs, 4 groups of C57BL/6 mice 
were immunized with 20 µg of HVRI-CLPs s.c. in IFA on days 0, 14, 28 and 56 (see 
3.5.3.1). Serum titers were determined after bleeding at days 28, 56 and 84 by ELISA 
specific for the HVRI-variants (Fig. 4.3).  
Twenty-eight days after immunization, antibody titers reached values of 12,000 to 
15,000 in all variants. Mice immunized with R9 showed antibody titers of up to 24,000 
(Fig. 4.3, day 28). After the last booster immunization at day 56, antibody titers of 
24,000 could be detected for R9 and G31. Serum titers of mice immunized with 
YK5807 and YK5829 increased to 30,000 (Fig. 4.3, day 56). Twenty-six days after 
the last immunization (day 84) serum titers remained constant for G31, antibody titers 
of mice immunized with R9 and YK5829 raised to 30,000 in contrast to serum titers 
of YK5807 which declined again from 30,000 to 24,000 (Fig. 4.3, day 84).  
As a result, except for G31 which showed the highest antibody titers at 24,000, the 
remaining construct yielded antibody titers of up to 30,000 after the last bleeding (day 
84). This shows a very high and early antibody response in mice against the 
presented HVRI-variant. 
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Fig. 4.3: Antibody response titers of sera from mice immunized with single HVRI-CLPs 
Groups of 6 mice (C57BL/6-mice) were immunized s.c. with 4 different HVRI-variants (20 µg/variant) 
in IFA. Mice were immunized at days 0, 14, 28 and 56. Bleeding was done 4 times at days 0, 28, 56 
and 84. Serum obtained after each bleeding was tested for specific antibodies in ELISA. Serial 
dilutions were made and dilutions yielding at least 2 times the optical density at λ=495 nm obtained 
with pre-immune serum (day 0) were scored positive. Bars represent the mean of 3 replicate values 
and the error bars represent standard error of the mean (S.E.M.) -values. 
 
As core particles were shown to increase the immunogenicity of the presented 
peptides and they are expected to show a very high immunogenicity by themselves, 
in addition, the antibody response to the core protein was analyzed. Again serum 
titers were determined after bleeding at days 28, 56 and 84 by core-specific ELISA. 
As assumed, antibody titers were up to 80 times higher compared to titers against 
the HVRI-variants (Fig. 4.4). After 28 days each construct showed antibody titers of 
60,000. Mice immunized with G31 generated titers of up to 2,400,000 (Fig. 4.4, day 
28). At day 56 antibody titers increased to 2,400,000. Only the R9 titers remained 
constant at 60,000 throughout the immunization (Fig. 4.4, day 56). Twenty-six days 
after the last immunization (day 84), all serum titers remained constant (Fig. 4.4, day 
84).  
Analysis of the antibody response of serum from mice immunized with single HVRI-
variants confirmed the high immunogenic potential of the core protein.  
 
 
                                                                                                                         4 Results 
 
 
68
 
 
Fig. 4.4: Antibody response to the HBc-protein of sera from mice immunized with single HVRI-
CLPs 
Serum obtained from mice after each bleeding was tested for antibodies against the HBc-protein in 
ELISA. For more details see Fig. 4.3. 
 
4.2.2 Single HVRI-CLPs induce partially cross-reactive antibodies  
In order to test the cross-reactive potential of serum from mice immunized with single 
HVRI-variants, anti-sera (after day 84) of each group was tested against homologous 
and heterologous HVRI-variants in ELISA (Fig. 4.5). Monoclonal Ab against R9 was 
used as control. As expected, heterologous variants showed high antibody titers of 
24,000 in each case (shaded in grey). Serum of mice immunized with the R9 variant 
(anti-R9) showed antibody titers against the heterologous variants YK5807 and 
YK5829 of 3000. A relatively low titer of 750 was measured against the heterologous 
variant G31 (Fig. 4.5). Anti-G31 serum reacted weakly (titer of 750) with the R9 
variant. However, very high titers of 12,000 could be detected against the 
heterologous variants YK5807 and YK5829 (Fig. 4.5). Except for the very low 
antibody titer of <750 to R9, anti-YK5807 serum showed titers of 3,000 and 6,000 to 
the heterologous variants G31 and YK5829 respectively (Fig. 4.5). Anti-YK5829 
serum yielded a titer of 6,000 to the R9 variant but only an antibody titer of 750 or 
less could be detected against G31 and YK5807 (Fig. 4.5). The mAb R9 reacted only 
with the R9 peptide (titer of 3,000 at a concentration of 1.2 µg/µl Ab) (Fig. 4.5). 
As shown, analysis of the cross-reactive potential of serum from mice immunized 
with single HVRI-variants, revealed variable reactivity across the different groups. In 
general, serum of all groups showed potential for the induction of cross-reactive 
antibodies which could certainly be increased.  
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4.3 Characterization of the neutralizing capacity of mouse sera 
after immunization with single HVRI-CLPs 
As already described previously, increasing evidence indicates that neutralizing 
antibodies play an important role in controlling HCV infection (Shimizu et al., 1994), 
(Shimizu et al., 1996). It was shown, that despite the induction of cross-neutralizing 
Abs in the late phase of infection, lack of neutralizing Abs in the early phase of 
infection was associated with the development of chronic HCV. Instead viral 
clearance was associated with rapid induction of nAbs in the early phase of infection 
(Pestka et al., 2007). As the HVRI of HCV contains a major neutralizing epitope and 
is involved in viral entry, the induction of nAbs against the HVRI in the early phase 
could help to control HCV infection. Therefore, the neutralizing capacity of the anti-
sera to the HVRI was investigated. 
 
4.3.1 Evaluation of the neutralizing capacity to homologous HVRI-variants 
after single immunization 
To assess whether the HVRI-peptide specific response measured by ELISA could 
neutralize autologous HCVpp infectivity, sera (day 84) of mice immunized with single 
HVRI-variants were screened at different dilutions (1:25, 1:50, 1:100 and 1:200) for 
their ability to neutralize HCVpp infectivity bearing the four HVRI-variants included in 
 
 
Fig. 4.5: Single HVRI-CLPs induce partially cross-reactive antibodies 
Cross-reactive potential in ELISA (day 56). Serum of mice immunized with single HVRI-variants was 
tested for its cross-reactivity to the 4 different peptides used for immunization. Titers of homologous 
variants are shaded in grey. Titers of heterologous variants are white. Serial dilutions were made and 
dilutions yielding at least 2 times the optical density at λ=495 nm obtained with pre-immune serum 
were scored positive. Monoclonal Ab R9 (kindly rovided by P. Pumpens; Riga, Latvia) only reacted 
with the R9 peptide. 
                                                                                                                         4 Results 
 
 
70
the vaccine. HCVpp’s encoding a luciferase reporter were pre-incubated with pre- or 
post-immune sera for 2h and allowed to infect Huh-7.5 hepatoma cells. After 72h 
post-infection luciferase activity was measured and infectivity in the presence of pre- 
immune serum was compared to infectivity of post-immune serum. This was used to 
determine the percentage neutralization which is defined to start at 50% (Fig. 4.6; 
black continuous line) (see 3.2.7). Sera from all four groups of single immunized mice 
showed high neutralizing capacity against the homologous HCVpp (Fig. 4.6). R9 
serum inhibited homologous HCVpp infectivity still by 70% at a dilution of 1:200 (Fig. 
4.6 A, black dots). In comparison, G31 serum was able to show 70% neutralization of 
G31 HCVpp at a dilution of 1:100. Neutralization with 1:200 diluted serum revealed 
borderline neutralization (Fig. 4.6 B, black squares). At a 1:200 dilution, serum of 
HVRI-variants YK5807 and YK5829 still inhibited homologous HCVpp infectivity by 
67% and 60% respectively (Fig. 4.6 C & D, black open dots & triangles). Sera from 
all groups of mice were also able to neutralize HCVpp of the other groups to a 
different extend. G31, YK5807 and YK5829 serum showed cross-neutralization of R9 
HCVpp of 60 to 80% at a dilution of 1:50 (Fig. 4.6 A), whereas R9, YK5807 and 
YK5829 serum was hardly or not at all able to neutralize G31 HCVpp (Fig. 4.6 B). In 
contrast, YK5807 HCVpp could be neutralized relatively efficiently at a 1:50 dilution 
and declined to borderline neutralization at a 1:100 dilution (Fig. 4.6 C). YK5829 
HCVpp were still neutralized efficiently at a dilution of 1:100 and started to become 
inefficient at a 1:200 dilution (Fig. 4.6 D).  
Analysis of the neutralizing capacity of sera from single immunized mice 
demonstrated high neutralization of homologous variants and even cross-neutralizing 
capacity. However, none of them was able to neutralize all four variants efficiently. 
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Fig. 4.6: Neutralizing capacity to homologous HVRI-variants after single immunization in mice 
Day 84-serum of mice immunized with single HVRI-variants was tested in different dilutions (x-axis) for 
neutralization of HCVpp expressing the 4 HVRI-variants included in the vaccine. Percent neutralization 
was determined by comparing infectivity (luciferase relative light units – RLU) of HCVpp not incubated 
with serum to the infectivity in the presence of test immune sera. Symbols represent the mean of 3 
replicate values (pooled serum per group) and the error bars represent S.E.M. values.  
 
4.3.2 Evaluation of the neutralizing capacity to heterologous HVRI-variants 
after single immunization 
To further study the breadth of the immunizing response in mice, sera were also 
tested for their ability to neutralize HCVpp expressing diverse HVRI-variants. Fig. 4.7 
shows the amino acid sequences of the HVRI-peptides included in the vaccine 
(labelled in black), compared to the ones used to analyze the cross-neutralizing 
capacity of sera (labelled in grey). These three different HCVpp comprise HCV 
genotypes 1a, 1b and 2a. 
 
                                                                                                                         4 Results 
 
 
72
 
 
Fig. 4.7: HVRI-sequences used for the construction of HCVpp 
To test cross-neutralizing capacity of the serum, beside the generation of HCV pseudoparticles 
expressing HVRI-variants included in the vaccine (indicated in black), also HCVpp bearing HVRI-
variants of other genotypes were generated (indicated in grey). H77 HCVpp are GT1a, Ad78 HCVpp 
are derived from GT1b (these plasmids were kindly provided by S. Viazov from our Institute) and J6 
HCVpp are GT2a (kindly constructed by A. Walker from our Institute).  
 
Antibody responses generated following immunization with four different HVRI-
variants were able to neutralize infection of HCVpp bearing HVRI-variants of 
genotype 1a (H77) and genotype 2a (J6) but were less efficient against genotype 1b 
(Ad78) (Fig. 4.8). In brief, all four sera were able to efficiently neutralize H77 HCVpp 
with 50% to 80% at a dilution of 1:100. At a dilution of 1:200 sera started to become 
inefficient (Fig. 4.8 A). In contrast to that, only at a dilution of 1:25 R9, G31 and 
YK5807 serum was able to neutralize Ad78 HCVpp. The only exception was shown 
by YK5829 serum which inhibited infection up to a dilution of 1:100 (Fig. 4.8 B). J6 
HCVpp could be neutralized more efficiently. Sera of mice showed neutralization of 
approximately 70% at a 1:50 dilution and then started to decline drastically. Only G31 
serum was not able to neutralize infection at all (Fig. 4.8 C). 
Overall this shows that sera of mice immunized with single HVRI-variants were to 
some extend able to neutralize naturally HCV strains which bear quite different HVRI-
sequences from the ones used for immunization. 
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Fig. 4.8: Neutralizing capacity to heterologous HVRI-variants after single immunization in mice 
Serum of mice immunized with single HVRI-variants, was obtained 84 days after immunization and 
tested in different dilutions for neutralization of HCVpp expressing HVRI-variants not included in the 
vaccine. Percent neutralization was determined by comparing infectivity RLU of HCVpp not incubated 
with serum to the infectivity in the presence of test immune sera. Symbols represent the mean of 3 
replicate values (pooled serum per group) and the error bars represent S.E.M. values.   
 
4.4 A mixture of HVRI-CLPs induces high titers of cross-reactive 
antibodies 
Based on the previous results and in order to increase the cross-reactivity of the anti-
serum, a second immunization scheme was applied (see 3.5.3.2). A group of 
C57BL/6 mice was immunized s.c. with a pool of the four different HVRI-variants. 
The mice were immunized with 5 µg/variant (total of 20 µg) in IFA at days 0, 28, 56 
and 84. Antibody titers were determined by ELISA specific for the HVRI-variants. 
Two weeks after the first immunization anti-serum of variants G31, YK5807 and 
YK5829 showed titers of up to 15,000. The R9 group reached an antibody titer of 
30,000 (Fig. 4.9, day 28). At day 56 antibody titers of groups R9, G31 and YK5829 
remained constant. In contrast to that, the titer of group YK5807 increased to 30,000 
(Fig. 4.9, day 56). Serum titers of groups R9, YK5807 and YK5829 remained 
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constant after the last booster immunization. An increase of the titer from 15,000 to 
60,000 could be detected for the anti-serum of group G31 (Fig. 4.9, day 84). 
In summary, immunization of mice with a pool of the four HVRI-variants induced a 
higher antibody titer compared to mice immunized with single variants.  
 
 
 
Fig. 4.9: Antibody response titers of sera from mice immunized with a mixture of HVRI-CLPs  
A group of 6 mice (C57BL/6-mice) was immunized s.c. with a mixture of 4 HVRI-variants (5 
µg/variant) in IFA. For more details see Fig. 4.3.
 
Further, the anti-core response was analyzed in these mice. After the second 
immunization at day 28, an antibody titer of 600,000 could be detected which 
increased to 1,200,000 at day 56 (Fig. 4.10). Twenty-eight days after the last 
immunization the antibody titer increased again to 2,400,000 (Fig. 4.10, day 84).  
In conclusion the antibody response to the core protein yielded very high titers which 
are, like in the first immunization scheme, around 80 times higher compared to the 
anti-HVRI response. This confirms again the high immunogenic potential of the 
vaccine carrier.  
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Fig. 4.10: Antibody response to the HBc-protein of sera from mice immunized with a mixture 
of HVRI-CLPs 
Serum obtained from mice after each bleeding was tested for antibodies against the HBc-protein in 
ELISA. Serial dilutions were made and dilutions yielding at least 2 times the optical density at λ=495 
nm obtained with pre-immune serum (day 0) were scored positive. Bars represent the mean of 3 
replicate values (pooled serum per group) and the error bars represent S.E.M. values. 
 
Next, the true cross-reactive potential of the anti-sera was tested. Therefore, the 
binding capacity of sera to 326 randomly chosen HVRI-sequences from patients was 
analyzed by ELISA. To analyze whether immunization with the mixture of CLPs 
induced more cross-reactive Abs compared to the immunization with single HVRI-
CLPs, these two sera were compared. As shown in Fig. 4.11 A, the mixture (mixture 
immunization) reacted with about 25% of heterologous HVRI peptides compared to 
the pool of single sera (single immunization) which reacted with 19% of heterologous 
HVRI peptides. Also the strength of the response was much better when the mice 
were immunized with all four HVR-CLPs simultaneously compared to serum from 
mice immunized with single HVRI-variants (Fig. 4.11. B). Furthermore, it should be 
pointed out, that the anti-sera were tested in a 1:800 dilution which means that most 
likely an even higher antibody response could be detected with more concentrated 
serum. The experiments were carried out in the laboratory of Yury Khudyakov at the 
Centers For Disease Control and Prevention, Atlanta, USA. 
As a result, a mixture of HVRI-CLPs induced high titres of anti-HVRI antibodies, 
which were able to cross-react with 25% of naturally occurring HVRI, demonstrating 
that HVRI-CLPs are indeed able to induce cross-reactive HCV antibodies.  
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Fig. 4.11: Reactivity of mouse serum with patient derived HVRI-variants 
A. The cross-reactive potential of mouse serum with 326 randomly chosen HVRI-variants was 
analyzed by ELISA. Mixture sera (mice immunized with the mixture of HVRI-CLPs) reacted with 
24.8% of peptides tested. Pool of single sera (mixture of sera from mice immunized with the single 
HVR-CLPs) reacted with 19% of peptides tested. B. The strength of the response of mouse serum 
with patient derived peptides was tested by ELISA. Peptides giving a signal to cutoff (S/CO) > 1 were 
scored positive (p-value = 0.0001). Serum was tested in a dilution of 1:800. Experiments were carried 
out in the laboratory of Yury Khudyakov; Centers For Disease Control and Prevention, Atlanta, USA. 
 
4.5 Characterization of the neutralizing capacity of mouse sera 
after mixture immunization with HVRI-CLPs 
After showing an improved antibody response in mice immunized with a mixture of 
HVRI-variants, this hypothesis was also proven in neutralization experiments.  
 
4.5.1 Evaluation of the neutralizing capacity to homologous HVRI-variants 
after mixture immunization 
In the first series of experiments, the ability of sera (day 84) from mice immunized 
with the mixture of HVRI-variants to neutralize HCVpp expressing the four variants 
included in the vaccine was tested (Fig. 4.12). HCVpp bearing HVRI-variants R9, 
YK5807 and YK5829 were neutralized very efficiently. At a dilution of 1:200 the 
serum was still able to neutralize R9 and YK5829 HCVpp with approximately 90% 
(Fig. 4.12, black dots and open triangles). At the same dilution YK5807 HCVpp 
neutralization showed borderline values, but a 1:100 dilution revealed neutralization 
of 80% (Fig. 4.12, open dots). Only HCVpp bearing G31 could not be neutralized as 
efficiently as the other variants. Serum did not show further neutralization at higher 
dilutions after a neutralization of 60% at a 1:50 dilution (Fig. 4.12, black squares). 
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As predicted from ELISA data, the sera of mice immunized with the mixture showed 
significantly higher neutralization ability (with the only exception to neutralize G31 
HCVpp) than sera from mice immunized with single HVRI-variants.  
 
 
Fig. 4.12: Neutralizing capacity to homologous HVRI-variants after mixture immunization in 
mice 
Day 84-serum of mice immunized with a mixture of 4 HVRI-variants was tested in different dilutions 
for neutralization of HCVpp expressing the 4 HVRI-variants included in the vaccine. Percent 
neutralization was determined by comparing infectivity RLU of HCVpp not incubated with serum to 
the infectivity in the presence of test immune sera. Symbols represent the mean of 3 replicate values 
(pooled serum per group) and the error bars represent S.E.M. values.   
 
4.5.2 Evaluation of the neutralizing capacity to heterologous HVRI-variants 
after mixture immunization 
The next series of experiments was directed to the ability of sera obtained from mice 
immunized with the mixture of HVRI-variants to neutralize the series of HCVpp which 
bear HVRI-sequences quite different form the ones included in the vaccine 
preparation (sequences shown in Fig. 4.7). 
As already demonstrated in mice immunized with single HVRI-variants, serum 
showed very high activity to neutralize infection with HCVpp bearing genotype 1a 
(H77, black dots), however values were low against infection with HCVpp bearing 
genotype 1b (Ad78, black squares) and 2a (J6, black triangles) (Fig. 4.13). Serum 
inhibited heterologous HCVpp H77 infectivity by 80% at a 1:25 dilution and started to 
show borderline values at a dilution of 1:200. In contrast to that, neutralization of 
HCVpp Ad78 and J6 was relatively ineffective. Already at a dilution of 1:50, 
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neutralization of HCVpp Ad78 was ineffective while at the same dilution the serum 
was unable to inhibit HCVpp J6 infectivity at all.  
Results showed that serum of mice was able to inhibit HCVpp infectivity bearing 
heterologous HVRI-variants, but demonstrated lower neutralization activity compared 
to inhibition of HCVpp bearing homologous sequences. 
 
 
 
Fig. 4.13: Neutralizing capacity to heterologous HVRI-variants after mixture immunization in  
mice 
Serum of mice immunized with a mixture of 4 HVRI-variants, was obtained 84 days after 
immunization and tested in different dilutions for neutralization of HCVpp expressing HVRI-variants 
not included in the vaccine. Percent neutralization was determined by comparing infectivity RLU of 
HCVpp not incubated with serum to the infectivity in the presence of test immune sera. Symbols 
represent the mean of 3 replicate values (pooled serum per group) and the error bars represent 
S.E.M. values.   
 
4.6 A modified mixture immunization with HVRI-CLPs increases 
cross-reactive and cross-neutralizing antibody titers 
In order to analyze the immunogenicity of the mixture immunization with HVRI-CLPs 
with an approved adjuvant and to shorten the vaccination protocol, the adjuvant 
AS03 was used in a 14-day immunization scheme (see 3.5.3.3). Therefore, the 
course of immunization and bleeding as well as the administration routes has been 
modified. In brief, C57BL/6 mice were immunized with a pool of the 4 different HVRI-
variants (5 µg/variant) at days 0, 14 and 28. One group of mice was immunized i.m. 
applying AS03 (Fig. 4.14 A) while the second group was immunized s.c. applying IFA 
(Fig. 4.14 B). Evaluation of the immune response was performed as before. As 
shown in Fig. 4.14 A, 14 days after the first immunization, AS03 vaccinated mice 
showed antibody titers of around 3,000 to all peptides, except for G31 which elicited 
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a titer of only 200. In contrast to AS03 vaccinated mice, IFA vaccinated mice showed 
decreased titer levels of around 500 (Fig. 4.14 B, day 14). After the next bleeding, 
antibody titers were increased significantly in both groups. AS03 vaccinated mice 
demonstrated antibody titers of up to 32,000 to peptides R9, YK5807 and YK5829 
whereas G31 elicited titers of 2,500 (Fig. 4.14 A, day 28). In comparison, the 
induction of antibodies was lower in IFA vaccinated mice. Titers of up to 4,000 were 
detected for G31 and YK5807, while R9 and YK2829 elicited only titers of 500 at 
most (Fig. 4.14 B, day 28). Two weeks after the last booster immunization AS03 
vaccinated mice showed a repeated increase of antibody titers. Titers of 20,000 were 
detected for R9 and G31, whereas YK5807 and YK5829 elicited titers of 80,000 and 
40,000 respectively (Fig. 4.14 A, day 42). Also an increase in antibody titers could be 
detected in IFA vaccinated mice however, the overall values were lower. While R9 
revealed a titer of 2,000, a titer of up to 10,000 was detected for G31 and a value of 
20,000 could be measured for YK5807. YK5829 induced a titer of 5,000 at most (Fig. 
4.14 B, day 42). Comparison of the antibody response to HVRI-variants included in 
the vaccine, measured for the group immunized i.m., were significantly higher than 
those detected in mice immunized s.c.. 
 
 
Fig. 4.14: Antibody response titers of sera from mice immunized with a mixture of HVRI-CLPs 
(i.m. and s.c.) 
A. A group of 10 mice (C57BL/6-mice) was immunized i.m. with a mixture of the 4 HVRI-variants (5 
µg/variant) in AS03. Mice were boosted 3 times and bled 4 times every 2 weeks. Serum obtained after 
each bleeding was tested for specific antibodies in ELISA. Serial dilutions were made and dilutions 
yielding at least 2 times the optical density at λ=495 nm obtained with pre-immune serum (day 0) were 
scored positive. B. A group of 5 mice was immunized s.c. with a mixture of the 4 HVRI-variants (5 µg/ 
variant) in IFA. The bleeding scheme and analysis of the obtained serum was done as indicated in A. 
Bars represent the mean of 3 replicate values (pooled serum per group) and the error bars represent 
S.E.M. values. 
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In addition, the immune response of both groups to the core protein was measured. 
AS03 vaccinated mice showed a titer of 20,000 after 14 days and a titer of around 
40,000 at day 28. Two weeks later, the titer increased to 100,000 (Fig. 4.15 A). In 
comparison, a titer of around 10,000 was measured for IFA vaccinated mice at day 
14. At day 28 the titer increased to 40,000 and a further cumulation to 100,000 could 
be measured two weeks after the last immunization (Fig. 4.15 B). In general, both 
groups showed the same titer after the last bleeding. 
Analysis of the immune response to the core protein showed considerably lower 
titers compared to the values of the first mixture immunization. However, the antibody 
response to core was still higher in comparison to the HVRI-peptides.  
 
 
 
Fig. 4.15: Antibody response to the HBc-protein of sera from mice immunized with a mixture of 
HVRI-CLPs (i.m. and s.c.) 
A. AS03 vaccinated mice were immunized i.m. with a mixture of 4 HVRI-variants. B. IFA vaccinated 
mice were immunized s.c. with a mixture of 4 HVRI-variants. Serum obtained from mice after each 
bleeding was tested for antibodies against the HBc-protein by ELISA. Serial dilutions were made and 
dilutions yielding at least 2 times the optical density at λ=495 nm obtained with pre-immune serum 
(day 0) were scored positive. Bars represent the mean of 3 replicate values (pooled serum per group) 
and the error bars represent S.E.M. values.    
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4.6.1 Evaluation of the neutralizing capacity to homologous HVRI-variants 
after improved mixture immunization 
Compared to previous neutralization results with mixture immunization (Fig. 4.12) a 
similar and even better pattern of neutralization activity was observed in sera (day 
42) of mice which obtained the shortened vaccination strategy of s.c. and i.m. 
administration (Fig. 4.16). In this case, AS03 vaccinated mice showed extremely 
effective neutralization. At a 1:50 dilution, neutralization activity to all four HCVpp 
started very slowly to decrease from up to 100% showing only borderline values at a 
1:3200 dilution with around 40% to 60% neutralization (Fig. 4.16 A). In comparison, 
serum of IFA vaccinated mice reacted less effectively with HCVpp bearing the HVRI-
variants included in the vaccine preparation. Infection with HCVpp R9 and YK5807 
was inhibited the best by the serum, which means that borderline values were 
detected at a dilution 1:400 (Fig. 4.16 B, black dots and open dots). Neutralization to 
HCVpp YK5829 and G31 became already ineffective at a dilution of 1:200 and 1:100, 
(Fig. 4.16 B, open triangles and black squares). 
In general, these data correspond to the ELISA data (Fig. 4.14) showing that mice 
immunized with AS03 i.m. had high antibody titers and these Abs are able to better 
neutralize the Abs from mice immunized with IFA as adjuvant (Fig. 4.9). Furthermore, 
G31 HCVpp were regularly the most difficult to neutralize. 
In conclusion, serum of AS03 immunized mice showed a very high capacity to 
neutralize HCVpp bearing the HVRI-variants included in the vaccine. 
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Fig. 4.16: Neutralizing capacity to homologous HVRI-variants after mixture immunization i.m. 
and s.c. in mice 
A. AS03 vaccinated mice were immunized i.m. with a mixture of 4 HVRI-variants. B. IFA vaccinated 
mice were immunized s.c. with a mixture of 4 HVRI-variants. Serum of day 42 post immunization, of 
both groups was tested in different dilutions for neutralization of HCVpp expressing the 4 HVRI-
variants included in the vaccine. Percent neutralization was determined by comparing infectivity RLU 
of HCVpp not incubated with serum to the infectivity in the presence of test immune sera. Symbols 
represent the mean of 3 replicate values (pooled serum per group) and the error bars represent 
S.E.M. values. 
 
4.6.2 Evaluation of the neutralizing capacity to heterologous HVRI-variants 
after improved mixture immunization 
To assess whether serum of mice immunized with the modified vaccine strategy 
induced more potent neutralization activity to HCVpp bearing heterologous HVRI-
variants, different dilutions of serum (day 42) of AS03 vaccinated mice and IFA 
vaccinated mice were also analyzed in the HCVpp assay (Fig. 4.17). As expected, 
serum of AS03 vaccinated mice appeared to induce more potent neutralization titers, 
especially for HCVpp H77 and Ad78 (Fig. 4.17 A, black dots and black squares). 
Infection with HCVpp J6 could not be inhibited by the serum at all (Fig. 4.17 A, black 
triangles). Serum of IFA vaccinated mice showed neutralization of HCVpp H77 and 
Ad78 at a dilution of 1:50 with 65% and 71%. Thereafter, neutralization efficiency 
decreased rapidly. As shown for AS03 vaccinated mice serum of IFA vaccinated 
mice was neither able to block infection with HCVpp J6 at all (Fig. 4.17 B).  
In general, these data again showed a high cross-neutralizing capacity of the serum. 
Furthermore, these data are consistent with values of homologous neutralization 
assays as well as ELISA data, which showed that serum of mice immunized with the 
modulated vaccine strategy revealed continuously better neutralization activity or 
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antibody responses (see Fig. 4.14 and Fig. 4.16). In addition, in homologous as well 
as in heterologous neutralization assays, HCVpp J6 were hardly neutralized. 
 
 
Fig. 4.17: Neutralizing capacity to heterologous HVRI-variants after mixture immunization i.m. 
and s.c. in mice  
A. AS03 vaccinated mice were immunized i.m. with a mixture of 4 HVRI-variants. B. IFA vaccinated 
mice were immunized s.c. with a mixture of 4 HVRI-variants. Day 42-serum of both groups was tested 
in different dilutions for neutralization of HCVpp expressing HVRI-variants not included in the vaccine. 
Percent neutralization was determined by comparing infectivity RLU of HCVpp not incubated with 
serum to the infectivity in the presence of test immune sera. Symbols represent the mean of 3 
replicate values (pooled serum per group) and the error bars represent S.E.M. values.     
 
4.7 The true cross-neutralizing potential after mixture 
immunization in mice 
The next goal was to determine the true cross-neutralizing potential of the serum to 
randomly selected HVRI-variants isolated from patients. As serum of AS03 
vaccinated mice always showed the best antibody responses as well as 
neutralization activity, this serum, obtained at day 42 after immunization, was used 
for further characterization. Experiments were carried out in the laboratory of William 
O. Osburn at the Johns Hopkins School of Medicine, Baltimore, USA. The serum was 
screened at a single dilution of 1:50 for its ability to neutralize HCVpp bearing 
different patient derived envelope sequences (HVRI-variants). The amino acid 
sequences as well as the corresponding genotype of the different variants in 
comparison to the sequence of R9 are shown in Fig. 4.18. Serum showed weak 
neutralization of 4 variants, namely HCVpp 1a31, 1a38, 1a46 and 1b20 by 
approximately 47% indicated in orange. Four other variants 1a129, 1b44, 1b52, and 
1b58 could be highly neutralized by the serum. HCVpp 1a129 was neutralized by 
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55%, while HCVpp 1b44 was neutralized by 59%, HCVpp 1b52 by 63.7% and 
infection with HCVpp 1b58 was inhibited by 73.3%. These values are indicated in 
green in Fig. 4.18. Neutralization of the remaining 11 HCVpp bearing other HVRI-
variants showed values of less than 50%. Pseudotype viral particles expressing the 
Murine Leukemia Virus (MLV) glycoprotein were used as negative control. The same 
results are depicted as a histogram in Fig. 4.19. The dashed line indicates the 
starting point for positive neutralization at 50%, while the spotted line indicates weak 
neutralization (approximately 47%) of the corresponding bars. 
This study showed that the serum was indeed able to neutralize 21% of randomly 
selected HVRI-variants, demonstrating a high cross-neutralizing potential. When also 
including the variants which were neutralized weakly, the cross-neutralizing capacity 
of the serum accounts for even 42%.  
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Fig. 4.18: Immunization of mice with a mixture of HVRI-CLPs induces cross-neutralizing 
antibodies 
Mice were immunized i.m. with a mixture of 4 HVRI-variants in AS03. Day 42-serum was tested in a 
1:50 dilution for neutralization of HCVpp expressing diverse HVRI-variants of GT1. As these HVRI-
variants were not included in the vaccine, sequences are aligned to the R9-variant included in the 
vaccine. Percent neutralization was determined by comparing infectivity (luciferase relative light units 
– RLU) of HCVpp in the presence of pre-immune sera to the infectivity in the presence of test immune 
sera. Pseudotype viral particles expressing MLV gp were used to confirm serum neutralization 
specificity. Sera showed neutralization of <50% to most HVRI-sequences. 4 HVRI-variants 
(GT1a129, 1b44. 1b52 and GT1b58), indicated in green, were highly neutralized. 4 other HVRI-
variants indicated in orange, were weakly neutralized (GT1a31, 1a38, 1a46 and GT1b20). 
Experiments were carried out in the laboratory of William O. Osburn; Johns Hopkins School of 
Medicine, Baltimore, MD, USA. 
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Fig. 4.19: Mixture immunization of mice (i.m.) elicits cross-neutralizing antibodies to naturally 
occurring HVRI-variants 
Serum of AS03 vaccinated mice was tested in a 1:50 dilution for neutralization of HCVpp expressing 
diverse HVRI-variants of GT1 not included in the vaccine preparation. For more details see Fig. 4.18. 
 
4.8 Immunoglobulin isotype switch in mice immunized with HVRI-
CLPs 
In order to stimulate B-lymphocytes to produce antibodies, antigens presented on 
MHC-II require the specific recognition by helper T-cells. Stimulation of antibody 
responses towards certain antigens may result in a selective increase in IgG 
antibodies of certain subclasses (Soderstrom et al., 1985), (Burton and Woof, 1992). 
In contrast to CD8 T-cells, CD4 T-cells can differentiate into a number of different 
effector T-cell subsets like TH1, TH2 and TH17 cells. TH1 and TH2 cells can contribute 
to humoral immunity by inducing the production of antibodies. Besides the activation 
of macrophages, TH1 cells activate B-cells to produce strongly opsonizing antibodies 
belonging to certain IgG subclasses (IgG1 ang IgG3 in humans, and their homologs 
IgG2a and IgG2b in the mouse). TH2 cells, in contrast, can subsequently stimulate B-
cells to differentiate and produce immunoglobulins of other isotypes as well as 
neutralizing and/or weakly opsonising subclasses of IgG (Murphy et al., 2008).  
Comparative to the previous results and in order to show a possible link to the 
neutralization efficiency of the sera to IgG subclass generation, the ratio of IgG 
subclasses IgG2a, IgG2b and IgG3 in comparison to IgG1 in the serum of mice was 
determined by ELISA (see 3.6). The following tables represent the levels of IgG-
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subclasses present in the serum of mice immunized with the mixture of HVRI-
variants either delivered in AS03 (Tab. 4.1) or in IFA (Tab 4.2). 
 
Coating of plates with the peptide R9 revealed a slight increase in IgG2a and IgG2b 
compared to IgG1 levels during vaccination of AS03 mice. IgG3 levels also increased 
but remained below the amount of IgG1 (Tab. 4.1). ELISA to the other peptides G31, 
YK5807 and YK5829, demonstrated besides IgG1, also induction of IgG2a and 
IgG2b levels. Slightly lower amounts of IgG3 were measured in most tests (Tab. 4.1). 
In general, the ratio of IgG subclasses determined in the serum of AS03 vaccinated 
mice points towards a mixed TH1/ TH2-response with a TH1-trend. However, also the 
fact that mice were immunized with constructs not bearing the nucleic acid binding 
domain of the HBc protein which normally induces a TH2-response, should be taken 
into account. 
 
Tab. 4.1 Ratio of IgG-subclasses in AS03 vaccinated mice 
 
coating IgG Subclass day 14 serum  day 28 serum day 42 serum 
R9 IgG1 1 1 1 
 IgG2a 0.76 1.18 1.08 
 IgG2b 0.61 1.13 1.09 
 IgG3 0.48 0.80 0.90 
G31 IgG1 1 1 1 
 IgG2a 1.09 0.75 0.97 
 IgG2b 1.0 0.7 0.8 
 IgG3 0.7 0.5 0.6 
YK5807 IgG1 1 1 1 
 IgG2a 0.77 0.91 0.98 
 IgG2b 0.96 0.99 0.97 
 IgG3 0.77 0.85 0.91 
YK5829 IgG1 1 1 1 
 IgG2a 0.97 0.75 0.92 
 IgG2b 1.06 0.98 0.99 
 IgG3 0.65 0.70 0.96 
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In comparison to AS03 vaccinated mice (i.m.), the serum of IFA vaccinated mice 
(s.c.) showed a significantly increased IgG2a/b level against G31. These levels 
started to decrease during the remaining course of vaccination (Tab. 4.2). The other 
peptides induced slightly higher amounts of IgG2b compared to values measured for 
IgG2a during the vaccination trial, but remained lower compared to values in AS03 
vaccinated mice (Tab. 4.2). The IgG3 levels to all four peptides were slightly lower 
compared to the results of AS03 vaccinated mice 
In the early phase, the IgG ratio of subclasses determined in the serum of IFA 
vaccinated mice also points more towards a TH1-response. However, in the later 
phase the IgG ratio shifted to a TH1/TH2-response. Also in this group it should be 
considered that mice were immunized with HVRI-CLPs not bearing the nucleic acid 
binding domain anymore, which normally leads to the induction of a TH2-response. 
 
Tab. 4.2 Ratio of IgG-subclasses in IFA vaccinated mice 
 
coating IgG Subclass day 14 serum  day 28 serum day 42 serum 
R9 IgG1 1 1 1 
 IgG2a 0.85 0.29 0.29 
 IgG2b 1.86 0.75 0.74 
 IgG3 0.59 0.35 0.63 
G31 IgG1 1 1 1 
 IgG2a 1.58 0.56 0.77 
 IgG2b 1.80 1.02 0.94 
 IgG3 0.83 0.19 0.22 
YK5807 IgG1 1 1 1 
 IgG2a 0.79 0.88 0.93 
 IgG2b 1.02 0.93 0.98 
 IgG3 0.63 0.76 0.89 
YK5829 IgG1 1 1 1 
 IgG2a 0.85 0.25 0.31 
 IgG2b 1.03 0.51 0.54 
 IgG3 0.88 0.20 0.28 
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4.9 Immunization with HVRI-CLPs elicits an HVRI-specific immune 
response in guinea pigs 
In 2007 Stamataki et al. (Stamataki et al., 2007) demonstrated an enhanced anti-
glycoprotein response in guinea pigs after immunization with different variants of 
HCV GT1a glycoproteins E1 and/or E2, compared to mice. In order to proof this 
outcome, also guinea pigs were immunized with a mixture of the four different HVRI-
variants used before (3.5.3.4). Therefore, groups of five female guinea pigs (Cavia 
procellus) were immunized s.c. with 5 µg/variant at 0, 30 and 90 days. The adjuvant 
IFA was used with the mixture of antigens described. In addition to the anti-HVRI 
response, the serum was also analyzed for its neutralizing capacity. The experiments 
were carried out in collaboration with Abdel-Rahman Zekri in Cairo; Virology and 
Immnunology Unit, National Cancer Institute, Cairo, Egypt. 
 
4.9.1 A mixture of HVRI-CLPs is less immunogenic in guinea pigs compared to 
mice 
The HCV HVRI-specific antibody response in guinea pigs was measured at days 30, 
90 and 120. Thirty days after the first immunization an antibody titer of 1,600 was 
detected to R9 and a titer of up to 400 to the variant YK5829. Due to volume 
limitations of serum at this time point, the reactivity with G31 and YK5807 could not 
be tested (Fig. 4.20, day 30). After 90 days, the antibody titer increased to levels of 
8,000 to 16,000 against R9, and levels of 2,000 to 4,000 could be detected to 
YK5807 and YK5829, respectively. G31 reacted with a titer of 100 (Fig. 4.20, day 
90). After the third immunization, antibody titers increased further to approximately 
32,000 to R9 and YK5807. At this time a titer of 2,000 was detected to G31 and a 
titer of up to 16,000 was detected to YK5829 (Fig. 4.20, day 120).  
Analysis showed an antibody response in guinea pigs against the presented HVRI-
variant which was lower compared to antibody responses in mice. 
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Fig. 4.20: Antibody response titers of sera from guinea pigs immunized with a mixture of 4 
HVRI-CLPs 
A group of 5 guinea pigs (Cavia procellus) was immunized with a mixture of 4 HVRI-variants (5 
µg/variant) in IFA. Guinea pigs were immunized at days 0, 30, 90. Bleeding was done 4 times at days 
0, 30, 90 and 120. The obtained serum was tested for specific antibodies by ELISA. Serial dilutions 
were made and dilutions yielding at least 2 times the optical density at λ=495 nm obtained with pre-
immune serum (day 0) were scored positive. Bars represent the mean of 3 replicate values (pooled 
serum per group) and the error bars represent S.E.M. values. 
 
In addition, the antibody response to the carrier of the vaccine, the HBc-protein, was 
analyzed. At day 30, antibody titers of 320,000 to 800,000 to the core protein could 
be detected in the serum of guinea pigs (Fig. 4.21, day 30). After the second booster 
immunization (day 30), increased antibody titers of 3,200,000 at day 90 could be 
detected (Fig. 4.21, day 90). Antibody titers stayed constant at 3,200,000 30 days 
after the last booster immunization (Fig. 4.21, day 120). 
In conclusion, the guinea pigs showed a very high anti-core response compared to a 
relatively low anti-HVRI response. This is in contrast to mice which showed a high 
antibody response to the HVRI. The core response was much higher in guinea pigs. 
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Fig. 4.21: Antibody response to the HBc-protein of sera from guinea pigs immunized with a 
mixture of HVRI-CLPs 
Serum obtained from guninea pigs after each immunization was tested for antibodies against the 
HBc-protein by ELISA. Serial dilutions were made and dilutions yielding at least 2 times the optical 
density at λ=495 nm obtained with pre-immune serum (day 0) were scored positive. Bars represent 
the mean of 3 replicate values (pooled serum per group) and the error bars represent S.E.M. values.   
 
4.10  Characterization of the neutralizing capacity of guinea pig sera 
after immunization with HVRI-CLPs 
The importance of nAbs in HCV infections was already described. In order to analyze 
whether the anti-HVRI Abs measured by ELISA could neutralize HCVpp infectivity 
and compare the neutralizing capacity in guinea pigs to mice, the serum of guinea 
pigs immunized with the mixture of HVRI-variants was also tested for its neutralizing 
activity. 
 
4.10.1 Evaluation of the neutralizing capacity to homologous HVRI-variants 
after mixture immunization 
Sera obtained at day 120 after immunization of guinea pigs were tested in the 
HCVpp neutralization assay as described (3.2.7). The serum showed very high 
neutralizing capacity against all the homologous HCVpp (Fig. 4.22). Only 
neutralization of infection with HCVpp G31 (Fig. 4.22, black squares) showed a rapid 
decrease in neutralization activity, becoming inefficient at a 1:400 dilution (45%), 
compared to the efficiency of the serum to inhibit infection with the other three 
HCVpp. The neutralization efficiency started to decline and drop below 50% at a 
dilution of 1:1600 for YK5829 and 1:3200 for YK5807 (Fig. 4.22, open triangles and 
                                                                                                                         4 Results 
 
 
92
open dots). Interestingly, at a dilution of 1:3200, serum was still able to neutralize 
HCVpp R9 with 65% (Fig. 4.22, black dots).  
In comparison to the neutralizing capacity in mice (immunized with the mixture) which 
already showed very good results, neutralization activity in guinea pigs was even 
more potent. However, serum of both animals showed the most potent neutralization 
activity to HCVpp R9 but again relatively inefficient neutralization of HCVpp G31. 
 
 
 
Fig. 4.22: Neutralizing capacity in guinea pigs to homologous HVRI-variants after mixture 
immunization 
Day 120-serum of guinea pigs immunized with a mixture of 4 HVRI-variants was tested in different 
dilutions for neutralization of HCVpp expressing the 4 HVRI-variants included in the vaccine. Percent 
neutralization was determined by comparing infectivity RLU of HCVpp not incubated with serum to 
the infectivity in the presence of test immune sera. Symbols represent the mean of 3 replicate values 
(pooled serum per group) and the error bars represent S.E.M. values.   
 
4.10.2 Evaluation of the neutralizing capacity to heterologous HVRI-variants 
after mixture immunization 
The serum of guinea pigs (day 120) was further tested at different dilutions (1:50, 
1:100, 1:200 and 1:400) for its ability to neutralize HCVpp bearing heterologous 
variants of the HVRI (Fig. 4.23). Serum showed relatively high neutralization of 
HCVpp J6 and HCVpp Ad78 of approximately 80% at a dilution of 1:50. Thereafter, 
neutralization activity started to decrease slowly and showed a final value of 
approximately 40% at a dilution of 1:400 (Fig. 4.23, black triangles). In comparison, 
the serum was only able to inhibit HCVpp H77 infection at a dilution of 1:100 (Fig. 
4.23, black squares).  
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Surprisingly, neutralization of HCVpp H77 showed relatively low values compared to 
serum of mice which showed the least neutralization activity to HCVpp J6. In general, 
also a high cross-neutralizing potential could be demonstrated in guinea pigs. 
 
 
 
Fig. 4.23: Neutralizing capacity to heterologous HVRI-variants after mixture immunization in 
guinea pigs 
Serum of guinea pigs immunized with a mixture of 4 HVRI-variants, was obtained 120 days after 
immunization and tested in different dilutions for neutralization of HCVpp expressing HVRI-variants 
not included in the vaccine. Percent neutralization was determined by comparing infectivity RLU of 
HCVpp not incubated with serum to the infectivity in the presence of test immune sera. Symbols 
represent the mean of 3 replicate values (pooled serum per group) and the error bars represent 
S.E.M. values.    
 
4.11 WHc-CLPs displaying HVRI-R9 are assembly competent 
The application of HBc-CLPs as vaccine carrier is particularly difficult because anti-
HBc Abs are used as diagnostic markers for HBV. During vaccination against HBV 
only antibodies to the HBs-protein are induced, while antibodies against the HBc-
protein and the related HBeAg are routinely used as diagnostic marker for acute or 
chronic HBV infections (Trepo et al., 1993). One possibility to circumvent the problem 
of cross-reactivity in diagnostic tests is the usage of different hepadnaviral core-
proteins as vaccine carriers. The possibility to use the Woodchuck Hepatitis C Virus 
core protein (WHc) as vaccine carrier was already demonstrated resulting in a 
reduced cross-reactivity of anti-WHc antibodies with the diagnostic anti-HBc test-
system (Billaud et al., 2005a), (Billaud et al., 2005b). Another fact that also supports 
the usage of the WHc protein as vaccine carrier is that patients chronically infected 
with HBV show T-cell tolerance to the HBV core-protein (Whitacre et al., 2009). For 
this reason it was analyzed whether WHc CLPs bearing HVRI-variants would still be 
able to form particles. As a representative for the 4 HVRI-variants used before, the 
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R9-variant was fused to the N-terminal part of the SplitCore-WHc-protein as 
described in section 4.1. The vector-card of this construct is shown in the appendix in 
Fig. 9.4 
 
The ability of the WHc-protein bearing the HVRI-variant R9 to form CLPs was 
analyzed by SDS-PAGE (see method section 3.4.2) after protein expression in 
BL21*CP cells (see 3.1.3), cell lysis (see 3.1.4) and sucrose gradient centrifugation 
(see 3.4.7). Co-sedimentation of fragments of the corresponding size (12 kDa and 
8.9 kDa) into fractions 8 to 14 (peak in fraction 13) was observed suggesting that the 
fusion protein at least partially was present as intact CLPs (Fig. 4.24 A, lane 8-14). 
The band at 12 kDa corresponds to the CoreN fragment (white arrow), and the band 
at the bottom of the gel corresponds to the small CoreC fragment (8.9 kDa, white 
arrow). In order to confirm the previous results, native gel electrophoresis was done 
(see 3.4.3). Upon staining with Coomassie, distinct bands, corresponding to 
particulate structures of the putative fusion protein, were detected in fractions 8-10 
(Fig. 4.24 A, lane 8-10). The blue smears which appear specifically in the first lanes 
indicate protein monomers. The same results were shown by transfer of a 1% NAGE 
onto a PVDF-membrane and staining with Ab 10E11. Distinct bands indicating 
particle formation of WHc-R9 were observed in fractions 6 to 11 (Fig. 4.24 B lane 6-
11). Protein monomers which stayed in the slot were detected in the remaining 
fractions 13 to 14 (Fig. 4.24 B lane 12-14). To further prove the presence of WHc-R9 
CLPs, fraction 9 of the gradient was investigated by electron microscopy at a 
magnification of 140,000 showing regular formed particles (Fig. 4.24 C). This 
confirms that SplitCore-WHc-R9 is able to form CLPs. 
In summary, these observations demonstrate in proof of principle that WHc-CLPs 
bearing HVRI-variants are potential vaccine candidates for HCV. 
The generation and successful assembly of chimeric SplitCore CLPs consisting of 
different hepadnaviral core proteins would also be a desirable aim for the future.  
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Fig. 4.24: WHV-CLPs displaying R9 are assembly competent 
A. Coomassie SDS-PAGE After separation of non-denatured cell lysate on a sucrose gradient, 14 
fractions were separated on a 15% SDS-gel and proteins were visualized with Coomassie. The 
arrows indicate the position of bands of HVRI-R9 in the gel. Marker: PeqGold protein marker I; 
PeqLab. Wild-type core protein served as positive control (K). B. CLP-specific native agarose gel 
(NAGE) 10 μl aliquots of gradient fractions were loaded on a 1% agarose gel visualized by 
Coomassie. Particulate structures appear as distinct bands in particle-typical fractions. Alternatively, 
proteins on a agarose gel were transferred to a PVDF-membrane. Detection was done with the 
particle-specifi Ab 10E11. Wild-type core protein served as positive control. C. EM-picture HVRI-
CLPs were stained with 2% uranyl acetate and investigated by electron microscopy (Pathology, UK 
Essen). 
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5 Discussion 
Since there is still no protective or therapeutic vaccine available against HCV, the 
number of new infections did not decrease during the last decades. The WHO 
estimates that over 170 million people are persistently infected with HCV, of whom 
350,000 people die each year from hepatitis C-related liver diseases (WHO, 2011b). 
Despite ongoing research, therapeutic options are still limited. Current standard 
therapy of direct-acting antivirals (DAAs) with pegylated interferon and Ribavirin 
(PEG-IFN/RBV) is often difficult to tolerate and results in a sustained virological 
response in only 50% of patients which makes therapy against HCV in most cases 
not satisfactory (Zeuzem, 2004). However, enormous costs limit the therapy for most 
patients. Even though the treatment of hepatitis C with specific targeted antiviral 
therapies (STAT-C) directed against protease, polymerase or other nonstructural 
proteins continues to evolve striving for constant improvement, new approaches for a 
prophylactic vaccine against HCV are needed.  
It is well documented that not only a broad and vigorous HCV specific T-cell 
response but also the induction of virus-neutralizing antibodies is needed to 
efficiently control HCV infection (Lechner et al., 2000), (Pestka et al., 2007). Indeed, 
studies indicate that patients who induce nAbs in the early phase of infection, 
subsequently clear the viral infection (Pestka et al., 2007). In contrast, patients who 
do not completely eliminate the virus develop high titers of neutralizing antibodies 
during the chronic phase which are not able to control HCV infection. HCV has 
therefore developed various mechanisms to evade immune elimination, allowing it to 
persist in the majority of infected individuals (Di Lorenzo et al., 2011). Despite the 
continuous generation of HCV escape mutants predominantly in the HVRI, studies 
have shown that positive selection is not evenly distributed across HVRI but instead 
is focused on a few discontinuous residues (McAllister et al., 1998), (Penin et al., 
2001), (Brown et al., 2007). Therefore, it was assumed that a number of HVRI-
variants would be able to induce antibodies that could cross-react with different HCV 
strains occurring in nature (Puntoriero et al., 1998). Moreover, recent data have 
demonstrated that antibodies to HVRI are able to block both cell-free as well as cell-
to-cell transmission of HCV (Brimacombe et al., 2011). Hence, the presentation of 
HVRI-variants on HBc-CLPs which leads to the induction of cross-neutralizing anti-
HVRI antibodies, would demonstrate a new type of immunogen for the protective 
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immunization against HCV. Numerous clinical trials of prophylactic immunization 
exploited peptide, recombinant protein, DNA and vector-based vaccines; however 
none of them has reached approval yet (Halliday et al., 2011). A novel approach to 
overcome viral persistence includes virus-like particles (VLPs ) or CLPs-based 
vaccines that have been successfully employed for viral infections such as hepatitis 
B (Hilleman, 2001), (Kao and Chen, 2002). A HCV CLP vaccine approach could 
facilitate the induction of nAbs and specific T-cell epitopes in a single construct 
resembling mature HCV virions which could enhance immunity (Halliday et al., 2011). 
By the presentation of foreign peptides or proteins on CLPs, general properties of the 
viral capsid, like the repetitive arrangement of the surface, and activation of the 
innate immune system can be transferred to foreign sequences. HBV-CLPs are the 
most promising carrier systems as they are able to trigger vigorous immune 
responses in humans without eliciting serious side effects. The immune boosting 
effect was already demonstrated for several different foreign peptides and protein 
fragments (Koletzki et al., 1999), (Ulrich et al., 1999) (Pumpens and Grens, 2001). 
The most adequate insertion site of the HBc protein is the surface exposed but 
centrally located c/e1 epitope (Pumpens and Grens, 2001). Due to the application of 
the so-called SplitCore-system, splitting the HBc protein in two fragments the 
structure of the inserted antigen as well as the potential B- and T-cell epitopes are 
still conserved. After co-expression in E. coli the HBc protein is again able to 
spontaneously assemble into CLPs. 
 
In the current study it was shown that SplitCore-CLPs displaying different HVRI-
variants are assembly competent and after immunization of mice show exceptional 
immunogenicity. Furthermore, immunization with single HVRI-CLPs induced partially 
cross-reactive antibodies. However, a mixture of HVRI-CLPs induced significantly 
high titers of cross-reactive and cross-neutralizing antibodies. Similar results could be 
observed in guinea pigs. Also the possibility of the WHc protein, bearing the R9 
variant and to assemble to CLP demonstrates the possibility of a new strategy for a 
prototype vaccine against HCV. 
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5.1 Characterization of SplitCore-HVRI-CLPs 
The first aim of this study was to prove whether SplitCore-CLPs carrying four 
different variants of the HVRI are assembly-competent. These variants were fused 
via a short linker to CoreN (N-terminal part) of the HBc protein lacking the nucleic 
acid binding domain. The results of this study showed that SplitCore-CLPs are able 
to present all four different variants of the HVRI which can be expressed in high 
amounts and assemble to properly formed spherical particles as demonstrated by co-
sedimentation in gradients (see Fig. 4.2 A), migration as distinct bands in NAGE (see 
Fig. 4.2 C) and EM pictures (see Fig. 4.2 D).  
In the generated constructs, particles sedimented also in the bottom fractions (9-14) 
and not only in the middle fractions as it was already shown (Birnbaum and Nassal, 
1990). However, due to the collection of the gradient from the top fractions, most 
likely material is displaced in deeper fractions. In order to prevent this displacement, 
the gradient could be collected from the bottom. So far, no attempts in this direction 
were undertaken since this gradient is used only for enrichment of particles.  
As mentioned in section 4.1, it was already shown in former experiments that the 
complete E2 ectodomain (E2-655) presented on HBc-CLPs successfully forms 
particles but is insoluble when purified (master thesis M. Lange, 2009). Due to this 
reason, this construct exhibits no properties for a possible immunogen preparation. 
Furthermore, the highly conserved neutralizing epitope AP33 of HCV which would 
demonstrate another promising construct (Owsianka et al., 2005), (Tarr et al., 2006), 
(Sabo et al., 2011) was also shown to be unable to form particles (master thesis M. 
Lange, 2009). The reason for its insolubility is not completely clear. One explanation 
could be that the HVRI located directly in front of AP33 is needed for proper protein 
functionality. Although HVRI-sequences vary between HCV strains, the overall 
charge properties remain conserved making this region very hydrophilic. It was 
already shown that HCV uses this conservation of positively charged residues most 
likely to interact with negatively charged molecules such as lipids, proteins or 
glycosaminoglycans (Basu et al., 2004). This could lead to the fact that AP33 alone is 
not able to form particles. Furthermore, sterical constrains may also lead to 
aggregation of this construct as the absence of the flexible HVRI may reduce the 
flexibility of the chimeric protein. 
In general, the current study showed successful generation and particle formation of 
HBc-CLPs carrying different variants of the HVRI. Moreover, the formed particles 
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could easily be purified and used for immunization studies in mice. Most likely every 
other sequence of the HVRI could be presented by HBc-CLPs. 
 
5.2 Immune response in mice after immunization with HVRI-CLPs 
Vaccines based on VLPs have gained a great interest because of their ability to 
stimulate robust humoral and cellular immune responses. As this system should lead 
to an optimal presentation of the antigen, and the induction of a robust immune 
response in vivo, the immunization of mice with single HVRI-CLPs was performed.  
5.2.1 Characterization of the HVRI-specific immune response after single 
HVRI-CLP immunization in mice 
The results of the presented study clearly showed that expression of HVRI-variants 
on HBc-CLPs resulted in a very strong humoral immune response in mice as a high 
anti-HVRI antibody response could be detected (see Fig. 4.3). Serum of these mice 
was also partially cross-reactive to the other HVRI-variants (see Fig. 4.5). These 
results confirmed the high antigen expression provided by the HVRI-CLPs. A pattern 
of HVRI-sequence similarity of the used constructs with respect to the ability of the 
corresponding sera to induce cross-reactive antibodies preferably to one construct 
compared to another one could not be detected. Furthermore, it is not evident 
whether immunization with mimotopes induces some difference in the immune 
response compared to the outcome after immunization with naturally occurring 
variants. Nevertheless, most likely the induced antibodies seem to be predominantly 
directed at the C-terminus of the HVRI. The observed results are consistent with 
previous findings, which also demonstrated the simultaneous presence of variant-
specific and cross-reactive Ab responses in the serum of mice immunized with HVRI-
mimotopes. The induced antibodies were also directed to the C-terminus of the HVRI 
(Cerino et al., 2001). These results demonstrate the possibility to induce a cross-
reactive B-cell response to HVRI isolates which is not immediately evident as the 
HVRI has been traditionally considered structurally flexible and antigenically variable 
(Taniguchi et al., 1993). Moreover, it was already shown, that anti-HVRI antibodies 
effectively captured HCV in vitro. Furthermore, it was found that anti-HVRI antibodies 
could immunoprecipitate an isolate of HCV unrelated to the original antigenic HCV 
isolate. These findings suggest that anti-HVRI antibodies induced in mice have the 
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ability to bind HCV particles in an isolate cross-reactive manner. Therefore, the 
combination of several HVRI-sequences should generate a broadly reactive anti-
HVRI response (Esumi et al., 1998).  
In general, these results showed the possibility of the induction of partially cross-
reactive antibodies after immunization of mice with single HVRI-CLPs.  
 
5.2.2 Characterization of the HVRI-specific immune response after mixture 
HVRI-CLP immunization in mice 
Due to the results obtained after single immunization of mice and the suggestions of 
previous reports in order to enhance cross-reactivity (Puntoriero et al., 1998), (Esumi 
et al., 1998), mice were also immunized with a mixture of the generated HVRI-
variants (immunization with all four HVRI-variants in one group). In contrast to the 
anti-HVRI response induced in mice immunized with single HVRI-variants, the 
induced anti-HVRI response was much higher (see Fig. 4.9). Those results support 
the findings of Roccasecca et al., who demonstrated the possibility to achieve a 
broadly cross-reactive immune response in rabbits by immunization with a mixture of 
HVRI derived mimotopes (Roccasecca et al., 2001).  
To further analyze the improved antibody response observed in mice immunized with 
a mixture of HVRI compared to the one of mice immunized with single HVRI-variants 
(see section above), both sera were tested for their true cross-reactive potential by 
binding to 326 randomly selected HVRI-sequences isolated from patients (see Fig. 
4.11) (Experiments were carried in the laboratory of Yury Khudyakov; Centers for 
Disease Control and Prevention, Atlanta, USA). Results showed 19% and 25% 
cross-reactivity of single immunized sera and mixed immunized sera to the panel of 
naturally occurring HVRI-variants. Also the strength of the response was much higher 
in mixed immunized mouse serum compared to single immunized mouse serum. Due 
to the fact that this analysis was done with serum diluted 1:800, most likely the cross-
reactive activity could be significantly increased with the use of more concentrated 
serum. One reason for a better immune response in serum of mice immunized with 
the mixture, could be that a broader antibody repertoire can be induced resulting 
from the fact that 4 different HVRI-variants provide more alternatives for the induction 
and combination of various antibodies. Concordant to the presented cross-reactivity 
demonstrated by the induced Abs, Cerino et al. already provided a plausible 
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explanation saying that the very similar hydropathy and antigenicity profiles of HVRI-
variants reveal a substantial conformational conservation. This confirms also the 
existence of an active selection process (Cerino et al., 2001). On the other hand, 
Zucchelli et al. stated that titers per se are not responsible for the observed increase 
in cross-reactivity after mixture immunization, but rather that some immunogenic 
cooperation occurs between the different chimeric proteins when they are 
simultaneously presented to the immune system (Zucchelli et al., 2001). 
Shang et al. already suggested that with an appropriate HVRI peptide immunization 
scheme, high titer, broadly cross-reactive, blocking antibodies to HCV can be 
produced (Shang et al., 1999). In order to achieve a protection against most HCV 
isolates, Campo et al. already showed that 19 cross-reactive HVRI-variants would in 
principal be sufficient to achieve this protective rate (Campo et al., 2012). Also the 
human pneumococcal polysaccharide vaccine (PPSV23) showed that it is indeed 
possible to induce antibodies to 23 antigens (Manoff et al., 2010), (Musher et al., 
2010). According to these data, an immunizatin sheme applying a higher number of 
HVRI-variants would be a desirable experiment for the future. 
In summary results showed that immunization of mice with a mixture of HVRI-CLPs 
induces high titers of anti-HVRI antibodies, which are able to cross-react with 25% of 
naturally occurring HVRI-sequences, showing the high potential of this vaccine 
strategy. 
 
5.2.3 Characterization of the neutralizing capacity in mice after single HVRI-
CLP immunization  
The development of neutralizing antibodies directed against the HVRI is crucial for 
the resolution of the HCV infection in humans. Therefore, one of the most important 
tasks of this project was to analyze whether the induced anti-HVRI antibodies were, 
besides their cross-reactivity, also able to neutralize virus infection. After 
immunization of mice with the single HVRI-variants, serum of each group was highly 
able to neutralize HCVpp bearing the homologous variants (see Fig. 4.6). Serum was 
also able to partially cross-neutralize HCVpp bearing the HVRI-variants present in 
the vaccine of the other groups, but none of the sera was able to neutralize all of the 
variants used for immunization of the different groups (see Fig. 4.6). When sera were 
tested for their neutralizing ability to heterologous variants not included in the vaccine 
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(H77, Ad78 and J6) a similar pattern was observed. Infection with HCVpp bearing 
H77 could be neutralized effectively while infection with HCVpp, Ad78 and J6 
demonstrated reduced efficiency of neutralization (see Fig. 4.8). Nevertheless, 
results showed cross-neutralizing ability of the sera. These data are in accordance 
with other studies which evaluated the neutralization effects of sera in BALB/c mice 
immunized with mimotope proteins. These data also showed that the mimotope 
proteins could react to the HCV positive sera (Yang et al., 2008).  
The obtained results indicate clearly that immunization with single HVRI-CLPs 
induces partially cross-neutralizing antibody responses in mice. 
 
5.2.4 Characterization of the neutralizing capacity in mice after mixture HVRI-
CLP immunization  
After showing an improved antibody response in mice immunized with a mixture of 
HVRI-variants, this hypothesis was also proven in neutralization results. As expected, 
compared to the neutralization results demonstrated after single immunization of 
mice, the immunization of mice with mixed HVRI-variants revealed even better 
neutralization results (see Fig. 4.6 and Fig. 4.12). Outstanding in both immunization 
schemes (single and mixture) is that HCVpp bearing the G31 variant was mostly the 
least neutralized (compare Fig. 4.6 and Fig. 4.12). These data are not in accordance 
with ELISA data which did not show differences in the immune response of this 
sequence to the other variants (compare Fig. 4.3 and Fig. 4.9). One explanation 
could be that antibodies against G31 are able to bind but they are not able to 
neutralize infection. Moreover, it was already argued by others that Abs raised 
against HVRI peptides are unable to recognize the same sequence when expressed 
in the context of a correctly folded complete E2 glycoprotein that includes HVRI 
(Cerino et al., 2001).  
The neutralizing capacity to heterologous variants, not included in the vaccine 
(HCVpp bearing H77, Ad78 or J6), showed similar results after mixture (see Fig. 
4.13) and single immunization (see Fig. 4.8). In general the cross-neutralizing 
capacity of the sera from mice immunized with the mixture was shown very clearly. 
The neutralization results generated to heterologous variants showed in most cases 
a reduced capacity of the sera to neutralize HCVpp bearing J6 (GT2a). However, this 
was not an unexpected result as most likely this is due to the fact that this variant is 
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GT2a and could just not be recognized by the antibodies. This is also in accordance 
with previous experiments, which tested the true cross-reactivity of the used HVRI-
variants (Fig. 4.11), and already showed that a cross-reactivity of 25% was achieved, 
providing a plausible explanation for the fact that specific HVRI-variants are just not 
recognized. However, for all used HVRI-variants it applies that specific aa residues of 
the HVRI may determine (cross)-reactivity levels in general, which was already 
demonstrated by several gropus. Consistently, Callens et al. showed that HCVpp 
infectivity increased with the number of basic residues in HVRI and the presence or 
absence of basic residues at specific positions modulated HCVpp infectivity (and 
were found to modulate virus entry) (Callens et al., 2005). Similarly, differential 
incorporation of E1E2 (resulting from a different aa composition of the HVRI) into 
HCVpp was shown to result in altered neutralization sensitivities in other studies 
(Tarr et al., 2006). On the other hand, it was already shown by several groups that 
the inter-genomic swab in HVRI had little effect on virus infectivity, consistent with the 
flexibility of this segment, its relative independence from the rest of E2 (Forns et al., 
2000), (McCaffrey et al., 2007) and it shows tolerance to certain mutations (Vieyres 
et al., 2010). Moreover, it was already believed that cross-neutralizing antibodies 
recognize overall shapes rather than primary sequences (Puntoriero et al., 1998) as 
shown for the V3 loop of HIV gp120 (Nara et al., 1991).  
In general, it should be considered that only three different variants of the HVRI 
(representing 2 out of seven genotypes) were used to analyze the cross-neutralizing 
capacity. To achieve more significant results, the sera were tested with a higher 
amount of variants (see section 5.2.6).  
In conclusion, these results demonstrate that sera from mice immunized with the 
mixture of HVRI-CLPs are highly able to cross-neutralize naturally HCV strains which 
bear a quite different HVR-sequence compared to the ones used for immunization. 
 
5.2.5 Immunization with an improved HVRI-CLP mixture induces a more 
vigorous neutralizing immune response in mice 
In order to analyze the immunogenicity in mice with an approved adjuvant (AS03), 
immunization with the mixture of the HVRI-variants in AS03 (i.m.) was compared to 
the immunization results with the mixture applied in IFA (s.c.) (improved vaccine 
strategy). ELISA data revealed a much better immune response in mice when the 
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vaccine was applied in AS03 compared to IFA (see Fig. 4.14). Also in accordance 
with ELISA, the mixture immunization of mice applied i.m. revealed an even better 
neutralizing capacity compared to s.c. immunization (see Fig. 4.16). Serum of these 
mice demonstrated a significantly high ability to neutralize infection with homologous 
HCVpp (see Fig. 4.16 A) and similar values to heterologous variants compared to 
s.c. immunization (see Fig. 4.17). The reason for the demonstrated improvement of 
the immune response by the i.m. route is not completely clear, yet. However, when 
also taking into account the core-specific immune response, a reduced response in 
comparison to the first single and mixture immunization (see Fig. 4.4. and Fig. 4.10) 
can be oserved in both vaccine preparations (see Fig. 4.15). A reason for the 
different core response in mice immunized with the improved vaccine strategy, AS03 
i.m, could be that during the immunization procedure with IFA, HVRI-CLPs degrade, 
meaning that IFA has some unfavourable influence on the stability of CLPs while 
AS03 has not. Moreover, it is likely that during immunization with AS03 HVRI-CLPs 
stay intact which leads to a high, correctly folded, epitope presentation on the 
particles accompanied by a high HVRI-specific immune response and a lower core 
response as the core protein is more hidden by the presented epitopes. However, in 
this case a difference in the titer to the core protein in mice immunized s.c. with the 
improved vaccine strategy as well as with the “first mixture” in comparison to mice 
immunized with the improved vaccine strategy i.m. would be expected, but this was 
not the case, both titers showed the same values (see Fig. 4.15). Only in the first 
mixture immunization trial (s.c.), a higher core response could be detected (see Fig. 
4.10). A difference in titer with respect to the administration route was detected only 
against the HVRI but not against core (compare Fig. 4.14 and Fig. 4.15), why this 
was not the case also in the improved vaccine strategy administered s.c. remains still 
unclear.  
Another explanation for the demonstrated improvement of the immune response by 
the i.m. route could be, besides the adjuvant used, the applied injection modes. This 
explanation would be in accordance with the arguments stated by Nakano et al., who 
argued that at least in the HCV E2 model, a different spectrum of immunogenic 
sequences appears to be exploited by the host and/or at different degrees, in part 
depend on the injection mode. It remains determined whether differences in the 
amount of expressed antigens or in the processing of the expressed antigen on the 
presentation of the determinant(s) to the immune system account for the observed 
differences. Expression of the injected plasmid probably takes place in different types 
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of cells, and processing of the expressed antigens could consequently be different. In 
addition, depending on the immunization mode, different antigen-presenting cells 
(APCs) may be recruited. Unfortunately, to date only very few studies have 
addressed this question (Nakano et al., 1997).  
Nevertheless, in our opinion the enhanced results demonstrated by the improved 
vaccine preparation may most likely be linked to the adjuvant used. As already 
suggested from the ELISA results, these data show again that most likely, i.m. 
application of the vaccine is the most favourable administration route for HVRI-CLPs. 
This result is not only favourable when considering the use of this prototype vaccine 
in humans as the use of IFA in humans in forbidden. Further this application could be 
confirmed by a study of Frey et al. in which three different dosages of HCV E1E2 
adjuvanted in AS03 to healthy HCV-negative adults were applied, who showed a well 
tolerability of the vaccine administered i.m. (Frey et al., 2010).  
Taken together, these findings led to the conclusion that improvement of the vaccine 
strategy results in significantly higher induction of neutralizing antibodies in mice. 
These results confirm the effective strategy to improve HCV HVRI-specific immune 
responses making our strategy very promising. 
 
5.2.6 Optimization of the mixture immunization leads to the induction of a 
potent cross-neutralizing response in mice 
Further, the true cross-neutralizing potential of the serum to randomly selected HVRI-
variants isolated from patients was determined (see Fig. 4.18 and Fig. 4.19). The 
results showed the ability of the serum to weakly neutralize 4 out of 19 patient 
derived HVRI-sequences, while 4 other variants could be highly neutralized (see Fig. 
4.18 and Fig. 4.19). When taking into account both, the variants which were weakly 
neutralized as well as the ones which could be highly neutralized, the cross-
neutralizing capacity of the serum accounts for 42%. When evaluating these data 
one should consider that examination of the data was done in a stricter way 
compared to analysis of the residual neutralization data (experiments were carried 
out in the laboratory of William O Osbourn; John Hopkins School of Medicine, 
Baltimore, USA). After taking into account all the limitations used for the analysis of 
these data, the significantly high capacity of the serum (AS03, i.m.) to neutralize 
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HVRI-variants bearing quite different sequences compared to the once included in 
the vaccine becomes clear one more time.  
When comparing the sequences of HVRI-variants which could be highly neutralized 
to the ones which were only weakly or not neutralized by the serum, no specific 
pattern in amino acid composition becomes obvious (compare Fig. 4.7 and Fig. 
4.18). In the beginning of our experiments we thought that the PG-motif (Proline, and 
Glycine) at position 22/23 may influence the binding of nAbs, however the variants 
tested by W. Osburn which were highly neutralized by the serum do only exhibit the 
G residue at position 23. Possibly the Glutamine (Q) at position 26 also regulates 
some binding. This would be in accordance with data obtained in rabbits immunized 
with the HVRI, which suggested the presence of a conserved, partially 
conformational, epitope located at the C-terminus of HVRI, including the conserved G 
and Q amino acids in positions 23 and 26 (Shang et al., 1999). This was further 
confirmed by Li et al. who showed that anti-HVRI cross-reactivity of a rabbit 
polyclonal antibody and one mouse mAb was highly dependent on the presence of 
these two conserved amino acids in their respective positions. The replacement of 
either or both by Leucine (L) or Valine (V) amino acids resulted in a significant loss or 
a complete disappearance of antigenic recognition by cross-reactive HVRI antibodies 
(Li et al., 2001). Nevertheless, it is still not completely clear whether some other 
residues regulate binding of nAbs or whether this binding occurs arbitrarily.  
It has often been argued that vaccines using a nAb approach to HVRI will fail, as the 
HVRI has been traditionally considered structurally flexible and antigenically variable. 
However, not only the results of this project but also other groups already suggested 
that utilizing virus neutralization Abs that target highly conserved, functionally 
constrained epitopes will limit the likelihood of viral escape, and therefore maximize 
virus neutralizing Abs therapeutical potential. Even if escape occurs within these 
conserved epitopes, it is likely that this will come at a replicative cost to the virus, 
such as decreased receptor binding (Beaumont et al., 2004), (Pinter et al., 2004), 
(Pugach et al., 2004). Moreover, even an immune response of 40% to HCV (as 
demonstrated by the neutralization data of W. Osburn; see Fig. 4.18, 4.19) would 
probably result in a lower viral load. In this case one could speculate about a stronger 
and earlier stimulation of the T-cell response leading to an acute or even resolving 
HCV infection and no progression to the chronic phase which makes the vaccine 
strategy generated in this project again very promising. 
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In general, the results showed that anti-HVRI antibodies are able to neutralize 40% of 
patient derived HCVpp, demonstrating that HVRI-CLPs are indeed able to induce a 
high level of cross-neutralizing HCV antibodies. 
 
5.2.7 Characterization of the immunoglobulin isotype switch in mice 
immunized with the improved HVRI-CLP mixture 
In order to determine the balance of TH1 and TH2-responses among AS03 and IFA 
immunized mice, the IgG-subclass ratio in this serum was analysed. Analysis of IgG-
subclasses in mice immunized with the HVRI-mixture in AS03 revealed the induction 
of a mixed TH1/ TH2-response with a TH1-trend (see Tab. 4.1). In mice immunized 
with the HVRI-mixture in IFA the induction of a TH1-response was not as strong as in 
AS03 vaccinated mice but rather a mixed TH1/TH2-response was detectable (see 
Tab.4.2).  
The haplotype of C57BL/6-mice is H2b which preferentially drives the immune 
response into TH1 direction in these animals. Vaccination of these mice with CLPs 
bearing the nucleic acid binding domain would even potentiate the TH1-response 
however, vaccination trials with HBc-CLPs not harbouring the nucleic acid binding 
domain, as done in this project (see Fig. 4.1), are able to shift the immune response 
to activate TH2-cells. This should result in the production of higher amounts of 
specific antibodies to the presented peptide (Riedl et al., 2002). Furthermore, 
application of immunogens in adjuvants composed of oil-in-water emulsions, like 
AS03 are known to induce TH2-responses, contrary, the use of water-in-oil 
emulsions, like IFA induce a TH1-response (Guy, 2007). Moreover, the lack of co-
stimulatory TLR-ligands (e.g. RNA) and the repetitive arrangement of the used CLPs 
normally leads to the activation of TH2-cells to produce cytokines that drive B-cells to 
differentiate and produce IgGs of other types and to proliferate and secrete IgM to 
the detected virus-like structure. Subsequently TH2-cells can initiate the production of 
neutralizing antibodies (Murphy et al., 2008). It was also shown that adjuvantation of 
vaccines leads to better persistence of neutralizing antibodies (Moris et al., 2011). 
Taking into account all these influencing factors, one could most likely expect the 
induction of a TH2-respsonse in the conducted experiments. However, in comparison 
to the data obtained in these experients, the induction of TH1-responses in both 
groups of mice is uncommon and the expected TH2-response was not confirmed. 
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Also with respect to the obtained neutralization data in which the serum of both 
groups showed high neutralizing capacity (pointing to a TH2-response), the expected 
results were not cofirmed by this experiment (see Fig. 4.16). The reason for this 
difference is not completely clear, yet. One reason might be the ration of IgG-
subclasses and their ability to bind but not being able to neutralize. The ratio of the 
different IgG-subclasses could also influence the capability of the antibodies to 
neutralize infection. Even though, we expected a TH2-response in our experiments, 
some studies in which the same adjuvant (AS03) was used in humans, confirmed our 
results. Patients who obtained the influenza vaccine to strain H1N1 delivered in 
AS03, showed an overall bias to a H5N1-specific TH1-response. Moreover, it was 
shown that all responses, i.e. antibodies, B-cell memory, and CD4 T-cells, were 
increased when the vaccine was formulated with AS03 adjuvant (Moris et al., 2011). 
Also exploratory analyses in children immunized against influenza indicated that the 
induction of CD4 T-cell responses polarized in favour of a TH1-profile (Diez-Domingo 
et al., 2010). On the other hand, one could also argue that the vaccine carrier used 
(not bearing the nucleic acid binding domain) had no or minor effects on a shift of the 
immune response to a TH2-induction. However, most likely the reason for the 
detected difference in IgG-subclass ratio and neutralization response was caused by 
both, the amount and the isotype ratio of the antibodies. Because it was already 
demonstrated that vaccine adjuvants change the clonal composition of antigen-
specific CD4 T-cell populations responding to vaccines and favouring the selection of 
higher-affinity T-cells (Malherbe et al., 2008). In general these findings suggest that 
most likely the adjuvant changes the T-cell response both, quantitatively and 
qualitatively.  
 
5.2.8 Characterization of the immune response in mice against the vaccine 
carrier HBc 
Finally, the expected effect of a high immune response to the carrier protein, HBc, 
was analyzed and could be confirmed in all immunization trials. The immunization 
with single HVRI-variants as well as the mixture immunization revealed high titers to 
the core protein (see Fig. 4.4 and Fig. 4.10). Nevertheless, due to several reasons 
(see section 1.5.1) the induction of a preferably little amount of antibodies to HBV 
core protein based vaccine-carriers would be desirable. As shown in the performed 
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experiments (see sections 4.2.1, 4.4 and 4.6) it would not be possible to completely 
avoid the induction of core-specific antibodies as in all immunization trials also 
antibodies against the core protein were detected. However, in principle anti-carrier 
antibodies do not provide an additional advantage as they do not present any 
protection. Furthermore, in case of a higher induction of antibodies to the carrier 
compared the induction of antibodies to the antigen, the intense self-immunity of the 
vaccine-carrier could also have negative influence on the effectiveness of a vaccine, 
as a too high core response could also increase the risk of a refreshment of the anti-
carrier immune response, while disregarding the presented peptide after each 
booster immunization. This leads to a problem in HBV-core protein based vaccine 
carriers, as over 2 billion people have already been infected with HBV and therefore 
already show a core protein-specific B-cell response. Nevertheless, the possibility to 
use the woodchuck Hepatitis B Virus core protein as vaccine carrier was already 
demonstrated and resulted in a reduced cross-reactivity of anti-WHc antibodies with 
the diagnostic test-system for anti-HBc. The reason for this reduced cross-reactivity 
is probably the sequence difference between the human and woodchuck core protein 
in the area of the tip of the spikes (Billaud et al., 2005a), (Billaud et al., 2005b). In 
order to test this hypothesis and to further improve our vaccine, it was analyzed 
whether WHc-CLPs bearing HVRI-variants would still be able to form particles. As 
shown in Fig. 4.24, the generation of SplitCore-CLPs carrying the HVRI-variant R9 
was successfully demonstrated. The insertion of HVRI-variants in the SplitCore-WHc 
was as possible as the insertion in the SplitCore-HBc system. After successful 
generation of WHc-CLPs carrying the other HVRI-variants or even more variants, it 
would be interesting to analyze their immunogenic potential in mice and compare 
these data to the values obtained with HBc-CLPs.   
In conclusion, HBc SplitCore-CLPs as well as WHc SplitCore-CLPs carrying HVRI-
variants are assembly competent. For this reason WHc-CLPs carrying HVRI-variants 
could be used as new type of immunogen which would be absolutely effective and 
show no cross-reactivity with diagnostic HBc-tests.  
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5.3 Immune response in guinea pigs after immunization with HVRI-
CLPs 
In order to compare the current data demonstrated in mice to the publication of 
Stamataki et al. who showed an increased immune response and neutralizing 
capacity to HCV glycoproteins in guinea pigs compared to mice, the generated HVRI-
CLPs were also tested in guinea pigs. After the last booster, high antibody titers 
specific to the HVRI could be detected in guinea pigs (see Fig. 4.20), while an even 
higher antibody-response to the core-protein was shown (see Fig. 4.21). Also the 
neutralizing capacity of the serum was comparable to mice (compare Fig. 4.22 and 
Fig. 4.16 A). The ability to inhibit infection with heterologous variants (H77, Ad78 and 
J6) was slightly higher in guinea pigs. Surprisingly, in comparison to heterologous 
neutralization in mice which always showed least neutralization of HCVpp J6, serum 
of guinea pigs was able to neutralize HCVpp J6, but HCVpp bearing H77 was 
neutralized less efficient (see Fig. 4.23) Nevertheless, interpretation of the results 
should be done with caution as the vaccination experiments were carried out in Egypt 
under non pathogen free conditions. It may be argued that during the vaccination 
approach, animals were already infected with other e.g. flaviviruses like the Yellow 
Fewer Virus which could lead to a cross-reactive immune response. Furthermore, 
simultaneous bacterial infections could activate the complement system which in turn 
interfered with the neutralization results. In order to prevent this intervention in the 
sera of guinea pigs, in the current project sera were heat inactivated at 56°C. 
However we did not see any variation in the results compared to sera not heat 
inactivated. This may be due to other heat-stable compounds of the innate immune 
system. Consistently, also other groups already showed that neutralization titers of 
E2 significantly increased mAbs to HVRI mimotopes upon addition of guinea 
complement (Meyer et al., 2002). Due to this reason, Stamataki et al. purified their 
antibodies before using them in neutralization experiments which specified their 
results. 
As already mentioned, in general our data are similar to the data demonstrated by 
Stamataki et al.. Nevertheless, these experiments should be repeated under specific 
pathogen free conditions. 
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6 Summary 
More than 170 million people worldwide are chronically infected with the Hepatitis C 
Virus (HCV). The recommended treatment with interferon-α in combination with 
Ribavirin does not lead to satisfactory results. A prophylactic vaccine against HCV is 
not available yet, and its development is a challenging task. It is well documented 
that the viral persistence is caused by effective evasion of the virus from adaptive 
immune response. On the other hand, HCV clearance is associated with rapid 
induction of neutralizing antibodies in the early phase of infection, as well as a 
cooperation between CD8+ cytotoxic and CD4+ helper T-cell responses. Recent data 
have demonstrated that antibodies to the hypervariable region I (HVRI) of HCV E2 
are able to block both, cell-free as well as cell-to-cell, transmission of HCV. 
Therefore, the induction of HVRI-specific B-cells by a prophylactic vaccine is a very 
promising strategy for future vaccines. Previous vaccination trials with peptide, 
recombinant protein, DNA and vector-based vaccines in patients did not result in an 
induction of an effective immune response, which would effectively prevent the HCV 
infection. Due to this, a new strategy is required for the generation of a prophylactic 
vaccine. A particularly encouraging approach is the usage of cross-reactive HVRI 
variants presented on capsid-like particles (CLPs) to boost their immunogenicity  
For this purpose, an improved HBc-CLP vaccine displaying four different highly 
cross-reactive HVRI-variants was constructed. The efficiency of the vaccine was 
tested in mice and guinea pigs. Upon immunization of mice with single HVRI-
variants, high titers of cross-reactive anti-HVRI antibodies were detected. A 
significantly stronger immune response was detected after immunization with a 
mixture of these CLP-HVRI-variants. These particles induced high titers of anti-HVRI 
antibodies, which were able to cross-react with 25% of naturally occurring HVRI 
sequences. In a neutralization assay with HCV pseudoparticles (HCVpp) the anti-
HVRI antibodies were able to neutralize homologous as well as heterologous 
HCVpp. Moreover, the analysis of the neutralizing capacity of sera from these mice 
to HCVpp bearing envelope proteins derived from 19 patients showed that anti-HVRI 
antibodies were able to neutralize 40% of patient-derived HCVpp, demonstrating that 
HVRI-CLPs are indeed able to induce cross-neutralizing HCV antibodies.  
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Furthermore, the induction of cross-reactive and cross-neutralizing antibodies could 
be verified in guinea pigs. Here guinea pig serum showed similar neutralizing 
capacity compared to mice serum.  
Additionally, it was demonstrated that CLPs formed by the woodchuck core protein 
(WHc) that presents HVRI-variants, are similarly competent for assembly.  
The presented results indicate that this new vaccine approach induces a potent anti-
HVRI cross-reactive immune response, as well as cross-neutralizing HVRI-specific 
antibody responses. They consequently constitute a new strategy for a prototype 
vaccine against HCV infection in humans. 
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7 Zusammenfassung 
Weltweit sind derzeit mehr als 170 Millionen Menschen chronisch mit dem Hepatitis 
C Virus (HCV) infiziert. Die empfohlene Behandlungsstrategie, eine 
Kombinationstherapie mit Interferon-α und Ribavirin, führt jedoch zu keinen 
zufriedenstellenden Ergebnissen. Die Entwicklung einer prophylaktischen Impfung 
stellt eine anspruchsvolle Aufgabe dar, welche bis heute nicht gelöst werden konnte. 
Forschungsergebnisse haben gezeigt, dass die Viruspersistenz durch die Evasion 
des Virus vor der adaptiven Immunantwort verursacht wird. Die Eliminierung des 
Virus wird mit einer raschen Induktion von neutralisierenden Antikörpern, sowie einer 
Kooperation zwischen CD8+ zytotoxischen T-Zellen und CD4+ T-Helferzellen 
assoziiert. Aktuelle Studien beweisen, dass Antikörper gegen die Hypervariable 
Region I (HVRI) des E2-Proteins in der Lage sind, zellfreie, aber auch eine 
Übertragung des Virus von Zelle-zu-Zelle zu verhindern. Daher wurde bereits 
angenommen, dass die Induktion von HVRI-spezifischen B-Zellen eine der 
vielversprechendsten Ansatzmöglichkeiten für eine neuartige Vakzinierungsstrategie 
ist. Vorangegangene klinische Studien zur Entwicklung neuer Impfstoffe gegen HCV 
unter Verwendung von Peptiden, rekombinantem Protein, DNA und 
vektorbasierenden Vakzinierungsstrategien in Patienten waren ohne Erfolg und 
führten zu keiner ausreichenden Immunantwort. Infolgedessen werden neue 
wirksame Vakzinierungsstrategien dringend benötigt. Einen besonders 
vielverpsrechenden Ansatz stellt die Präsentation von kreuz-reaktiven HVRI-
Varianten auf partikulären Trägern wie CLPs (capsid like particles) dar, welche deren 
Immunogenität um ein Vielfaches steigern können. 
Zu diesem Zweck wurde eine Vakzine bestehend aus vier verschiedenen stark 
kreuz-reaktiven HVRI-Varianten, die auf HBc-CLPs präsentiert werden, konstruiert. 
Die Wirksamkeit wurde zunächst in Mäusen und anschließend in Meerschweinchen 
getestet. Nach der Immunisierung von Mäusen mit Einzelvarianten der HVRI konnten 
hohe Titer kreuz-reaktiver HVRI-Antikörper detektiert werden. Eine signifikant 
stärkere Immunantwort wurde beobachtet, nachdem die Mäuse mit einer Mischung 
der CLP-HVRI-Varianten immunisiert wurden. Diese Partikel induzierten starke Titer 
von HVRI-Antikörpern, welche außerdem in der Lage waren mit 25% natürlich 
vorkommender HVRI-Sequenzen kreuz zu reagieren. Im so genannten HCV-
Pseudopartikel (HCVpp) Neutralisationssystem, konnte gezeigt werden, dass anti-
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HVRI Antikörper sowohl homologen als auch heterologen HCVpp neutralisieren 
können. Des Weiteren konnte gezeigt werden, dass die HVRI-Antikörper im Serum 
dieser Mäuse in der Lage waren, HCVpp mit 19 verschiedenen, von Patienten 
isolierten HCV Hüllproteinen, zu 40% zu neutralisieren. Diese Ergebnisse zeigen, 
dass HVRI-CLPs tatsächlich kreuz-neutralisierende HCV Antikörper induzieren 
können.  
Darüber hinaus konnte die Induktion von kreuz-reaktiven und kreuz-neutralisierenden 
Antikörpern im Meerschweinchen bestätigt werden, denn das Serum der 
Meerschweinchen wies vergleichbare Ergebnisse der Neutralisationseffizienz zu 
denen der Mäuse auf.  
Abschließend konnte gezeigt werden, dass HVRI-präsentierende CLPs auch durch 
das Core-Protein des Waldmurmeltiers (WHc) produziert werden können. 
Diese Ergebnisse verdeutlichen, dass der gewählte Ansatz zur Generierung einer 
neuen Prototypvakzine eine wirksame anti-HVRI kreuz-reaktive Immunantwort 
hervorruft, sowie zu einer Induktion von kreuz-neutralisierenden HVRI-spezifischen 
Antikörpern in der Lage ist. Die in dieser Arbeit beschriebenen Ergebnisse stellen 
somit eine neue Impfstrategie einer Prototypvakzie gegen Hepatitis C Infektionen im 
Menschen dar. 
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9 Appendix 
9.1 Vector-cards 
The maps of all plasmids that were generated and used during the experiments are 
shown in the following figures (Fig. 9.1 - Fig. 9.6). 
 
 
Fig. 9.1: pET28a2-HBc149-Nterm-HVR-R9  
PCR was done on the template pET28a2_HBc-Nterm-HVRI-149H6-St with the primers T7-promotor 
and Primer-(-)-HVR-R9. The PCR product as well as the template vector were digested with NcoI nd 
BamHI and ligated to pET28a2_HBc149H6-Ntermn-HVR-R9 (H16). For the remaining 3 constructs 
PCR was done on the template pET28a2_HBc149H6-Ntermn-HVR-R9 (H16) with the primers T7-
promotor and Primer-(-)-HVR-G31, indicated by the black arrow. Therefore also the primers Primer-(-
)-HVR-YK5807 and Primer-(-)-HVR-YK5829 respectively, were used. The PCR product was digested 
with EcoRI and BamHI and inserted to CoreN in the vecotor pET28a2_HBc149H6-Ntermn-HVR-R9 
(H16), digested with the same enzymes. This vector-card is a representative for all 4 generated 
HVRI-vriants. It contains the Ampicillin resistant gene (ApR) and was used as E. coli expression 
plasmid. The core potein does not contain the nucleic acid binding domain anymore, indicated by 
“149” in the name of this construct. 
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Fig. 9.2: pET28a2-HBc_c1-79_80-149H6 (149-St1)  
Kindly provided by M. Nassal (Freiburg). Wild type HBc protein lacking the ribososome binding site 
was used as positive control, backbone for cloning, ELISA coating and protein expression. This 
plasmid contains an Ampicillin resistant gene. 
 
 
 
 
Fig. 9.3: pET28a2-HBc_c1-79_80-183S_H6 (183-St1)  
Kindly provided by M. Nassal (Freiburg). The wild type HBc protein was used as positive control, 
backbone for cloning and protein expression. This plasmid contains an ApR. 
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Fig. 9.4: pET28a2_WHc-Nterm-183-R9  
The 89 base pair fragment of pET28a2_HBc149H6-Ntermn-HVR-R9 (H16) (digested with MroI and 
BamHI) was ligated with the 1.08 kb MroI/MluI fragment of pET28a2_WHc-Nterm-HVRI-149 and the 
4.7 kb BamHI/MluI fragment of pET28a2_WHc-185H6-St1 W14real to pET28a2_WHc-Nterm-183-R9. 
The pET28a2_WHc-Nterm-183-R9 vector was used for protein expression. This plasmid contains an 
ApR. 
 
 
 
 
Fig. 9.5: pHCMV-IRES-AD78-E1E2 
This expression plasmid contains the ApR gene, the CMV promoter (P CMV), the ß-globulin intron, 
the IRES sequence of EMCV and the envelope proteins of the east German anti-D cohort (AD78). E1 
starts at bp 2306-2880 and E2 starts at bp 2881-3979. The polyA signal matures the process of 
mRNA translation. This expression vector was used as template for the construction of HCVpp’s with 
different HVRI-sequences (kindly provided by S. Viazov from our Institute). 
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Fig. 9.6: pHCMV-IRES-E1-E2_HVR-R9 
PCR was done on the template pHCMV-IRES-E1/E2 with the primers (-)-pHCMV-Minus-BglI and 
Primer-(+)-HCVpp-R9. The PCR product as well as the template vector were digested with SaII and 
BglI and ligated to pHCMV-IRES-E1-E2_HVR-R9. The same was done for all 4 HVRI-variants, 
indicated by the black arrow. Therefore also the primers Primer-(+)-HCVpp-YK5807, Primer-(+)-
HCVpp-YK5829 and Primer-(+)-HCVpp-G31 respectively, were used. This vector-card is a 
representative for all 4 generated HVRI-variants. The same cloning strategy was used for the 
generation of heterologous HCVpp. 
 
 
9.2 Supplementary tables 
 
Tab. 9.1 Endotoxin determination using the LAL-test 
 
Name Protein  
concentration 
Endotoxin  
concentration 
EU/mg 
protein 
1st immunization trial in mice 
R9 (H16) 2.5 mg/ml 600 EU/ml 240 EU/mg 
YK5807 (H19) 1.5 mg/ml 90 EU/ml 60 EU/mg 
YK5829 (H20) 0.5 mg/ml 125 EU/ml 250 EU/mg 
G31 (H21) 0.6 mg/ml 60 EU/ml 100 EU/mg 
wt-Core 5 mg/ml 1250 EU/ml 250 EU/mg 
2nd immunization trial in mice 
R9 (H16) 1.4 mg/ml 1250 EU/ml 893 EU/mg 
YK5807 (H19) 0.6 mg/ml 125 EU/ml 208 EU/mg 
YK5829 (H20) 0.6 mg/ml 125 EU/ml 208 EU/mg 
YK5829 (H20).1 0.4 mg/ml 60 EU/ml 150 EU/mg 
G31 (H21) 0.3 mg/ml 600 EU/ml 2000 EU/mg 
G31 (H21) 0.5 mg/ml 60 EU/ml 120 EU/mg 
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10 Abbreviations 
α   anti 
aa   amino acid  
Ab   antibody 
approx  approximately 
APS   Ammonium persulfate 
bp   base pair 
BCR   B-cell receptor  
BSA   Bovine serum albumine 
°C   degree Celsius 
CD   Cluster of differentiation 
CLDN1  Claudin-1 
CLP(s)  Capsid-like particle(s) 
CMC   critical micelle concentration 
CMT   critical micelle temperature 
C-terminus  Carboxy-terminus 
DAAs   direct-acting antivirals 
DC   dendritic cell 
DMEM  Dulbecco’s Modified Eagles’s Medium  
DMSO  Dimethyl sulfoxide 
DNA   Desoxyribonucleic acid 
dNTP   Desoxynucleotidetriphosphate 
dsRNA  double-stranded RNA 
E1   envelope 1 
E2   envelope 2 
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EDTA   Ethylenediaminetetraacetic acid 
E.coli   Escherichia coli 
EU   Endotoxin units 
e.g.   for example 
ELISA   Enzyme-linked immunosorbent assay 
EM   electron microscope  
ER   Endoplasmatic reticulum 
et al.   and others (lat. et alii) 
FCS   fetal calf serum 
FDA   Food and Drug Administration 
Fig.   figure 
g   Gram 
GAG(s)  Glycosaminoclycan(s) 
GFP   green fluorescent protein 
GT   genotype 
H   hour 
HBc   Hepatitis B virus core protein 
HBcAg  Hepatitis B virus core antigen 
HBV   Hepatitis B virus  
HCC   Hepatocellular carcinoma 
HCV   Hepatitis C Virus 
HCVcc  Hepatitis C Virus cell culture 
HCVpp  Hepatitis C Virus pseudo particle 
HDL   high-density lipoproteins  
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV   Human Immunodeficiency Virus 
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HLA   human leukocyte antigen 
HRP   Horseradish-Peroxidase 
HS   heparan sulphate 
HVRI   Hypervariable region 1 
IFN   Interferon 
Ig   Immunoglobulin 
IPTG   Isopropylthiogalactoside 
IRES   Internal ribosome entry site 
kb   kilo base pair 
kDa   kilo dalton 
LB   Lurian broth 
LPS   lipopolysaccharide 
LRW   limulus reagent water 
M   Molar 
μ   micro 
m   milli 
mAb   monoclonal antibody 
mDC   myeloid dendritic cell 
MHC   Major Histocompatibility Complex 
min   minute 
MLV   Murine Leukemia Virus 
mRNA  messenger RNA 
MVA   modified vaccinia ankara 
MW   Molecular Weight 
n   nano  
nAb   neutralizing antibody 
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NAGE   Native Agarose Gelelectrophoresis 
NK cell  natural killer cell 
NKT cell  natural killer T cell 
NS   non-structural protein  
Nt   nucleotide(s) 
N-terminus  Amino-terminus 
OD   optical density 
ORF   open reading frame 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PD-1   programmed death-1 
pDC   plasmacytoid dendritic cell 
PEG   pegylated 
pH   -log [H+] (lat. potential Hydrogenii) 
p.i.   post infection 
PKR   protein kinase regulated 
PVDF   Polyvinylidene fluoride 
RBS   Ribosome binding site 
RIG-I   retinoic-acid-inducible gene I 
RLU   Relative-Light-Units 
RNA   Ribonucleic acid  
rpm   rounds per minute 
RT   room temperature 
s   second 
SAA   serum amyloid A 
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SDS   Sodiumdodecylsulfate 
SR-B1  Scavenger receptor class B member 1 
STAT-C  specific targeted antiviral therapies 
SVR   sustained virological response 
Tab.   table 
TEMED  Tertramethylethylenediamine 
TLR   Toll-like receptor 
TNF   Tumor necrosis factor 
TTBS   Tris tween buffered saline 
Treg cell  regulatory T-cell 
Tris   Tris-(hydroxymethyl)-aminomethane 
U   Unit  
UTR   Untranslating Region 
UV-light  Ultra violet light 
V   Volt 
VLDL   very low density lipids 
VLP   virus like particle 
VSV   Vesicular stomatitis virus 
WB   Western Blot 
WHcAg  Woodchuck hepatitis virus core antigen 
WHO   The World Health Organization 
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